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Alkaptonuria (AKU) is an ultra-rare, autosomal recessive disorder of tyrosine catabolism due 
to mutations within the homogentisate 1,2-dioxygenase (HGD) gene. The resulting enzyme 
deficiency leads to accumulation of homogentisic acid (HGA) and deposition of melanin-like 
pigment polymers in the connective tissues of the body in a process called ochronosis. This 
leads to debilitating early onset osteoarthropathy, renal damage and aortic valve disease. As 
a multisystem disorder, AKU results in progressive and chronic pain and severe morbidity. 
Most management approaches for AKU are palliative and rely largely on analgesia and 
arthroplasty. Several therapeutic approaches have been tested with low degrees of clinical 
effectiveness. Nitisinone is a promising drug that blocks the enzyme catalysing the formation 
of HGA and thus lowers its plasma concentration. HGA lowering therapy has been widely 
used in another rare inborn error of metabolism, Hereditary Tyrosinemia type 1 (HT-1) for 
over 20 years. Nitisinone is highly efficacious in terms of its metabolic effect as it decreases 
HGA to very low levels, but there is limited toxicology data available for its use in AKU. There 
are also concerns relating to the adverse side effects of elevated tyrosine and potential 
neurotoxicity if treatment was implemented in children. 
The work presented within this thesis presents novel findings to inform the future licensing 
process for the use of nitisinone in AKU and investigates the safety of implementing 
treatment in younger patients. Nitisinone treatment had no detrimental effect on learning, 
memory or motor function in young AKU or wild type mice. The thesis also includes new data 
from mouse dosing studies concerning the correlation between plasma HGA and ochronotic 
pigmentation and reveals that plasma HGA must be lowered to a critical level before 
pigmentation is beneficially reduced. Finally, this thesis reports on the lability of the 
arteriovenous metabolome relating to AKU and initiates a discussion relating to the HPPA to 
HPLA excretory conversion pathway along with important considerations for collection, 
analysis and comparison of blood samples in future studies. 
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 2 
1.1 ALKAPTONURIA 
Alkaptonuria (AKU) is an ultra-rare, autosomal recessive condition commonly referred to as 
“black bone disease”. The condition is a disorder of phenylalanine and tyrosine catabolism 
due to mutations within the homogentisate 1,2-dioxygenase (HGD) gene. The resulting 
enzyme deficiency leads to accumulation of homogentisic acid (HGA) and deposition of 
melanin-like pigment polymers in the connective tissues of the body in a process called 
ochronosis. This leads to debilitating early onset osteoarthropathy, osteopenia, tendon and 
ligament ruptures, renal damage and aortic valve disease. As a multisystem disorder, AKU 
results in progressive and chronic pain and severe morbidity.  
 
 
Figure 1.1 - Diagram detailing the enzyme defect in AKU and formation of ochronotic 
pigment. Other conditions of the tyrosine pathway are also included: phenylketonuria 
(PKU) and hereditary tyrosinemia type 1, 2 and 3 (HT-1, HT-2, HT-3). 
 3 
1.1.1 History 
Sir A E Garrod notably described the “chemical individuality”, congenital nature and familial 
prevalence of AKU in a series of papers published between 1899-1907 [1-5]. He later 
presented the condition as one of the first inborn errors of metabolism during his Croonian 
lecture series in 1908 [6]. Here, he described how the condition followed the laws of 
Mendelian inheritance, by observing how children of unaffected parents could suffer from 
the condition and that incidences of AKU were higher in the offspring of consanguineous 
marriages. He also reported evidence in relation to a defective gene in AKU and made links 
to how dietary intake of tyrosine affected the amount of HGA excreted in individuals with 
AKU [4]. Neubauer and colleagues aided with this understanding by mapping the tyrosine-
degradation pathway a year later. They discovered that oral administration of 
phenylalanine or tyrosine to AKU patients resulted in urinary excretion of large quantities 
of HGA, concluding it must be an intermediary metabolite of the two [7]. Preceding 
Garrod’s lectures, several other cases of Alkaptonuria are described in the literature with 
the earliest known case found in the Egyptian mummy, Harwa, dating back to 1500 BC [8, 
9]. The term “alcapton” was devised in 1859 by Boedeker meaning “to greedily swallow 
alkali” when he referred to a reducing compound present in a patients urine with an 
affinity for alkali [10]. The term ochronosis was devised by Rudolph Virchow in 1866, when 
he observed that upon microscopic inspection, the macroscopic blue-black pigmentation in 
the connective tissues of an elderly male post-mortem were actually yellow ochre coloured 
[11]. Alcapton was later isolated and named homogentisic acid (HGA) in 1891 by Wolkow 
and Baumann. [12]. Between 1947-1956, Siťaj and colleagues significantly contributed to 
the knowledge of AKU by collecting a set of 102 patients and detailing the clinical 
manifestations and development of the condition culminating in the first international 
publication [13-15]. In 1958, La Du and colleagues demonstrated the absence of HGD 
enzyme activity in liver homogenates from a liver biopsy extracted during abdominal 
surgery of a 57 year old, male AKU patient. This represented biochemical proof that the 
mutation in AKU is associated with a single enzyme arising from a defective gene [16, 17]. 
This gene was localised and mapped to chromosome 3q2 by Pollak and colleagues in 1993 
[18].   
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1.1.2 Epidemiology  
The incidence of AKU is estimated at 1 in 250,000 to 1 in 1,000,000 in most populations 
[19]. As of 2013, there were 950 reported cases of AKU across 40 countries worldwide [20]. 
There are incidences of countries with a higher prevalence of the condition such as 
Slovakia, India and Jordan where the incidence is as high as 1 in 19000 [21, 22]. This is 
predominantly due to the founder effect, where there is establishment of a new population 
by a small number of original founders resulting from migration. Higher numbers of 
consanguineous marriage taking place within these regions has led to a loss of genetic 
variation and higher incidences of the condition [23]. 
 
1.1.3 Pathophysiology and diagnosis  
Phenylalanine and tyrosine are obtained through diet and endogenous protein turnover for 
the production of hormones, melanin and synthesis of new proteins within the body. AKU 
is a disorder of phenylalanine and tyrosine catabolism due to mutations within the 
homogentisate 1,2-dioxygenase (HGD) gene (HGNC:4892). The encoded HGD enzyme (EC 
1.13.11.5) is responsible for converting HGA into the pathway intermediate, 
Maleylacetoacetic acid (MAA) with around 95% of dietary tyrosine metabolised in this way 
[24]. The genetic mutation within AKU results in a deficiency of the HGD enzyme, blocking 
the tyrosine catabolic pathway at the level of HGA. HGA is the hallmark metabolite of AKU 
and accounts for the clinical features synonymous with the condition - homogentisic 
aciduria, ochronosis and ochronotic osteoarthritis [24]. These clinical features present at 
difference stages of life with homogentisic aciduria – urinary excretion of HGA, being 
present from birth. HGA readily oxidises into benzoquinone acetic acid (BQA) which forms 
discolouring melanin-like, pigment polymers. Daily urinary excretion of HGA occurs in gram 
quantities; this darkens upon standing and is usually the first sign towards diagnosis in 
children. Over a period of years, HGA accumulates and pigment polymers are deposited 
into cartilage and connective tissues in a process called ochronosis. This results in 
macroscopic blue/black discolouration of the affected tissues - the origin of the term “black 
bone disease”. Accumulation of ochronosis over time alters the mechanical properties of 
the connective tissues and cartilage causing them to become brittle. This leads to 
degradation of the articular surface, relative unloading and therefore absorption of the 
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subchondral bone, osteoarthritis and eventual collapse of the load-bearing joints in many 
patients. Accumulation and polymerisation of HGA cause the multisystem manifestations of 
AKU including severe early onset osteoarthropathy, osteopenia, renal, gall, prostatic and 
salivary gland calculi and renal damage [24-27]. Post-mortem analysis of the cardiovascular 
involvement in AKU has shown pigmentation of the heart valves that is associated with 
calcification and clinically significant aortic stenosis. Intense pigmentation has also been 
observed within the fibrolipid components of atherosclerotic plaques [103]. Obvious 
clinical features include darkening of the sclera and cartilage of the ears, black earwax and 
discolouration of the sweat and sweat glands. Joint involvement in AKU is associated with 
severe morbidity including chronic pain and decreased quality of life with orthopaedic 
surgical intervention often required by patients in their early thirties. Weight-bearing joints 
are primarily affected (vertebral column, hips and knees) although smaller synovial joints 
often become symptomatic between 30-40 years [44, 52]. Despite homogentisic aciduria 
from birth, symptoms including joint involvement are often absent in youth followed by 
progressive disease development from the third decade of life, explaining why AKU was 
often missed in the past and diagnosis occurred in adulthood for the majority of cases. 
Thankfully, this is not the case for the present day due to the internet and the work of the 
AKU society providing information to aid with early diagnosis. A rapid semi-quantitative 
reliable method of diagnosis of AKU is via pigment development of urine spots applied to 
alkalised paper. Diagnosis is usually confirmed with analysis of urine and plasma HGA using 
high performance liquid chromatography and mass spectrometry [28-30]. 
 
1.1.4 HGD Gene 
The HGD gene has a genomic location of 3q13.33 spanning 14 exons and containing 54,404 
base pairs. The functional HGD gene encodes a 445 amino acid protein structure consisting 
of a hexamer formed by a dimer of trimers that metabolises HGA to MAA [31]. HGD gene 
expression in humans is apparent in multiple tissues of the body including the kidney, liver, 
prostate, small intestine and colon [33]. Laschi and colleagues reported expression in 
osteoarticular cells by testing human normal and AKU cells for HGD gene expression by 
reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. They 
revealed expression in chondrocytes, synoviocytes and osteoblasts [32]. The HGD enzyme 
is predominantly produced by hepatocytes in the liver and within the kidney [33]. The 
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defect of AKU is caused by recessive mutations of the HGD gene that directly or indirectly 
affect active site residues, subunit interactions and overall protein folding structure 
resulting in the total loss of function or reduced HGD enzyme production associated with 
AKU. There are currently 129 mutations in the HGD mutation database with over 60% of 
these being missense. These mutations are distributed throughout the HGD gene but a 
higher prevalence is found in exons 6, 8, 10, and 13 [34, 35]. No correlations between type 
of HGD mutation and the severity of the disorder have been observed. 
 
1.1.5 Ochronosis  
Ochronosis of tissues in AKU is thought to follow localised changes in composition and 
organisation of the extracellular matrix (ECM) prior to spreading to chondrocytes. Taylor 
and colleagues examined cartilage matrix components in samples obtained from hip and 
knee surgeries of AKU, OA and non-OA patients. They reported disorganisation and a 
reduction in extractable glycosaminoglycans as well as a very low cell turnover state in the 
ECM of cartilage from the AKU patients compared with OA and non-OA [36, 37]. Whether 
this disorganisation is a cause or consequence of pigmentation is currently unknown. By 
comparing samples obtained at various stages of the disease, ochronotic pigmentation is 
thought to initiate in the calcified zone of articular cartilage in both mice and humans with 
progression of pigmentation following a similar age related pattern. Further work by Taylor 
and colleagues described these progressive stages in the Hgd-/- mouse [71]. Early stage 
pigmentation is present within the pericellular matrix of chondrocytes as early as 15 weeks. 
By 40 weeks, pigmentation has progressed to the cellular compartment in many of the 
chondrons of the articular calcified cartilage. At 65 weeks, advanced stage, extensive 
pigmentation is apparent throughout the femoral and tibial articular cartilage although 
some chondrocytes appear to be at an earlier stage of the pigmentation process even 
though they are very near to others with intense pigmentation, suggesting that the process 
is not uniform throughout. No end stage “blanket pigmentation” is observable in the 
mouse but is found in AKU patients. This disparity between species, despite a very similar 
biochemical status, is thought to be due to a number of factors including the shorter 
lifespan of the mouse, quadrupedal locomotion reducing load bearing and faster metabolic 
and cellular turnover of HGA adducted proteins prior to polymerisation. These factors may 
all contribute to the reduction in severity of the condition in the Hgd-/- mouse [70, 71]. 
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Investigation of pigmented cartilage specimens from AKU patients by Taylor and colleagues 
revealed a distinct pattern of binding of ochronotic pigment [38].  They reported a periodic 
banding pattern of ochronotic shards on individual collagen fibres, which suggested a 
possible preferential binding site for HGA and concluded other local factors must be 
involved in promoting or inhibiting the ochronotic pigmentation process along with HGA. In 
support of this, nuclear magnetic resonance (NMR) investigation into ochronotic cartilage 
by Chow also found a marked decrease in collagen molecular order and demonstrated that 
the ochronotic deposits altered the fibre structure by “invasion and crosslinking” [39].  
Additional work by Taylor and colleagues [40] characterised the progression of 
pigmentation reporting that intact cartilage is resistant to pigmentation and focal changes 
to the calcified cartilage occur prior to initiation of pigment deposition. Pigmentation then 
spreads throughout the cartilage, altering its mechanical properties, with advanced stage 
ochronosis leading to aggressive resorption of calcified cartilage and loss of the 
subchondral plate. This group has suggested that the stiffening of the cartilage shields the 
underlying bone from normal mechanical stresses leading to bone resorption and final 
catastrophic collapse of the joint structure. The intermediate steps resulting in the 
production of ochronotic pigment polymers remains to be fully elucidated but several 
mechanisms or contributing factors have been suggested. In a separate paper, Taylor and 
colleagues suggested that tyrosinase might be implicated in the ochronosis that occurs in 
AKU [41]. They proposed that changes in the substrate specificity of tyrosinase, a 
polyphenol oxidase involved in the production of melanin from tyrosine, might be the 
missing link involved in the pigmentation process whereby HGA is polymerised under 
certain conditions instead of or in addition to tyrosine. Other evidence suggests damage is 
more likely attributable to the enzyme HGA polyphenol oxidase, and its product BQA 
binding and altering the structural integrity of the connective tissues. This leads to free 
radical production as a result of the oxidative process, which may incite further damage by 
promoting inflammation [42]. Decreased activity of lysyl hydroxylase, an enzyme important 
for pyridinoline cross-linking and stabilisation of cartilage has also been observed in 
patients with ochronosis [42, 43]. 
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1.1.6 Current therapeutic options  
Most management approaches for AKU are palliative and rely largely on analgesia and 
arthroplasty. Several therapeutic approaches have been tested with low degrees of clinical 
effectiveness. Future treatment options such as gene or enzyme replacement therapy 
would effectively cure AKU by replacing the defective HGD enzyme, ensuring HGA is broken 
down as in the healthy individual but unfortunately, these treatment options are not yet 
available. 
 
1.1.6.1 Ascorbic acid 
Ascorbic acid has antioxidant properties that were proposed could prevent the oxidative 
formation of BQA from HGA by inhibiting HGA polyphenol oxidase, in turn reducing 
ochronosis [44, 48]. This was shown to be achievable in vitro with the use of 10 mM 
ascorbic acid [45] but such concentrations are impossible to achieve in vivo. Administration 
of ascorbic acid to AKU patients was shown to reduce urinary BQA but no effect was 
observed for HGA excretion [46]. Furthermore, a study by Wolff et al demonstrated two 
fold increases in urinary excretion of HGA in ascorbic acid treated infants with AKU, 
presumably through its effect as a cofactor on the immature HPPD enzyme [47]. Alongside 
concerns about the effect of increased HGA on formation of renal oxalate stones, therapy 
with ascorbic acid for AKU is generally regarded as ineffective. Other antioxidants including 
phytic acid, taurine, ferulic acid and lipoic acid have been shown to have some efficacy in 
counteracting the production of BQA [49] but it is believed efforts are better spent in 
researching a therapy that blocks the formation of HGA itself. 
 
1.1.6.2 Low protein diet 
As HGA is a product of tyrosine catabolism, limiting dietary intake of phenylalanine and 
tyrosine is a seemingly logical therapy for AKU. A study by de Haas and colleagues [50] 
showed  low protein diet to be effective for the reduction of HGA in patients under 12 but 
past this age, any effect was negligible. Behavioural influences were noted within the study 
presumed due to the severe dietary restriction. Although rational, restriction of dietary 
protein requires strict supervision and personal discipline, and poor compliance is often 
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encountered. Furthermore, reports of efficacy in treatment with a low protein diet remain 
to be proven in long-term studies [19, 24].  
 
1.1.6.3 Nitisinone 
Nitisinone or 2-(2-nitro-4-trifluromethylbenzoyl)-1,3-cyclohexanedione (NTBC) was 
originally developed as one of the first synthetic triketone herbicides by Zeneca 
Agrochemicals [51]. Some plants and lichens produce natural triketones, such as 
production of leptospermone by the bottlebrush plant (Callistemon citrinus) [53]. 
Triketones suppress the growth of surrounding plants by selective inhibition of 
hydroxyphenylpyruvate dioxygenase (HPPD; EC 1.13.11.27) to prevent the production of 
HGA and synthesis of plastoquinone and ubiquinone. These function as transporters in the 
electron transport chain of photosynthesis and play crucial roles in plant growth. Electron 
exchange is impeded in the affected plant leading to reduced chlorophyll production, 
bleaching and suppression of growth [54]. Nitisinone is a related chemical entity, and has 
been developed, tested and licenced as an orally administered, HPPD blocking therapy that 
has already been widely used in another rare inborn error of metabolism, Hereditary 
Tyrosinaemia type 1 (HT-1) for over 20 years. Nitisinone is highly efficacious in terms of its 
metabolic effect for AKU as it decreases HGA to very low levels in the AKU mouse [71, 72] 
and humans [55, 56]. A recent human study investigating the effect of once daily nitisinone 
on 24-hour urinary HGA excretion in AKU patients observed a clear dose response 
relationship with 8mg per day reducing urinary HGA levels by 98.8% [55]. A second phase 
of the study is ongoing, involving 140 patients across Europe, and is due to finish in 2019. 
Half of the patients will receive nitisinone with the study aiming to compare the treated 
and untreated patients after four years to assess the effects of nitisinone via blood 
biochemical measurements and the AKUSSI, a combinatorial clinical assessment tool for 
clinical severity [165]. 
 
1.1.6.3.1 Nitisinone induced tyrosinemia  
As part of its mechanism of action of inhibiting HPPD, the enzyme catalysing the formation 
of HGA, nitisinone also causes undesirable ‘upstream’ increases in circulating tyrosine. 
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Upon commencement of nitisinone treatment, a protein-restricted diet is advised to 
control the amount of circulating tyrosine provided from food although patient compliance 
varies. Previous studies of nitisinone use in AKU have shown serum tyrosine to increase 
from ~50mM baseline up to 1500mM in extreme cases (average 800mM), though these 
values are usually well tolerated [56]. In some treated patients, however, oculocutaneous 
adverse reactions relating to elevated circulating tyrosine may occur including 
conjunctivitis, corneal opacity, keratitis, photophobia and eye pain. Tyrosine has low 
solubility compared to most amino acids and readily crystallizes in tissues at high 
concentrations, deposition of crystals can occur in the cornea resulting in an inflammatory 
response. Two published reports of tyrosine keratopathy in AKU detail occurrence at low 
nitisinone doses – 1mg and 2mg daily with serum tyrosine measured at 941mM and 
~550mM respectively. Both cases recovered fully upon cessation of treatment with one 
able to restart nitisinone with reduced dietary protein intake [57]. The other case was twice 
restarted on nitisinone but due to reoccurring ocular symptoms, treatment was 
permanently stopped. The study concluded that this patient showed predisposition to 
toxicity independent of peak plasma tyrosine levels (his was approximately 200mM below 
the average for the treated cohort) and that this contra-indication to treatment may occur 
in about 5% of AKU patients on nitisinone [58]. Although tyrosine is elevated in nitisinone 
treated AKU patients, Taylor and colleagues have shown this does not contribute to, or 
exacerbate, the process of ochronosis [59]. 
 
The tyrosinemia post-nitisinone resembles the metabolic status in genetic deficiency of 
HPPD; a condition termed hereditary tyrosinemia type 3 (HT-3) (Figure 1.1). Increased 
plasma tyrosine levels from birth have been proposed as a contributing factor to the 
impaired cognitive function and intermittent ataxia observed in some patients with HT-3. 
Nitisinone was originally developed as a herbicide, for this reason there is limited 
toxicology data available for its use as a HGA lowering therapy in AKU. Continuous and 
long-term monitoring of the efficacy, toxicity and safety post-nitisinone is currently ongoing 
as suggested in a best practice review by Ranganath and colleagues [24]. The issues relating 
to tyrosine toxicity as a result of HPPD inhibition must be considered when implementing 
treatment. Clearance of excess tyrosine is dependent on tyrosine aminotransferase (TAT) 
(EC 2.6.1.5). This is the first and rate-limiting enzyme within the catabolic pathway (Figure 
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1.1), the activity of which differs between species - rat: 1.7 ± 0.2, mouse 7.8 ± 1.5, human 
7.17 ± 1.17 [60, 61]. The significantly lower hepatic TAT activity in the rat results in greater 
accumulation of tyrosine and is responsible for the higher incidence of toxicities observed 
within the species. Toxicity testing for mesotrione, another triketone herbicide with a 
shorter half-life than nitisinone, has shown a clear plasma tyrosine concentration threshold 
for ocular toxicity in rats (approximately 1000umol/L) above which the incidence of corneal 
lesions, but also elevated liver and kidney weights and reduced bodyweight, increases 
significantly. [60, 62-64]. Ocular toxicity in the mouse occurred with mesotrione but at 
much higher doses, attributable to the higher TAT activity in this species enabling efficient 
tyrosine clearance. This also indicated that humans are likely less prone to ocular toxicity 
due to having similar TAT activity as mice. 
 
Within AKU, symptoms accumulate over time due to high HGA levels. Commencement of 
nitisinone therapy from birth has the potential to reduce and maintain low HGA levels 
throughout life and thus prevent or substantially delay the pathological complications 
associated with the condition. A primary concern of such a course of treatment is that the 
elevated circulating tyrosine may cause intellectual impairment particularly if administered 
in childhood during brain development [110]. Similar concerns have been raised in HT1 
patients treated with nitisinone in whom the treatment is lifesaving. Within this condition, 
mutations within the fumarylacetoacetate hydrolase gene (FAH; HGNC:3579) result in FAH 
enzyme deficiency (EC 3.7.1.2) and accumulation of the substrate fumarylacetoacetate and 
succinylacetone, large quantities of which are hepato- and nephrotoxic. Several studies 
examining the use of nitisinone in early treated children with HT1 have shown patients 
scoring lower than average in assessments of intelligence, cognitive development, motor 
function and speech, which the authors of the study have linked to the elevation of plasma 
tyrosine [112]. Significant elevation of tyrosine in the cerebrospinal fluid (CSF) and impaired 
serotonin synthesis has also been observed in HT1 patients receiving nitisinone treatment 
[65]. Serotonin is involved in regulation of mood, motivation and arousal; it could therefore 
influence learning and memory [66]. Toxicity studies evaluating inhibition of HPPD in 
neonatal animals have indicated no increased sensitivity to elevated tyrosine compared 
with adults [60]. The effect of nitisinone in utero has been evaluated using rabbits, rats and 
mice and shown reproductive toxicity but at doses 2.5-125 times higher than used in HT1 
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patients. The doses used in AKU patients are lower still. There is little information relating 
to nitisinone toxicity in utero for humans. Three cases of women with HT1 who received 
nitisinone throughout pregnancy are described in the literature with the children reported 
as suffering no adverse effects and displaying normal psychomotor development within the 
first years of life [67-69]. 
 
1.2 HGD-/- AKU MOUSE MODEL 
The effects of early nitisinone therapy and high circulating tyrosine levels can be assessed 
using the AKU mouse model (Hgd-/-). This model was developed at the Institut Pasteur in 
1994 having been recognised during a chemical mutagenesis study using N-ethyl N-
nitrosourea (ENU) intraperitoneal injection (250mg/kg). Confirmation of AKU in the mice 
was by observed darkening of the urine when pipetted onto filter paper soaked in 0.5M 
sodium hydroxide [73]. The aku gene mutation, later mapped to murine chromosome 16, is 
a missense mutation at intron 12 (GTAAGT to GAAAGT) causing the complete deletion of 
exon 12. This leads to a frame-shift and premature stop codon in the fourth codon of exon 
13 [74]. The resulting phenotype is analogous to one of the known mutations responsible 
for AKU in humans (D16Mit4 locus in the mouse, homologous to human 3q), producing a 
HGD deficient mouse with similar blood chemistry to human AKU and urine containing HGA 
that blackens upon oxidation. The AKU mouse model is a vital tool for testing potential 
therapies including nitisinone and any possible developmental neurotoxicity that could 
result from therapy prior to use in children.  
 
Taylor and colleagues first observed ochronosis within the AKU Hgd+/− FAH−/− mouse (a 
mouse that can model either HT-1 or AKU depending on selection conditions) [71]. They 
described macroscopic ochronotic renal nodules and microscopic pigmentation throughout 
the kidneys. Various stages of ochronotic pigmentation were also observed at the 
subchondral junction of the distal femur at 13 months of age. Further work by Preston and 
colleagues [70] described pigmentation of the articular cartilage apparent as early as 15 
weeks that steadily increased with age. Commencement of nitisinone therapy resulted in a 
reduction of plasma HGA throughout the mouse’ lifetime and completely prevented further 
accumulation of pigment at a dose of 4mg/L. Previous studies in Hgd-/- mice within our lab 
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have used 4mg/L nitisinone as this was the dose originally determined by the Grompe lab 
that allowed the FAH-/- HT-1 mouse model to survive [75].  This FAH-/- model was the 
precursor strain from which the Hgd-/- mouse used within this thesis was derived. Previous 
Hgd-/- mouse work assessing the nitisinone dose response has included a mid-life study 
carried out by Keenan and colleagues [72] in which 54-week-old mice were treated with an 
ad libitum supply of water containing doses between 0.125-4mg/L of nitisinone for 13 days.  
Plasma HGA concentrations were highly variable in AKU mice but HGA responded in a dose-
dependent manner to nitisinone treatment. Higher concentrations of nitisinone resulted in 
greater suppression of plasma HGA and removal of nitisinone after 13 days resulted in 
plasma HGA levels returning to pre-treatment levels. Studies have shown progressive 
pigmentation of chondrocytes in the mouse model but no severe osteoarthropathy along 
with few overt effects on welfare [70-72]. 
 
1.3 BEHAVIOURAL STUDIES 
Animals are an invaluable tool in biomedical research for the understanding of disease and 
development of novel treatments. Animal models of cognitive impairment have long been 
used to determine the neural basis of cognitive functioning, helping to enhance our 
understanding of the networks involved in learning and memory. These have led to a 
greater understanding of neurodegenerative diseases such as Parkinson’s and Alzheimer’s 
as well as psychiatric disorders such as schizophrenia, depression and bipolar disorder [88, 
173]. Behavioural pharmacology allows the efficacy and toxicity of a pharmaceutical 
intervention to be evaluated by observing the neurocognitive effect in the form of 
behavioural responses [76]. Mice are widely used in behavioural studies to approximate 
human responses as they share many of the same important brain functions– learning, 
memory, anxiety and circadian rhythm. Many factors can alter behaviour in mice including 
general health, background strain (differences in anxiety/aggression), age, sex and 
environment (diet, housing, noise). These factors must be considered and standardised 
when testing to ensure influence on behaviour is minimal [77]. Mice are nocturnal animals; 
several recent studies have shown light exerts widespread effects on physiology and 
behaviour and that testing during the light phase can induce pronounced behavioural 
inhibition and cognitive disruption. Testing during the inactive period may also be 
detrimental to the animal’s welfare due to increased stress [78-81]. For this reason, a 
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reverse light cycle was implemented for all experiments within this thesis to ensure testing 
took place during the active phase and behaviour was less likely to be affected by 
perturbations of circadian rhythm. This ensured neurocognitive testing was more sensitive 
in detecting any treatment related effects. Diet, strain, housing and time of testing were 
standardised.  As there have been concerns that the tyrosinemia in nitisinone treated HT-1 
patients and high tyrosine from birth in HT-3 may contribute to the cognitive impairment 
and lower intelligence observed in some patients, a behavioural test of learning and 
memory - indicators of cognition, could examine these in nitisinone treated Hgd-/- mice. It 
is important to evaluate the effects of nitisinone related tyrosinemia in an AKU murine 
phenotype prior to use in children to ensure the elevated tyrosine is not neurotoxic to the 
developing brain. 
 
1.3.1 Morris Water Maze 
The Morris water maze (MWM) is a widely accepted behavioural task for assessing 
hippocampal dependent learning and retrieval of spatial memory in rodents. Mice or rats 
swim within a pool, first to measure their ability to learn the position of a submerged 
platform, and then to measure their ability to recall the platforms position after a period of 
time. Richard Morris originally developed the MWM in 1981 at the University of St 
Andrews to test spatial localisation in the rat and to investigate the controversies 
surrounding the neural basis of spatial learning and working memory (82, 83). The MWM 
protocol can be adapted for many neurobehavioural applications including validation of 
rodent disease models and evaluation of drug treatments and the related effects on 
cognition, learning and memory [84]. Advantages of the MWM include insensitivity to 
variances in bodyweight, absence of non-performers (close to 100% rodents will perform 
swimming tasks) and minimal training compared to other behavioural tasks [86]. The 
motivation to escape in the MWM is also uniform between animals, which is not the case 
for other behavioural tasks. Submersion in water tends to be constant at motivating escape 
for all test subjects. In behavioural tasks containing food as a stimulus on the other hand, 
motivation can differ depending on differences in appetite between animals. During the 
MWM task, the use of external visual cues aids the rodent in determining the location of a 
submerged platform from varying starting positions within a circular pool. The rodent 
cannot see the platform as the water is opaque via the addition of non-toxic tempera paint. 
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Alternatively, a black pool is used with a clear plastic platform, as within this thesis. An 
additional advantage of a water-based task is that rodents cannot rely on odour trails from 
previous test subjects as an escape cue. Within the MWM, the use of external navigatory 
cues allows for the allocentric processing of the hippocampus and entorhinal cortex to be 
tested. Allocentric navigation is object centred, in that the use of external cues and their 
location relative to one another enables the location of another object or place to be 
determined [85]. For example, perception of a landmark such as a tall monument in the 
distance, provides relational information about one’s own location compared to other 
landmarks and can be used as an aid for navigation.  
 
The place cells of the hippocampus are considered to play a primary role in acquisition and 
retrieval of spatial information as well as the consolidation of spatial memory. These place 
cells form an internal spatial map that continuously updates as an organism moves to allow 
awareness of its location within an environment [86]. Communication between 
hippocampal place cells and other place cells in the entorhinal cortex forms a 
hippocampal–entorhinal circuit with the entorhinal cortex also containing grid cells used to 
map larger spaces [86, 92]. Lesions or damage within these regions has been shown to 
have a detrimental effect on performance within the MWM. Riedel and colleagues 
reported serious impairment of MWM performance in rats who had inactivated 
hippocampal networks using AMPA receptor antagonists. These transmembrane glutamate 
receptors mediate fast synaptic transmission within the hippocampus [90]. Furthermore, 
animals with damage to other areas of the brain including the basal forebrain, striatum and 
cerebellum all exhibit deficits within the MWM, suggesting navigation is dependent on the 
coordinated action of numerous brain regions, which together contribute to a functional 
neuronal network [84]. Activation of dopaminergic receptors, specifically D1R and D5R of 
the prefrontal cortex, striatum and hippocampus has also been shown to be necessary for 
normal spatial information processing. Sariñanaa et al used in situ hybridisation probes to 
show that forebrain D5R activation plays a unique role in spatial learning and memory in 
conjunction with D1R activation. Interestingly, their data also suggested that prefrontal 
cortical and striatal, but not hippocampal D1R activation was essential for this process [93].  
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Performance and analysis of the MWM test is automated by tracking and analysis software 
which measures the position of the mouse continuously and calculates parameters such as 
path latency, path length and swim speed. A progressive reduction of these parameters 
during testing indicates spatial learning of the platform location [86]. The task involves a 
number of consecutive days of training followed by a probe test on the final day to assess 
the consolidation and retrieval of memory. The probe is not only an important assessment 
of the learning and acquisition of memory that has taken place over the previous days of 
testing, but also a test of long term memory consolidation. The MWM is an aversively 
motivated behavioural task and therefore stress is a continuous factor to consider when 
analysing results. Stress is known to influence cognitive function and has been shown to 
affect acquisition and retention of memory within the MWM. De Quervain and colleagues 
reported impaired probe trail performance in rats after they had received a foot shock and 
concluded that this was due to increased plasma corticosterone levels [89]. For this reason, 
supplementary stress must be actively minimised during testing. Within this thesis, this was 
achieved by following proven stress reducing handling techniques and by allowing 
adequate prior acclimatisation to the testing environment. This is detailed further within 
the methods section in chapter 2. For the Hgd-/- mouse and in the context of this thesis, 
the MWM has proved to be a valuable tool to assess whether elevation of tyrosine by 
nitisinone therapy has an effect on spatio-temporal awareness, place learning and memory. 
These studies therefore address concerns regarding the potential for neurotoxicity of 
tyrosine in the hereditary tyrosinemias, including nitisinone treated HT-1 patients. 
 
1.4 MOTOR FUNCTION ASSESSMENT 
Motor function assessment is the one of the most accessible domains of mouse 
behavioural science and forms an important part of the evaluation of animal behaviour. 
Assays for grip strength, motor coordination, balance, swimming speed and gait analysis 
are all widely used to assess motor function in various mouse models [94-95]. The type of 
assessment differs depending on whether the purpose is to monitor a treatment or to 
analyse a phenotype associated with a particular genetic mutation. As different tests assess 
different aspects of motor performance, it is often not sufficient to run a single test, 
therefore a range of tests are simultaneously required to ensure comprehensive evaluation 
and identification of subtle changes. Behavioural experiments, such as the MWM, measure 
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motor responses to sensory information e.g. processing visual information (3D visual cues) 
to induce a motor response (swimming to a submerged platform), it is thus important to 
consider the effects of motor functioning to ensure the behavioural data is properly 
interpreted [95]. Along with spatial learning, coordinated limb use during voluntary 
locomotion can also be assessed when mice are swimming in the MWM. Swimming has 
been shown to be a sensitive test of motor coordination in wild type and rodent models of 
disease [174-176]. Alongside motor assessment, a functional observational battery can be 
carried out to further detect any obvious behavioural effects of treatment. This is a 
neurobehavioral tool consisting of a series of observations that can be made while mice are 
in their home cage, with sufficient frequency to ensure detection of any behavioural or 
neurological abnormalities [177]. Behaviour and appearance of the animal are observed to 
look for any indications of neurotoxicity (in this case, as a result of nitisinone therapy or 
elevated tyrosine levels). Signs of neurotoxicity include convulsions, tremors, increased 
levels of lacrimation or salivation, piloerection, diarrhoea and increased vocalisation.  
 
1.4.1 Rota-rod  
The Rota-rod is a commonly used test of motor coordination and balance in the mouse, 
originally developed by a Dunham and Miya in 1957 and specifically designed to measure 
neurological deficits in rodents [97]. It has since been fully automated and is now one of 
the most popular tests of motor function owing to its ease of use and sensitivity. During 
the Rota-rod test, mice are placed on a horizontal, rotating rod arranged at a small distance 
from floor level, low enough for a fall to be innocuous to test subjects but high enough to 
induce the mouse’s natural avoidance to fall.  The mice must walk forwards to remain 
upright and maintain their balance to stay on the rotating rod, which continuously 
accelerates at a speed of 4-40rpm over 300 seconds. When the mouse is unable to 
continue, it falls onto a magnet trip plate, which records the latency to fall and speed of 
rotation at the time of fall. Mice with abnormalities affecting coordination or balance will 
tend to exhibit lower latencies to fall. Wang and colleagues showed mice with surgical 
destabilisation of the medial meniscus, for example, a commonly used model of OA, had 
statistically significantly lower latency times to fall compared to age matched naïve mice at 
8 and 16 weeks after surgery [98]. Mouse models of Parkinson’s disease also affect 
performance on the Rota-rod. Within the MTPT model, a Parkinson’s phenotype is induced 
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via damage to the nigrostriatal dopaminergic system by MTPT injection. This has been 
shown to lead to reduced Rota-rod latencies both short and long term [178]. Interestingly, 
a recent paper by Giraldo et al that employed a genetic (α-synuclein) Parkinson’s mouse 
model, reported abnormal locomotor behaviour but significantly increased latencies on the 
Rota-rod compared to control mice [179]. The authors suggested that the longer latencies 
to fall could be due to the mice exhibiting reduced anxiety levels due to elevated 
extracellular dopamine in the striatum produced by dysfunctional striatum-basal ganglia 
circuits. Increased levels of dopamine occurs in the early stages of Parkinson’s disease, 
which can lead to increased general activity and repetitive behaviours [179]. The Rota-rod 
will enable assessment of coordination and balance within nitisinone treated and control 
Hgd-/- and WT mice. The elevation of tyrosine post-nitisinone resembles the metabolic 
status in HT-3 where HPPD is also inhibited and occasional loss of balance and ataxia have 
been reported. It is therefore important to examine the effect of elevated tyrosine in 
nitisinone treated mice to investigate if this is the cause of the motor dysfunction observed 
in HT-3. 
 
1.4.2 Inverted grid suspension test 
The inverted grid suspension test (IGST) is a widely used, non-invasive general measure of 
grip strength originally devised by Kondziela in 1964 [180]. The test measures the ability of 
the mouse to remain clinging to an inverted wire mesh grid, suspended a small distance 
above a soft surface during which the latency to fall is measured. The test assesses the 
combined grip strength of both fore and hind limbs. Grip strength tests are highly specific 
in that they attempt to measure a single, well-defined aspect of behaviour, they are 
therefore combined with other motor function tests, in this case the Rota-rod, swimming 
within the MWM and gait analysis. Most healthy mice will easily reach the maximum grip 
latency time. The IGST has been used in mice to measure tolerance to drugs such as 
ethanol (which induces myorelaxation). The test has also been used to assess gross 
strength and disease progression in mouse models of muscular dystrophy and in mice with 
cerebellar dysfunction [95, 181]. 
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1.4.3 Catwalk XT gait analysis 
The CatWalk XT platform is a computer-assisted automated quantitative gait analysis 
system that allows simultaneous quantification of a large number of both static and 
dynamic gait parameters during voluntary walking. Briefly, the apparatus consists of an 
enclosed walkway on a glass plate that is traversed by a mouse from one side to the other. 
Green light enters at the long edge of the glass plate and is completely internally reflected. 
Light is able to escape only at those areas where the animal's paws make contact with the 
glass plate; as a result, the light is scattered which results in illumination of the exact area 
of contact. The image is captured by the camera and stored on a computer for analysis. The 
Catwalk platform has been used to measure numerous disease models leading to gait 
abnormality in rodents. These have included spinal cord injury, Parkinson’s disease, 
cerebellar ataxia and osteoarthritis [122, 131]. The platform has been shown to be capable 
of detecting very subtle alterations in gait as well as minor changes in neurological function 
[183]. In the context of AKU, ochronosis has been shown to pathologically alter gait in 
humans [96] but the effect of ochronosis on gait within the Hgd-/- mouse model is 
currently unknown. The Catwalk XT gait analysis platform will therefore be used to 
investigate whether any significant differences in gait are present between Hgd-/- and WT 
mice prior to treatment with nitisinone. 
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2. Materials and Methods 
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2.1 ETHICAL APPROVAL 
2.1.1 Procedures 
All procedures within this thesis were performed in accordance with the Animals Scientific 
Procedures Act (1986) and licensed by the United Kingdom Home Office under a project 
license granted to Professor Jonathan Jarvis (PPL 40/3743) and a personal license granted 
to Róisín Lewis (PIL I8B47F4AC). 
 
2.2 MICE 
2.2.1 Breeding 
Four Hgd-/- breeding pairs on a BALB/c.129/sv background were obtained from the 
University of Liverpool colony. This colony was originally established from breeders 
obtained from Dr. X Montagutelli (Pasteur Institute, France). Control wild type (WT) mice 
on a BALB/cAnNCrl background were purchased from Charles River laboratories (UK). 
 
2.2.2 Mouse husbandry 
Mice were bred, housed and maintained within the Liverpool John Moores University Life 
Sciences Support Unit in accordance with Home Office UK guidelines. Mice were 
maintained on an ad libitum supply of vegetal diet A30RMB (SAFE, Augy, France) and 
drinking water. A reverse light cycle (16-hour light/8-hour dark) was introduced to ensure 
behavioural testing took place during the active phase. 
 
2.2.3 Genotyping 
Genotyping was carried out at the University of Liverpool prior to obtaining the Hgd-/- 
breeding pairs. Genomic DNA was extracted from tail tips using DNeasy Blood and Tissue 
kits (Qiagen, UK), and the Hgd gene typed as previously described [119] with slight 
modifications. Primer sequences were: 
• forward primer 5’-CATTTTCACCGTGCTGACTG-3’ 
• reverse primer 5’-TTTAGTCGCTGCATCACCTG-3’ 
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A 25μl PCR reaction mix contained 12.5μl of HotStarTaq Mastermix (Qiagen, UK), 1μl of 
each 100mM primer stock, 2μl of DNA sample and 8.5μl of water. PCR conditions were: 
15min at 95°C + 30 cycles (30s at 94°C, 30s at 52°C, 1min at 72°C) + 7min at 72°C. A 1.5μl 
aliquot of product was digested at 37°C with 0.3μl of HpyCH4III, 1.5μl of New England 
BioLabs Buffer 4 and 11.7μl of water, for at least 2hrs. Samples were electrophoresed for 
30min at 200V on a 3% agarose gel containing SybrSafe (Invitrogen, UK). Wild type samples 
produced 170bp and 120bp digest bands, and mutant samples a nondigested 290bp band. 
Stability of the mutation and the effectiveness of nitisinone were continuously monitored 
by stability of urinary and plasma HGA in treated and untreated AKU mice. No signs of 
reversion of the mutation have been observed in five years of breeding of the homozygous 
colony within University of Liverpool/Liverpool John Moores University.  
 
2.2.4 Treatment 
2.2.4.1 Nitisinone 
Nitisinone powder was obtained as a personal gift from Dr Edward Lock from original 
development batches supplied for research. Purity was confirmed by mass spectrometry 
analysis performed by the Department of Clinical Biochemistry and Metabolic Medicine at 
the Royal Liverpool University Hospital (RLUH). 
 
2.2.4.1.1 Preparation of nitisinone stock solution 
3.04M Nitisinone 
75mM NaHCO3 
To prepare 200ml: 
• 3g NaHCO3 to 30ml RNAase free water (Sigma, UK)  
• Swirled and placed in oven at 55oC  
• Once dissolved 200mg NTBC added, returned to oven 
• Once dissolved 170ml water added to make a 1mg/ml stock solution 
• 1ml aliquots into eppendorfs and frozen at -20oc  
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These 1ml stock solutions were then ready to add to 250ml water bottles to produce 4mg/L 
concentrations when required and facilitated simple further dilution to produce additional 
doses.  
 
2.2.4.1.2 Nitisinone - Morris water maze & motor function testing  
Two cohorts (1 WT, 1 Hgd-/-) of 12 female BALB/c mice were provided with an ad libitum 
supply of drinking water containing 4mg/L nitisinone. A further two cohorts (1 WT, 1 Hgd-/-
) of 12 female BALB/c mice acted as controls with no nitisinone treatment. All mice were 
aged between 12-24 weeks upon commencing treatment. A different set of mice were 
used to assess gait on the Catwalk XT platform. These consisted of two cohorts (WT n=8, 
Hgd-/- n=12) of male BALB/c mice and two cohorts (WT n=10, Hgd-/- n=7) of female BALB/c 
mice. 
 
2.2.4.1.3 Nitisinone - Long-term dose response study 
Four cohorts of seven male BALB/c Hgd -/- mice were administered nitisinone straight from 
weaning (aged 3 weeks) for a period of forty weeks. Cohorts were group housed and 
provided with an ad libitum supply of drinking water containing either 2mg/L, 0.5mg/L, 
0.125mg/L or 0mg (control) of nitisinone.  
 
2.2.4.1.4 Nitisinone - Arteriovenous metabolome study 
Twelve male BALB/c Hgd-/- mice were provided with an ad libitum supply of drinking water 
containing 4mg/L nitisinone for one week. Nine male BALB/c Hgd-/- mice acted as control 
and received no nitisinone treatment. All mice were aged between 18-36 weeks upon 
commencing treatment. 
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Mouse ID Genotype Sex Age 
(weeks) 
Experiment Treatment cohort 
CHgd 100.1 Hgd -/- F 23.8 MWM/Motor function 0mg Control 
CHgd 100.2 Hgd -/- F 23.8 MWM/Motor function 0mg Control 
CHgd 105.1 Hgd -/- F 21.3 MWM/Motor function 0mg Control 
CHgd 105.2 Hgd -/- F 21.3 MWM/Motor function 0mg Control 
CHgd 105.3 Hgd -/- F 21.3 MWM/Motor function 0mg Control 
CHgdJ 2.1 Hgd -/- F 22.0 MWM/Motor function 0mg Control 
CHgdJ 5.1 Hgd -/- F 20.7 MWM/Motor function 0mg Control 
CHgdJ 5.3 Hgd -/- F 20.7 MWM/Motor function 0mg Control 
CHgdJ 11.1 Hgd -/- F 14.9 MWM/Motor function 0mg Control 
CHgdJ 11.2 Hgd -/- F 14.9 MWM/Motor function 0mg Control 
CHgdJ 12.1 Hgd -/- F 13.3 MWM/Motor function 0mg Control 
CHgdJ 15.1 Hgd -/- F 12.3 MWM/Motor function 0mg Control 
CHgd 100.3 Hgd -/- F 24.6 MWM/Motor function NTBC 4mg/L 
CHgd 100.4 Hgd -/- F 24.6 MWM/Motor function NTBC 4mg/L 
CHgd 106.1 Hgd -/- F 21.3 MWM/Motor function NTBC 4mg/L 
CHgd 106.2 Hgd -/- F 21.3 MWM/Motor function NTBC 4mg/L 
CHgd 106.3 Hgd -/- F 21.3 MWM/Motor function NTBC 4mg/L 
CHgdJ 2.2 Hgd -/- F 22.0 MWM/Motor function NTBC 4mg/L 
CHgdJ 5.2 Hgd -/- F 20.7 MWM/Motor function NTBC 4mg/L 
CHgdJ 5.4 Hgd -/- F 20.7 MWM/Motor function NTBC 4mg/L 
CHgdJ 9.5 Hgd -/- F 15.7 MWM/Motor function NTBC 4mg/L 
CHgdJ 11.3 Hgd -/- F 14.9 MWM/Motor function NTBC 4mg/L 
CHgdJ 11.4 Hgd -/- F 15.9 MWM/Motor function NTBC 4mg/L 
CHgdJ 12.2 Hgd -/- F 13.3 MWM/Motor function NTBC 4mg/L 
CHgdJ 13.1 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.2 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.3 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.4 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.5 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.6 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 13.7 Hgd -/- M 3.0 LTDRS NTBC 2mg/L 
CHgdJ 22.1 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 24.1 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 24.2 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 26.1 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 26.2 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 26.3 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 26.4 Hgd -/- M 3.0 LTDRS NTBC 0.5mg/L 
CHgdJ 29.1 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 29.2 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 29.3 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 29.3 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 29.5 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
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CHgdJ 29.6 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 29.7 Hgd -/- M 3.0 LTDRS NTBC 0.125mg/L 
CHgdJ 30.1 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.2 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.3 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.4 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.5 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.6 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 30.7 Hgd -/- M 3.0 LTDRS 0mg Control 
CHgdJ 42.2 Hgd -/- M 38.4 Catwalk XT 0mg Control 
CHgdJ 42.3 Hgd -/- M 38.4 Catwalk XT 0mg Control 
CHgdJ 42.4 Hgd -/- M 38.4 Catwalk XT 0mg Control 
CHgdJ 47.1 Hgd -/- M 31.9 Catwalk XT 0mg Control 
CHgdJ 47.2 Hgd -/- M 31.9 Catwalk XT 0mg Control 
CHgdJ 47.3 Hgd -/- M 32.2 Catwalk XT 0mg Control 
CHgdJ 47.4 Hgd -/- M 32.2 Catwalk XT 0mg Control 
CHgdJ 47.5 Hgd -/- M 32.2 Catwalk XT 0mg Control 
CHgdJ 49.1 Hgd -/- M 28.5 Catwalk XT 0mg Control 
CHgdJ 49.2 Hgd -/- M 28.5 Catwalk XT 0mg Control 
CHgdJ 51.1 Hgd -/- M 17.5 Catwalk XT 0mg Control 
CHgdJ 51.2 Hgd -/- M 17.5 Catwalk XT 0mg Control 
CHgdJ 46.2 Hgd -/- F 33.7 Catwalk XT 0mg Control 
CHgdJ 46.3 Hgd -/- F 33.7 Catwalk XT 0mg Control 
CHgdJ 48.1 Hgd -/- F 32.5 Catwalk XT 0mg Control 
CHgdJ 48.2 Hgd -/- F 32.5 Catwalk XT 0mg Control 
CHgdJ 48.3 Hgd -/- F 32.5 Catwalk XT 0mg Control 
CHgdJ 50.1 Hgd -/- F 25.9 Catwalk XT 0mg Control 
CHgdJ 50.2 Hgd -/- F 25.9 Catwalk XT 0mg Control 
CHgdJ 38.1 Hgd -/- M 36.0 AV metab study 1 NTBC 4mg/L 
CHgdJ 38.2 Hgd -/- M 36.0 AV metab study 1 NTBC 4mg/L 
CHgdJ 38.3 Hgd -/- M 36.0 AV metab study 1 NTBC 4mg/L 
CHgdJ 38.4 Hgd -/- M 36.0 AV metab study 1 NTBC 4mg/L 
CHgdJ 38.5 Hgd -/- M 36.0 AV metab study 1 NTBC 4mg/L 
CHgdJ 41.1 Hgd -/- M 23.1 AV metab study 1 0mg Control 
CHgdJ 41.2 Hgd -/- M 23.1 AV metab study 1 0mg Control 
CHgdJ 41.3 Hgd -/- M 23.1 AV metab study 1 0mg Control 
CHgdJ 42.1 Hgd -/- M 18.1 AV metab study 1 0mg Control 
CHgdJ 43.3 Hgd -/- M 24.6 AV metab study 2 0mg Control 
CHgdJ 44.1 Hgd -/- M 23.0 AV metab study 2 0mg Control 
CHgdJ 44.2 Hgd -/- M 28.9 AV metab study 3 NTBC 4mg/L 
CHgdJ 44.3 Hgd -/- M 28.9 AV metab study 3 NTBC 4mg/L 
CHgdJ 46.1 Hgd -/- M 25.4 AV metab study 3 NTBC 4mg/L 
CHgdJ 59.1 Hgd -/- M 18.6 AV metab study 4 0mg Control 
CHgdJ 59.2 Hgd -/- M 18.6 AV metab study 4 NTBC 4mg/L 
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CHgdJ 59.3 Hgd -/- M 18.6 AV metab study 4 NTBC 4mg/L 
CHgdJ 59.4 Hgd -/- M 18.6 AV metab study 4 NTBC 4mg/L 
CHgdJ 52.1 Hgd -/- M 29.6 AV metab study 4 NTBC 4mg/L 
CHgdJ 55.1 Hgd -/- M 20.7 AV metab study 4 0mg Control 
CHgdJ 55.2 Hgd -/- M 20.7 AV metab study 4 0mg Control 
WT BC/J 5.1 WT F 13.1 MWM/Motor function 0mg Control 
WT BC/J 5.2 WT F 13.1 MWM/Motor function 0mg Control 
WT BC/J 5.3 WT F 13.1 MWM/Motor function 0mg Control 
WT BC/J 5.4 WT F 13.1 MWM/Motor function 0mg Control 
WT BC/J 5.5 WT F 13.1 MWM/Motor function 0mg Control 
WT BC/J 8.1 WT F 24.0 MWM/Motor function 0mg Control 
WT BC/J 8.2 WT F 24.0 MWM/Motor function 0mg Control 
WT BC/J 10.1 WT F 21.6 MWM/Motor function 0mg Control 
WT BC/J 10.2 WT F 21.6 MWM/Motor function 0mg Control 
WT BC/J 10.3 WT F 21.6 MWM/Motor function 0mg Control 
WT BC/J 10.4 WT F 21.6 MWM/Motor function 0mg Control 
WT BC/J 10.5 WT F 21.6 MWM/Motor function 0mg Control 
WT BC/J 6.1 WT F 13.1 MWM/Motor function NTBC 4mg/L 
WT BC/J 6.2 WT F 13.1 MWM/Motor function NTBC 4mg/L 
WT BC/J 6.3 WT F 13.1 MWM/Motor function NTBC 4mg/L 
WT BC/J 6.4 WT F 13.1 MWM/Motor function NTBC 4mg/L 
WT BC/J 6.5 WT F 13.1 MWM/Motor function NTBC 4mg/L 
WT BC/J 8.3 WT F 24.0 MWM/Motor function NTBC 4mg/L 
WT BC/J 8.4 WT F 24.0 MWM/Motor function NTBC 4mg/L 
WT BC/J 8.5 WT F 24.0 MWM/Motor function NTBC 4mg/L 
WT BC/J 8.6 WT F 24.0 MWM/Motor function NTBC 4mg/L 
WT BC/J 12.1 WT F 18.6 MWM/Motor function NTBC 4mg/L 
WT BC/J 13.1 WT F 18.4 MWM/Motor function NTBC 4mg/L 
WT BC/J 13.2 WT F 18.4 MWM/Motor function NTBC 4mg/L 
WT BC/J 36.1 WT F 44.0 Catwalk XT 0mg Control 
WT BC/J 36.2 WT F 44.0 Catwalk XT 0mg Control 
WT BC/J 36.3 WT F 44.0 Catwalk XT 0mg Control 
WT BC/J 36.4 WT F 44.0 Catwalk XT 0mg Control 
WT BC/J 39.1 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 39.2 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 39.3 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 39.4 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 39.5 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 39.6 WT F 41.1 Catwalk XT 0mg Control 
WT BC/J 44.1 WT M 17.3 Catwalk XT 0mg Control 
WT BC/J 44.2 WT M 17.3 Catwalk XT 0mg Control 
WT BC/J 44.3 WT M 17.3 Catwalk XT 0mg Control 
WT BC/J 44.4 WT M 17.6 Catwalk XT 0mg Control 
WT BC/J 46.1 WT M 12.6 Catwalk XT 0mg Control 
WT BC/J 46.2 WT M 12.6 Catwalk XT 0mg Control 
WT BC/J 46.3 WT M 12.6 Catwalk XT 0mg Control 
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WT BC/J 46.4 WT M 12.6 Catwalk XT 0mg Control 
 
Table 2.1 – Details of individual BALB/c mice used within this thesis. Age in weeks 
indicates age at commencement of treatment. MWM/Motor function and Catwalk XT – 
chapter 3. Long-term dose response study (LTDRS) – Chapter 4. Arteriovenous metabolome 
studies (AV Metab Study 1-4) – Chapter 5. 
 
 
2.3 PLASMA SAMPLING 
2.3.1 Venous tail bleeds 
To measure plasma metabolites mid-study, plasma samples were obtained from tail bleeds. 
Mice were warmed in an incubator (mediHEAT, Peco Services, UK) at 37OC for 
approximately 5 minutes to aid with vasodilation prior to sample collection. Mice were 
then eased into a Broome style rodent restrainer (Plas Labs™) to minimise distress and risk 
of injury. A shallow incision was made to one of the lateral caudal tail veins with a sterile 
scalpel blade and a blood sample collected. These were collected into microvette collection 
tubes (Sarstedt, CB 300) and stored at 4 OC prior to processing within 2 h, using an 
adaptation of the Bory method [29, 104]. Briefly, whole blood was centrifuged at 1500g for 
10 min at 4OC and the plasma deproteinised by adding 5.8 M perchloric acid (Sigma, UK) 
equivalent to 10% of the plasma volume. Acidified supernatant was stored at -20OC. 
Volumes of blood taken were kept within Home Office limits. This is a maximum of 15% 
total blood volume within one month and a maximum of 10% total blood volume within 
any one bleed. We calculated our samples using a lower blood volume of 65ml/kg body 
weight and the minimum body weight within each study to ensure the blood removal was 
below the limits. Tail bleeds were approximately 50- 70 µl, giving 15µl acidified plasma. 
 
2.3.2 Terminal bleeds 
Immediately after culling, an incision was made within the left axilla and blood collected 
from the underlying brachial vessels into monovette collection tubes (Sarstedt, S-
monovette® K3E). These were stored at 4OC prior to processing within 2 h, using the same 
method as detailed above. 
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2.3.3 Morris water maze and motor function assessment (chapter 3)  
Tail bleed samples were collected after 2 weeks to measure metabolites and confirm 
efficacy of nitisinone treatment prior to commencing behavioural and motor function 
studies. Efficacy of nitisinone in treated Hgd-/- and wild type mice was indicated by 
elevated tyrosine. Hgd-/- treated mice would also show a reduction in plasma HGA. 
 
2.3.4 Long-term dose response study (chapter 4) 
Mid-term tail bleeds were collected at 20 weeks and terminal bleeds collected at 40 weeks. 
 
2.3.5 Arteriovenous metabolome study (chapter 5) 
Consecutive tail bleed samples were collected immediately followed by culling 
(pentoject/cervical dislocation) and terminal bleed sample collection. 
 
2.3.6 Analysis of plasma metabolites 
The concentrations of plasma tyrosine, HGA, phenylalanine, HPPA and HPLA were 
measured by liquid chromatography tandem mass spectrometry. All analyses were 
performed on an Agilent 6490 Triple Quadrupole mass spectrometer with Jet-Stream® 
electrospray ionisation (ESI-MS/MS) coupled with an Agilent 1290 infinity UHPLC pump and 
HTC autosampler. This method incorporates reverse-phase chromatographic separation on 
an Atlantis C18 column (100mmx3·0mm, 3µm). Initial conditions of 80:20 water:methanol 
with 0.1% formic acid (v/v) increased linearly to 10:90 over five minutes. Matrix-matched 
calibration standards and quality controls were utilised with appropriate isotopically 
labelled internal standards. Quantitation was achieved in multiple reaction mode (MRM) 
with two product ion transitions for both tyrosine (positive ionisation) and HGA (negative 
ionisation). Samples were prepared by dilution in a combined internal standard solution 
(final concentrations of 0.4µmol/L 13C6-HGA and 2µmol/L d2-tyrosine in 0.1% formic acid 
(v/v) in deionised water). All quantitation analyses were performed by the Department of 
Clinical Biochemistry and Metabolic Medicine at the Royal Liverpool University Hospital 
(RLUH). A detailed protocol of analysis is described by Hughes et al [28].  
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2.4 SCHEDULE 1 HUMANE CULLING METHODS 
All mice were humanely killed using methods detailed under Schedule 1 of the Animals 
(Scientific Procedures) Act 1986 [181] with all persons carrying out the procedure having 
received prior training and deemed confident and competent in using the specified 
techniques. 
 
2.4.1 Pentoject (pentobarbitone) overdose 
Mice were euthanised by lethal dose of Pentoject (sodium pentobarbitone 20% w/v) 
administered intraperitoneally to minimise any distress. This led to rapid loss of 
consciousness and death by respiratory arrest within 3-5 minutes. Death was confirmed via 
cervical dislocation. 
 
2.4.2 Cervical dislocation 
Mice were manually euthanised by pressing a rod at the base of the skull and pulling the 
animal backwards to sever the spinal cord at the base of the brain resulting in rapid loss of 
consciousness and death. The use of this method was necessary within the arteriovenous 
metabolome study to ensure no pharmacological method of culling would affect blood 
metabolites. 
 
2.5 HARVESTING OF THE TIBIO-FEMORAL JOINT 
Once mice were confirmed dead, the skin was removed from the hind limbs exposing the 
full anatomy of the joint. The surround leg musculature was dissected away and the joint 
dissected out by cutting close to the femoral head. The tibia was then cut above the ankle 
to leave a complete tibio-femoral joint. The joint was rinsed in phosphate buffered saline 
(PBS) and fixed with 10% phosphate buffered formalin solution (PBFS) prior to 
decalcification and embedding.  
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2.6 HISTOLOGY   
2.6.1 Reagents 
Potassium ferricyanide, ferric chloride, and nuclear fast red (NFR) were purchased from 
VWR, UK. Ethylenediaminetetraacetic acid (EDTA), chromic potassium sulphate, bovine 
gelatine and DPX mounting medium were purchased from Sigma, UK. Premium frosted 
glass slides and 50mm cover slips were purchased from VWR, UK. Histological methods 
were followed as published in a paper by Keenan et al [72]. 
 
2.6.2 Tissue fixation 
Carcasses of mice used in the behavioural and motor function studies (chapter 3) and long-
term dose response study (chapter 4) were fixed to enable future analysis of tissues if 
necessary. Tissues harvested were immediately fixed in 10% phosphate buffered formalin 
solution (PBFS) at room temperature to prevent autolysis. PBFS was changed regularly 
when pH indicator showed acidosis to maintain fixation. The amount of fixative used was 
generally 15-20 times greater than the tissue volume.  
 
2.6.2.1 Preparation of PBFS 
10mM Sodium phosphate dibasic (Na2HPO4) 
32mM Potassium phosphate (KH2PO4) 
123mM Sodium chloride (NaCl) 
3.7% (v/v) Formaldehyde 
To prepare 2.5L:  
• 250ml of Formaldehyde (37% w/v) 
• 250ml of phosphate buffered solution (PBS) (10x) 
• 2000ml distilled water 
• pH adjusted to 7.2-7.4 
• Few drops of phenol red (pH indicator, 0.01% in water) added and solution mixed. 
Phenol red is orange/pink at neutral pH, purple if alkaline and yellow when acidic. 
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2.6.3 Decalcification of mineralised tissue 
Decalcification is the process of removing calcium from mineralised tissue. This was 
necessary to section and analyse the tibio-femoral joints from mice within the long-term 
dose response study (chapter 4). Decalcification was performed using 12% EDTA, a 
chelating agent that binds calcium. 
 
2.6.3.1 Preparation of decalcifying solution 
12% (w/v) EDTA 
To prepare 2.5L: 
• 300g of EDTA 
• 2000ml d.H2O 
• Few drops of phenol red indicator added and solution mixed 
• pH adjusted to 8 to dissolve EDTA (NaOH pellets) 
• Once dissolved pH was adjusted to 7.2–7.4 
• Solution was then made up to a final volume of 2500ml 
 
Following fixation, mineralized tissues were placed into EDTA for an initial period of 24hrs. 
The EDTA solution was then changed and tissues left to decalcify for a further 6 days. 
Decalcification was complete when tissues were flexible and soft enough to bend. 
 
2.6.4 Processing of tissue 
Following decalcification, the tibio-femoral joints were removed from EDTA and washed 
several times with PBS. They were then processed, first through increasing grades of 
ethanol (70% (15mins), 90% (30mins), and 100% (x4) (1hr)) to dehydrate the tissue. Once 
dehydrated, tissues were cleared using two changes of xylene (45 minutes in each) before 
being passed through two changes of paraffin wax (1hr in each) to complete the 
processing. Processing was performed using a Leica TP1020 tissue processor (Leica, 
Germany). 
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2.6.5 Embedding of tissue 
Following processing, the tibio-femoral joints were placed into heated metallic moulds, 
submerged in molten paraffin wax and embedded in the coronal plane to enable 
simultaneous evaluation of the medial and lateral surfaces as recommended by the 
Osteoarthritis Research Society International (OARSI) histopathology initiative [105]. A 
plastic chuck was placed on top of the mould to allow sectioning of the block. Blocks were 
cooled to solidify and then removed from their metallic mould. 
 
2.6.6 Sectioning of tissue 
Tissue blocks were cut to remove excess wax, and shaped to have a trapezoid cutting 
surface. Blocks were initially trimmed at 10μm until the tissue could be viewed through the 
block. Sections were then taken every 5μm before being mounted on subbed slides and 
placed in an incubator at 50oC overnight. Sections from the knee joints of all mice were 
taken every 5μm from posterior to anterior until the whole joint had been sectioned. 
Blocks were sectioned using a Leica RM2245 semi-automated microtome (Leica, Germany). 
 
2.6.7 Subbing of slides 
Microscope slides were subbed with a gelatine solution to help sections adhere to the slide. 
 
2.6.7.1 Preparation of subbing solution 
0.1% (w/v) Bovine gelatine 
0.35mM Chromic potassium sulphate 
To prepare 400ml: 
• 400ml distilled water 
• 0.8g type B bovine gelatine 
• Gelatine dissolved in distilled water with heat – not exceeding 50oC 
• 0.08g chromic potassium sulphate added when gelatine dissolved 
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2.6.7.2 Subbing procedure 
• Slides rinsed in 100% ethanol for 30 seconds 
• Left to dry for 5 minutes 
• Slides then immersed in subbing solution for 30 seconds 
• Dried overnight at room temperature – cover slides to prevent dust building up 
 
2.6.8 Tissue staining 
2.6.8.1 Schmorl’s stain 
Schmorl’s stain demonstrates reducing substances in paraffin sections such as melanin, 
which reduce ferricyanide to ferrocyanide, producing varying shades of blue with a positive 
result. Melanin and ochronotic pigment are proposed to have similar structures and are 
both derived from the tyrosine catabolic pathway. By modifying the procedure to include a 
longer incubation time, Schmorl’s stain has been shown to identify the presence of 
ochronotic pigmentation in murine and human tissues [106]. 
 
2.6.8.1.1 Preparation of Schmorl’s incubating solution  
46mM Ferric chloride 
3mM Potassium ferricyanide 
To prepare 50ml: 
• 0.5g Ferric chloride in 50ml d.H2O (1%) 
• 0.1g Potassium ferricyanide in 10ml d.H2O (1%) 
• Add 37.5ml ferric chloride solution to 5ml potassium ferricyanide solution. 
• Make up to 50m with d.H2O  (7.5ml) 
This solution was used fresh and prepared immediately before use. 
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2.6.8.1.2 Schmorl’s staining procedure 
• Slides were deparaffinised in two changes of xylene - 5 minutes in each 
• Hydrated through ethanol (100%, 100%, 70%, 70% - 2 minutes in each) to water 
• Immersed in Schmorl’s stain for up to 15 minutes 
• Washed well in running cold water to remove any residual ferricyanide 
• Treated with 1% acetic acid for 5 minutes to prevent over-staining 
• Counterstained in nuclear fast red (NFR) for 3-5 minutes 
• Washed in running cold water to remove any residual NFR 
• Dehydrated through ethanol (70%, 70%, 100%, 100% - 2 minutes in each) 
• Cleared in two changes of xylene - 3 minutes in each 
• Mounted with DPX and left to dry 
 
2.7 HISTOLOGICAL ANALYSIS 
2.7.1 Tibio-femoral joints from long-term dose response study (chapter 4) 
The first ten sections that encompassed both the medial and lateral tibial plateaus and 
femoral condyles were selected as representative for each mouse, stained and analysed via 
light microscopy. 
 
2.7.2 Light microscopy 
Tibio-femoral joint pigmentation quantification was carried out using a Nikon Eclipse Ci 
microscope fitted with a Ds-Fi2 camera. A Zeiss Axio Imager 2 was used for acquiring 
panoramic images. NIS Br elements was used for image analysis. 
 
2.7.3 Quantification of ochronotic pigmentation  
From the stained sections, the most complete section that included the entire tibio-femoral 
joint was selected for quantification. The total number of pigmented chondrons present in 
the articular calcified cartilage and entheses of the femoral condyles, tibial plateaus and 
intercondylar regions was quantified (Fig. 2.1). Two sections from each cohort were 
quantified by a second blinded observer to assess inter-observer reliability. As previously 
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demonstrated by Preston et al [70], pigmentation can be classified via staging -  early stage, 
peri-pigmentation of the peri-cellular matrix forming a halo around chondrocytes and later 
stage, cellular pigmentation with advancement into the cellular compartment and dark 
staining of the nuclei of the chondrocytes (Fig. 2.2). In consideration of this, two counts for 
each section was carried out. The first included just later stage cellular pigmentation and 
the second included peri-pigmented and cellular pigmented chondrocytes combined. 
 
 
 
Figure 2.1 - Area of ochronotic pigmentation quantification in the mouse tibio-femoral 
joint. The area inside the red line was quantified encompassing the articular calcified 
cartilage of the medial and lateral tibial plateaus, femoral condyles and entheses. 
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Figure 2.2 - Classification of pigmentation for quantification of pigmented chondrons in 
the BALB/c Hgd-/- tibio-femoral joint. White arrow: unpigmented chondrocyte. Red arrow: 
Peri-pigmentation in the peri-cellular matrix forming a halo around chondrocytes of the 
articular calcified cartilage. Black arrow: Cellular pigmentation showing advancement into 
the cellular compartment and dark staining of the nuclei. Bar:20um. Stained with Schmorls. 
 
 
2.8 REDUCTION OF MOUSE ANXIETY 
A visit to the University of Liverpool’s Leahurst animal campus was arranged to speak with 
Professor Jane Hurst, Head of Mammalian Behaviour & Evolution at the Institute of 
Integrative Biology. Professor Hurst is widely regarded in the field of animal behaviour and 
has published several methods to aid in reduction of handling related anxiety in mice [106-
108]. Her methods include the use of handling tubes and cupping methods instead of the 
usual laboratory method of tail handling which can be aversive and impair reliability of 
behavioural test results. The use of handling tubes and cupping was implemented for all 
mice within this thesis. Prior to testing, mice were handled daily for 2 weeks to reduce 
anxiety during testing. This was carried out within the testing room to ensure they also 
became used to being transported from their home room. For each day of behavioural, 
motor function and gait analysis testing, mice were transported to the testing room and 
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allowed to acclimatise to their surroundings for 30 minutes prior to beginning trials. Lights 
were dimmed or switched off as testing took place during the mice’s dark cycle (most 
active period). Noise was kept to a minimum and no other person was permitted to enter 
the room during testing to minimise aversive stimulus.  
 
2.9 MOUSE IDENTIFICATION 
Mice were both tail and ear marked to ensure easy recognition during testing. Tails were 
marked with non-toxic marker. Mice were submerged in water during Morris water maze 
trials so tail marking was repeated daily before beginning trials. Ears were also marked 
using an ear punch (Interfocus, UK) to ensure mice were distinguishable if tail marks had 
faded. 
 
2.10 MORRIS WATER MAZE 
2.10.1 Introduction 
The Morris water maze (MWM) is a widely accepted behavioural task for assessing spatial 
learning and memory in rodents, originally developed by Richard Morris in 1981 at the 
University of St Andrews (82, 83). During the MWM task, the use of external visual cues 
aids the rodent in determining the location of a submerged platform from varying starting 
positions within a circular pool of water (Fig. 2.3, Fig 2.4). The use of external navigatory 
cues allows for the allocentric processing of the hippocampus and entorhinal cortex to be 
tested. The task involves a number of consecutive days of training followed by a probe test 
on the final day to assess the consolidation and retrieval of memory. Performance and 
analysis of the test is automated by tracking and analysis software which measures 
parameters such as path latency, path length and swim speed. 
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2.10.2 MWM equipment 
MWM equipment was obtained from HVS image (Buckinghamshire, UK) unless otherwise 
stated and included: 
• Tracking and analysis software (HVS image 2014 for Windows) 
• Laptop with Microsoft Windows operating system (Toshiba, Japan) 
• Large area high resolution camera with varifocal lens and ceiling mount 
• Long-range wireless mouse 
• Black polypropylene seamless pool, 150cm diameter, height 60cm  
• Clear platform, diameter 10cm, height 29.5cm with stable 30x30cm base 
• Curtains to mount around pool area to minimise additional spatial cues 
• Water pump to empty pool (Karcher GP40, Amazon, UK) 
• 200 watt thermostat water heater (Eheim, Germany) 
• 3D high contrast visual cues to mount around pool during hidden trials – small 
plastic chair, large inflatable ball, large 3 gallon plastic bucket, 1m long cylindrical 
tube (Amazon, UK) 
• Digital thermometer (Andrew James, Amazon, UK) 
• Flexible PVC tubing to fill pool (Amazon, UK) 
• Milton sterilising liquid (P&G, UK) 
• Pool tester kit for the measurement of pH and Chlorine (OPC, UK) 
• Red warming lamp (Ecoglow 20, Brinsea, UK) 
• 4 x 50 watt floor lamps (GU10, ML Accessories Ltd, UK) to provide diffuse lighting 
and minimised reflections in pool. 
 
2.10.3 Health and safety 
Before beginning MWM trials, time was taken to ensure the equipment set up met health 
and safety standards. As several electrical devices (water heater, pump and floor lamps) 
were being used in an area with a large pool of water, steps had to be taken to minimise 
risk of injury to mice and users of the animal facility including fitting residual circuit 
breakers to all plugs and taping down all trip hazards with high contrast tape. The head of 
health and safety and estate management inspected the test area to ensure all 
precautionary measures had been taken and these departments were liaised with 
regularly. As the probe test of the Morris water maze experiment had to be performed on a 
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Saturday, out of hours access had to be authorised by the Dean and head of security 
services and further health and safety assessment completed. 
 
2.10.4 Preparation of MWM pool 
At the beginning of a test week, the pool was filled with tap water and a water temperature 
of 24-26oC reached. Mice are prone to stress from hypothermia therefore it was crucial this 
temperature was maintained throughout testing. Water temperature was maintained 
overnight via the use of a water heater with thermostat. Filling the pool took approximately 
one hour due to the large quantity of water required to reach a depth of 28 cm. A body of 
water at this temperature poses a risk of Legionella therefore Milton sterilising liquid was 
added and the pH and chlorination of the pool assessed daily to ensure a safe environment 
for mice and other users of the animal facility. The pool water was also cleaned of visible 
debris multiple times a day during testing and thoroughly cleaned with ethanol solution 
once emptied with a water pump on a weekly basis.    
 
2.10.5 MWM testing procedure 
2.10.5.1 General information 
To enter the pool, each mouse was gently lifted and placed onto the arm of the 
experimenter to carry them to the pool. To begin a trial, the mouse was gently placed into 
the water immediately facing the perimeter (away from centre of pool) in the required 
starting position. The experimenter immediately started the tracking software by clicking 
the wireless mouse whilst quickly leaving the pool area to avoid becoming a spatial cue. 
Each mouse performed five trials per day during visible and hidden platform tasks and was 
allowed a maximal time of 90 seconds to locate the platform. Finding the platform was 
defined as staying on it for at least two seconds; mice that crossed the platform without 
stopping were left to swim. Mice that located the platform were left on the platform for 15 
seconds before being retrieved. When mice did not locate the platform in the maximal time 
allowed, they were gently guided to it using a hand and allowed to independently climb 
onto it and spend 15 seconds on the platform before being retrieved - these mice were 
assigned a latency of 90 seconds. The starting time of the experiment was kept constant 
each day for all cohorts. Between individual trials, mice were given an inter-trial interval of 
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15 minutes and placed under a red warming lamp to minimise fatigue and risk of 
hypothermia.   
 
2.10.5.2 Visible platform task (day 1) 
During visible platform trials, a high contrast black and yellow striped flag was mounted 
onto the platform within the pool with the platform itself being 1.5cm higher than the 
water level. The visible platform task enabled the mouse to learn the task of finding and 
mounting the platform, associating it as the goal (escape route), whilst ensuring the mice 
had no visual or motor impairments that could affect the subsequent days of the 
experiment. During the visible platform task, the entry point remained the same whilst the 
platform position within the pool was varied for each of the five trials (Table 2.1). 
 
2.10.5.3 Hidden platform task (day 2-5) 
Before beginning hidden platform trials, 3D visual cues were mounted around each side of 
the pool to aid with spatial navigation. The striped flag was removed from the platform and 
the pool was filled with additional water to submerge the platform by 5-8 millimetres to 
ensure it was hidden. Hidden platform trials took place over four days with each mouse 
performing five trials per day. The platform location was fixed but the mouses entry point 
was varied (Table 2.1). In total, each mouse performed twenty hidden platform trials over 
the four hidden platform testing days. Performance during training was measured by 
escape latency, swimming speed and path distance. 
 
2.10.5.4 Probe test (day 6) 
The probe test was completed around 20 hours after the final hidden platform trial on the 
following day. The platform was removed from the pool and each mouse completed a 
single, 30 second trial entering the pool diagonally opposite from where the platform was 
previously located. The probe trial is an important assessment of any spatial learning that 
has taken place over the previous four days testing and also tests long term memory 
consolidation and retrieval. Preference and increased time spent in the target quadrant is 
indicative that the mouse was able to memorise and recall the location of the platform. 
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Spatial retention in the probe trial was measured by the percentage of total time spent in 
each quadrant and a proximity measure of average distance to platform site (Gallagher’s 
measure). 
 
 
 Day 1 
(Visible) 
Day 2 
(Hidden) 
Day 3 
(Hidden) 
Day 4 
(Hidden) 
Day 5 
(Hidden) 
Day 6 
(Probe) 
 Platform 
location 
Starting 
direction 
Platform location: SW  
Starting direction as follows: 
No 
platform 
Trial 1 Centre S E SE E N NE 
Trial 2 NE S NE N NW E  
Trial 3 SE S NW NW NE S  
Trial 4 SW S SE NE N W  
Trial 5 NW S N E SE N  
Table 2.2 - Platform location and starting directions for the Morris water maze 
behavioural experiment. Starting directions were changed quasi-randomly. During hidden 
platform trials when the platform is fixed in the SW quadrant, starting directions in close 
proximity to this quadrant (S, W, SW) are initially unused as this increases the chance of 
mice finding the platform by merely bumping into it. 
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Figure 2.3 – Morris water maze pool quadrants, platform location and cardinal/ordinal 
compass point starting positions. Automated tracking software analyses the mouse’s 
position with the four pool quadrants. 
 
Figure 2.4 – Morris water maze equipment set up. High contrast 3D spatial cues are 
mounted around the pool during hidden platform trials to aid with spatial navigation to 
the submerged platform. Image edited and reused from Wikimedia commons [87] 
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2.11 MOTOR FUNCTION ASSESSMENT 
2.11.1 Rota-rod 
2.11.1.1 Introduction 
The rota-rod test is used to assess motor coordination and balance in rodents. Mice must 
maintain their balance to stay on a rotating rod that continuously accelerates at a speed of 
4 rotations per minute (rpm) to 40rpm over 300 seconds. The rota-rod consists of five 3cm 
diameter cylinders with six 25cm diameter dividers to form five lanes, each 5.7cm wide, 
enabling five mice to be tested simultaneously. The height to fall is 16cm and the rod is 
textured to ensure the mice can maintain an adequate grip. When a mouse falls off its 
cylindrical section of the rod onto the plate below, the plate trips and the corresponding 
magnetic switch is activated, thereby recording the latency to fall in seconds (Fig. 2.5).  
 
2.11.1.2 Rota-rod equipment  
• Rota-rod (4700, Ugo Basile, VA, Italy) 
• 50% EtOH to clean apparatus after each use 
• Blue tissue roll 
 
2.11.1.3 General information 
Motor function testing was carried out one week after mice completed MWM trials to 
minimise effects of fatigue. Mice were acclimatised to the rota-rod apparatus prior to 
testing by completing 3 trials whilst the rod rotated at 4rpm for 1-2 minutes at hourly 
intervals the day prior to testing. This allowed mice to become accustomed to the task and 
minimised anxiety related effects on performance. Mice completed three days of rota-rod 
testing with three trials per day, each separated by a 15 minute inter-trial interval. It was 
possible to run the next batch of mice consecutively in one trial before moving to the next.  
 
2.11.1.4 Positioning mice on the Rota-rod  
The mice could not be lowered directly onto the rota-rod from above as they would spread 
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their legs and block entry between the discs. It was therefore necessary to use a method 
whereby the mice were flipped up onto the rod by the tail, landing right side up but dorsal 
side in first between the rotating discs. This technique was innocuous for test subjects and 
was perfected using wild type mice prior to testing. 
 
2.11.1.5 Testing procedure 
The rota-rod was set to accelerating mode with the rod initially rotating at a constant 
speed of 4rpm to allow positioning of all the mice in their respective lanes. Once mice were 
positioned walking forwards, the start button was pressed and the rod began accelerating 
from 4 rpm to 40 rpm over 300 seconds. When mice fell, the latency to fall was 
automatically recorded then transferred onto the data sheet. During testing, if a mouse 
gripped the rod and completed a full passive rotation, the fall plate was tripped by the 
experimenter to stop the timer for that mouse as passive rotation was considered a failure 
in performance akin to falling. After each set of five mice had completed a trial, the 
apparatus was cleaned with water then 50% ethanol solution and wiped dry prior to testing 
the next set. 
 
 
Figure 2.5 - Rota-rod apparatus (4700, Ugo Basile, Italy). 
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2.11.2 Inverted grid suspension test 
The inverted grid suspension test (IGST) is a widely used, non-invasive general measure of 
grip strength. The test measures the ability of the mouse to remain clinging to an inverted 
wire mesh grid suspended a small distance above a soft surface (Fig. 2.6). 
 
2.11.2.1 Inverted grid suspension test equipment 
• Clear hollow acrylic cylinder, 30cm long x 20cm diameter 
• Wire mesh with 1 cm2 grids 
• Stopwatch 
• Soft rodent bedding to cushion fall 
• 50% EtOH to clean apparatus after each use 
• Blue tissue roll 
 
 
 
Figure 2.6 – Inverted grid suspension test apparatus set up. 
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2.11.2.2 Testing procedure 
Mice were placed in the cylinder topped with the wire mesh. Once mice had a sustained 
grip, the cylinder was slowly inverted onto the table top so that mice were suspended from 
the grid. Rodent bedding was positioned under the cylinder to cushion the fall. The 
stopwatch was started as soon as the cylinder was inverted and the latency to fall 
recorded. Mice completed three trials with a 1 minute inter-trial interval. A maximal 
hanging time of 180 seconds was allowed and the mean of the three trials analysed. 
Apparatus was thoroughly cleaned after each mouse had completed three trials.  
 
2.12 CATWALK XT GAIT ANALYSIS 
2.12.1 Introduction 
The CatWalk XT platform is a computer-assisted automated quantitative gait analysis 
system that allows simultaneous quantification of a large number of both static and 
dynamic gait parameters during voluntary walking. It consists of an enclosed walkway on a 
glass plate that is traversed by a mouse from one side of the walkway to the other. Green 
light enters at the long edge of the glass plate and is completely internally reflected. Light is 
able to escape only at those areas where the animal's paws make contact with the glass 
plate; as a result, the light is scattered which results in illumination of the exact area of 
contact (Fig 2.7). The image is captured by the camera and stored on a computer for 
analysis. 
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Figure 2.7 – The catwalk XT platform and illumination of footprints in a mouse traversing 
the glass walkway. 
 
 
2.12.2 Mice 
The Catwalk XT gait analysis platform assessed a cohort of 19 BALB/c Hgd-/- mice (12 male, 
7 female) and a separate control cohort of 18 BALB/c wild type mice (8 male, 10 female) to 
investigate whether any significant differences in gait were present between genotypes 
prior to treatment with nitisinone. Mice within this study received no treatment with 
nitisinone as we wished to assess whether joint ochronosis affected gait in the Hgd-/- mice, 
as observed in human AKU patients. Hgd-/- cohorts age ranged between 17 to 39 weeks, as 
by this age the ochronotic phase of the disease is observed within the joints of these mice 
[70]. 
 
2.12.3 Bodyweight 
Bodyweight was measured daily during testing using weighing scales and the average 
weight used for analysis. 
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2.12.4 Equipment 
• Catwalk XT system (10.6, Noldus, Netherlands) including high speed camera 
• Computer running Microsoft Windows and Catwalk 10.6 analysis software 
• 1% EtOH to clean apparatus after each use 
• Blue tissue roll 
• Microfibre glass cleaning cloth 
 
 
2.12.5 General information 
The walkway area was defined and software calibrated for mouse footprint analysis prior 
to beginning gait analysis. This was only necessary to complete once as the layout of the 
walkway and the calibration was stored within the application. Each mouses identification 
number (eg Hgd-/- 40.4, WT 35.6) and group (eg Hgd-/- female, WT male) was inputted 
prior to beginning acquisition so each mouse could be easily selected and run data 
acquired. It was essential to ensure the glass walkway was clean and free of streaks for 
every recorded run as even small smears or dirt particles would affect the scattering of 
light resulting in erroneous recording of paw prints. Each mouse was required to perform 
three compliant trials (see below) with the most consistent run selected for grouped 
analysis. Catwalk XT software automatically performed all data analysis. 
 
2.12.6 Training procedure 
Before acquiring runs, mice needed to learn to cross the walkway without interruptions 
(such as stopping or rearing on to its hindlimbs) so all animals started from a similar 
baseline, this was considered a “compliant run”. This was important in order to be able to 
compare different runs and pick up gait abnormalities that were the result of effects of 
treatment or in this case, genotype, rather than differences in quality of runs. Mice were 
habituated to the CatWalk system by individually placing them in the corridor for 1 minute 
over a number of consecutive days until they freely explored the walkway.  One week prior 
to starting gait analysis, mice were trained to run across the glass plate with a minimum of 
three runs per day. This was achieved by placing a goal box at the end of the walkway with 
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bedding and littermates from the mouses home cage to act as a olfactory stimulatory cue. 
In total, training took place over a two week period prior to beginning gait analysis. 
 
2.12.7 Test procedure 
In the Experiment Explorer, under Acquisition, the corresponding trial for the mouse being 
tested was highlighted and Acquire Runs selected. The Snap Background button was 
selected to acquire a background image of the empty, clean walkway – this step had to be 
completed before every trial so data acquisition could take place. Start Acquisition was 
selected and the apparatus was then ready to begin data acquisition indicated by the 
Status changing to “waiting for run to start”. The mouse was placed into the corridor from 
the side with acquisition starting automatically as soon as the animal’s contour was 
detected. The Status changed to ‘recording Run#’. More than one compliant run could be 
acquired by either taking the animal out of the corridor and placing it back in on the other 
side or by letting it turn around independently and run the opposite way along the 
walkway. When the set number of compliant runs has been acquired, the Acquisition 
Finished Tasks dialogue window opened and the next trial for the corresponding next 
mouse could be selected. 
 
2.12.8 Run classification 
Acquired runs had to be reviewed and footprints classified prior to analysis. Footprint 
classification could be automated or manual. All prints were automatically classified and 
then reviewed, with any wrong prints reclassified manually (Fig. 2.8). 
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Figure 2.8 – Footprint classification after data acquisition in the Catwalk XT platform. 
Prints were automatically classified and then reviewed to detect erroneous prints, which 
could then be manually corrected. White arrow indicates an erroneous left hindlimb (LH) 
print that was deleted and reclassified.  
 
 
2.12.9 Catwalk gait analysis parameters 
The following parameters were selected for analysis to enable comprehensive assessment 
of gait in the Hgd-/- and wild type mice:  
 
2.12.9.1 Static parameters 
• Regularity index: measurement of interlimb coordination. Expresses the number of 
normal step sequence patterns relative to the number of paw placements. This 
parameter can be used for the assessment of ataxia. 
• Stride length: distance between successive placements of the same paw. Stride 
length must be the same for all limbs if the animal is using a consistent gait pattern. 
Rodent models of rheumatic arthritis have decreased stride length, shorter stride 
to reduce weight bearing. 
• Maximum contact intensity: light intensity ranging from 0–255 arbitrary units. 
Intensity of the print depends on the degree of contact between a paw and the 
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glass plate and increases with increasing weight. This parameter is used to assess 
neuropathic pain where intensity would be reduced in a painful paw. 
• Paw print area: complete surface area contacted by the paw during a stance phase. 
Decreased print area is found in systematic models of arthritis. Main parameter 
associated with osteoarthritis. 
 
 
2.12.9.2 Dynamic parameters 
• Stance phase: duration in seconds of contact of a paw with the glass plate in a step 
cycle (stance phase + swing phase). Stance phase is decreased in rodent models of 
arthritis. This is the weight-bearing phase – pain would present as reduction in 
stance phase. 
• Swing phase: duration in seconds of no contact of a paw with the glass plate in a 
step cycle. Swing phase is increased if the stance phase is decreased as the animal 
tries to reduce weight on limbs by spending less time in the weight-bearing phase. 
• Duty cycle: stance duration as a percentage of the step cycle duration = stance 
phase/(stance + swing phases) × 100. 
 
2.13 ARTERIOVENOUS METABOLOME STUDY (CHAPTER 5) 
2.13.1 Mice 
A cohort of 12 nitisinone treated BALB/c Hgd-/- mice and a control cohort of 9 BALB/c Hgd-
/- receiving no treatment were divided between four separate smaller studies detailed 
below. Metabolite data was analysed from each separate study and then combined for 
further analysis. All mice were male and aged between 20-35 weeks upon commencing 
treatment. 
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2.14 STATISTICAL ANALYSIS 
2.14.1 Normality and homogeneity of variance 
Data was assessed for normality and homogeneity of variance prior to analysis using the 
Shapiro-Wilk and Brown-Forsythe test respectively. This confirmed the majority of data had 
a Gaussian distribution. Some metabolite and Morris water maze latency data failed the 
normality test due to outliers or mixed distributions but as ANOVA and T tests are 
considered robust to the assumption of normality due to making statistical inferences 
about means it was not necessary to transform the data. All statistics were calculated using 
GraphPad Prism 7 for Windows (GraphPad, CA, USA). 
 
2.14.2 Morris water maze data  
Means of the five trials for each day and each mouse were calculated to give a single 
escape latency, path length and path distance for each test subject. Subject means for the 
four days of hidden platform trials were analysed by three way ANOVA with genotype and 
treatment as a between-subjects factor and day as a within-subject factor. Data from 
Morris water maze visible platform and probe trial were subjected to a two-way ANOVA 
between genotype and treatment. When the ANOVA detected significant effects, pairwise 
differences between means for a given variable were evaluated using post hoc Tukey or 
Sidak multiple comparison test with significance set at P<0.05.  
 
2.14.3 Motor function testing data 
Latency to fall on the Rota-rod was analysed by three way ANOVA with genotype and 
treatment as a between-subjects factors and day as a within subject factor with post hoc 
Tukey multiple comparison test. Latency to fall on the inverted grid suspension test was 
analysed by two way ANOVA with between subject factors of genotype and treatment. 
 
2.14.4 Long-term dose response study data 
Comparisons of metabolites and pigmentation between control and nitisinone treated 
groups were performed using a one-way ANOVA with Dunnetts post hoc test. Comparisons 
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of metabolites between mid and term bleeds were performed using paired two-way 
students t tests. Results were considered statistically significant at p<0.05. An intraclass and 
Pearson’s correlation coefficient test with absolute agreement was carried out for 
pigmentation counts to assess inter-observer variability.  
 
2.14.5 Arteriovenous metabolome data  
Comparisons of metabolites between bleed site and cull method were performed using 
two way repeated measured ANOVA with bleed as a repeated measures factor and 
treatment as a between subject factor. Pairwise differences between means for a given 
metabolite were evaluated using Tukey or two-way student’s t tests. 
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3. Analysis of learning, memory and motor function in nitisinone treated and 
control cohorts of AKU (Hgd-/-) and wild type (WT) BALB/c mice. 
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3.1 INTRODUCTION 
Nitisinone is currently being trialled as a HGA lowering therapy for AKU patients over the 
age of 18. It has been widely used in children with hereditary tyrosinemia type 1 (HT1) for 
over 20 years where therapy is life saving and must be initiated as early as possible to 
prevent the fatal hepatic and renal manifestations associated with the disease. Nitisinone 
has dramatically increased survival rates in HT1 but some researchers have suggested an 
associated cognitive impairment in some children when reaching school age [111-114]. As 
part of its mechanism of action of inhibiting 4-hydroxyphenylpyruvate dioxygenase (HPPD), 
nitisinone causes increases in circulating tyrosine. There is concern that this tyrosinemia 
may be a contributing factor to the intellectual impairment observed in some children, 
particularly as treatment is started early in life during essential stages of brain development 
[110]. There are other possible causes for educational delay in HT1 patients such as liver 
dysfunction in early life, but for the purpose of this thesis, we wished to search for 
evidence of adverse effects of tyrosinemia on cognitive function in nitisinone treated mice. 
 
Several studies assessing the neurocognitive outcome of nitisinone use in early treated, 
HT1 patients have shown conflicting results ranging from normal IQ with no impairment to 
a high number of patients performing below normal in the assessment of psychomotor 
development and intellectual functioning [111-13]. None of these studies were able to 
identify a clear correlation between metabolic control and cognitive function although the 
most recent study from García and colleagues (2017) found a significant correlation 
between tyrosine/phenylalanine ratio and IQ concluding that some patients with HT1 
treated with nitisinone are at risk of presenting developmental delay and impaired 
cognitive functioning [114]. The tyrosinemia post nitisinone also resembles the metabolic 
status in hereditary tyrosinemia Type 3 (HT-3) where there is increased plasma tyrosine 
from birth due to genetic deficiency of HPPD. The neurological manifestations associated 
with the condition such as delayed cognitive and intellectual development, intermittent 
ataxia and seizures have been linked to the elevated blood levels of tyrosine [115].  
 
Nitisinone is a promising HGA lowering treatment but there is limited toxicology data 
available for its use in AKU. Some may argue that as sufferers of AKU have no clinical 
symptoms until adulthood there is no need to treat early, however, murine studies have 
indicated the process of ochronosis starts from as early as 15 weeks and cumulatively leads 
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to joint damage [70, 71]. Commencing treatment early in children with AKU could 
potentially reduce accumulation of damage over time due to high HGA levels and improve 
prognosis later in life. However, the side effect of elevated tyrosine poses potential safety 
issues to the developing brain that must be investigated prior to use in children. 
 
3.2 HYPOTHESIS AND AIM OF STUDY 
Hypothesis: Nitisinone treatment causes significant changes in learning, memory and 
motor control in Hgd-/- and WT mice. 
 
This study aimed to assess the effects of nitisinone-induced elevation of tyrosine on 
learning and memory, indicators of cognition, using the Morris water maze (MWM) in the 
AKU (Hgd-/-) BALB/c mouse. As ataxia has been reported in some HT-3 patients, where 
elevated tyrosine levels are present from birth, motor function was also assessed using the 
Rota-rod and Inverted Grid Suspension Test. The Catwalk XT gait analysis platform was 
used on a separate cohort of male and female, Hgd-/- and wild type (WT) mice to 
investigate whether any significant differences in gait were present prior to treatment with 
nitisinone. This type of analysis has not previously been reported for AKU mice. The 
Catwalk XT automated system enabled a comprehensive assessment of static and dynamic 
gait parameters. 
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3.3 RESULTS 
3.3.1 Plasma metabolites 
After 1 week of treatment with nitisinone (4mg/L), plasma tyrosine was elevated in Hgd-/- 
treated and WT treated mice (1390±68.0 and 1242±59.8 umol/L respectively) (Fig. 3.1A). 
HPPD inhibition reduced plasma HGA to very low levels in Hgd-/- treated mice compared to 
control (10.3±1.2 and 142.5±10.8 umol/L respectively) (Fig. 3.1B). Measuring these 
metabolites confirmed nitisinone treatment was effective prior to performing further 
cognitive and motor function assessment and treatment was continued at the same dose 
throughout the testing period. 
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Figure 3.1 – Plasma tyrosine and HGA levels in BALB/c Hgd-/- and WT control and 
nitisinone treated mice. Results confirmed nitisinone (4mg/L) elevated plasma tyrosine in 
Hgd-/- treated and WT treated mice (A). This was to ensure MWM and motor function 
testing assessed the effects of tyrosinemia (elevation of tyrosine) in both genotypes. 
Plasma HGA was reduced to low levels in Hgd-/- treated mice, which further confirmed 
effectiveness of nitisinone treatment prior to starting cognitive and motor function 
assessment (B). Mean ±SEM values shown, n=12 per cohort. 
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3.3.2 Morris water maze 
3.3.2.1 Visible platform (day 1) 
Escape latency decreased over the five trials of the visible platform test on day 1. All 
cohorts showed they were able to see the platform and learn the task of mounting the 
platform to escape the pool suggesting no apparent visual or swimming deficits were 
present that would affect subsequent hidden platform trials (days 2 to 5 of testing). There 
was a significant effect of trial number on latency (F (4, 220) = 12.27 P<0.0001) as the mice 
became more accustomed to the task and escaped the pool quicker. Hgd-/- control and 
treated mice were significantly slower at escaping during trial 4 than WT treated mice 
(P=0.0146 and 0.0324 respectively) (Fig. 3.2A). The significant effects of trial and genotype 
(F (1,220) = 7.961 P=0.0052) on escape latency are clearer when the first and last trial of 
the visual platform task are plotted (Fig. 3.2B). Swimming speed did not vary significantly 
between cohorts indicating no gross motor deficits were present that would affect further 
trials (Fig. 3.3). Swimming distance decreased significantly in all cohorts over the five trials 
as the mice learnt the location of the platform and swam a more direct path (F (4,220) = 
10.47 P<0.0001). However, Hgd -/- control mice swam a significantly further distance than 
WT treated mice during trial 2 (P=0.0380) (Figure 3.4A). Overall, Hgd-/- mice swam a 
significantly further distance than WT mice during visible trials shown by a main effect of 
genotype on swimming distance (F (1,220) = 7.68 P=0.0061) (Figure 3.4B). 
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Figure 3.2 - Mean escape latency (±SEM) of BALB/c Hgd-/- and WT mice during visible 
platform trials in the MWM, n=12 per cohort. A: All groups showed a progressive decrease 
in latency over the five training trials. This indicates all treatment groups were able to 
recognise and learn the task of finding and mounting the platform, suggesting no visual or 
motor defects prior to beginning hidden platform trials. B. The significant effect of trial on 
latency and the learning process is apparent when comparing the first and last trial of the 
day (F (4, 220) = 12.27 P<0.0001). At this early stage, analysis of data also showed genotype 
to be a significant factor in performance (F (1,220) = 7.961 P=0.0052). 
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Figure 3.3 - Mean swimming speed (±SEM) of BALB/c Hgd-/- and WT mice during visible 
platform trials in the MWM, n=12 per cohort. Swim speed did not vary significantly 
between cohorts suggesting no obvious deficits in swimming ability or motivation to swim. 
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Figure 3.4 - Mean swimming distance (±SEM) of BALB/c Hgd-/- and WT mice during visible 
platform trials in the MWM, n=12 per cohort. A: All groups showed a progressive decrease 
in distance over the 5 training trials indicating mice learnt to take a more direct path to the 
target platform with each trial. Hgd-/- control mice swam a significantly longer distance 
(P=0.0380) than WT treated mice during trial 2. B: The significant effect of trial on distance 
is apparent when the first and last trial of the day are compared (F (4,220) = 10.47 
P<0.0001). Genotype was also found to have a significant effect on swimming distance (F 
(1,220) = 7.68 P=0.0061). 
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3.3.2.2 Hidden platform (day 2-5) 
During hidden platform trials a main effect of genotype on escape latency was observed (F 
(1,176) = 12.39 P=0.0006). Both WT cohorts found the hidden platform significantly quicker 
over consecutive days compared with Hgd-/- mice (Fig. 3.5A). Test day had a nearly 
significant effect on escape latency (F (3,176) = 2.631 P=0.0516) as mice showed an overall 
decrease in latency over the hidden platform trials but this decrease was not steady over 
subsequent days. Importantly, treatment with nitisinone had no significant effect on 
latency for any cohort (F (3,176) = 0.1713) P=0.6794). All cohorts showed a progressive 
decrease in swimming speed over the hidden trials confirmed by a significant main effect of 
test day on swimming speed (F (3,176) = 6.501 P=0.0003). This could indicate the mice 
were becoming more accustomed to the task and less anxious about being in the pool (Fig. 
3.5B). There was no main effect of genotype or treatment on swimming speed but a 
significant genotype x treatment interaction was present (F (1,176 ) = 5.77 P=0.0173) as WT 
control mice swam faster than WT treated mice, whereas Hgd-/- treated mice were faster 
than Hgd-/- control mice.  All cohorts showed a progressive decrease in swimming distance 
over the hidden platform trials as they swam a more direct path to the platform, confirmed 
by a significant effect of day on swimming distance (F (3,176) = 16.76 P<0.0001). WT mice 
treated with nitisinone swam a significantly shorter distance than Hgd-/- control, Hgd-/- 
treated and WT control mice on day 3 (P=0.0262, P=0.0193 and P=0.0195 respectively). WT 
treated mice also swam a significantly shorter distance than Hgd-/- treated mice on day 5 
(P=0.0341) (Fig. 3.5C). A significant genotype x treatment interaction was also observed for 
swimming distance (F (1,176) = 4.853 P=0.0289). 
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Figure 3.5 - A: Mean escape latency (±SEM) B: Mean swimming speed (±SEM) C: Mean 
swimming distance (±SEM) of BALB/c Hgd-/- and WT mice during hidden platform trials in 
the MWM, n=12 per cohort.  A: During hidden trials, a main effect of genotype on latency 
was observed (F (1,176) = 12.39 P=0.0006). Both WT cohorts found the platform quicker 
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over consecutive days compared with Hgd-/- cohorts. Treatment with nitisinone and test 
day had no significant effect on escape latency. B: All cohorts showed a decrease in swim 
speed over the hidden trials confirmed by a significant effect of test day on swim speed (F 
(3,176) = 6.501 P=0.0003). C: All cohorts showed a decrease in swimming distance over the 
hidden platform trials confirmed by a significant effect of day on distance (F (3,176) = 16.76 
P<0.0001). WT treated mice swam a significantly shorter distance than other cohorts on 
day 3 and day 5. B & C: A significant genotype x treatment interaction was also observed 
for swimming speed and distance (F (1,176) = 5.77 P=0.0173 and F (1,176) = 4.853 
P=0.0289 respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
When the latency of the first and last trial of the hidden platform days are plotted, the 
significant effect of genotype is more apparent. Hgd-/- cohorts took longer to find the 
platform and showed no significant improvement over the four days of hidden platform 
testing. Hgd -/- treated mice performed marginally better than Hgd-/- control mice but this 
was not statistically significant. WT cohorts showed substantial improvement and located 
the platform quicker with each testing day. WT control mice showed the greatest 
improvement out of all cohorts with the largest decrease in latency from first to last trial. 
Again, there was no significant effect of nitisinone treatment on either genotype (Fig. 3.6). 
 
 
Figure 3.6 - Mean escape latency (±SEM) of BALB/c Hgd-/- and WT mice in the MWM: 
comparison of first and last run of hidden platform trials, n=12 per cohort. A significant 
effect of genotype on escape latency is apparent (F (1,88) = 3.961 P=0.0497). WT cohorts 
were quicker at finding the hidden platform. WT control mice were quickest to find the 
platform followed by WT treated with nitisinone. Hgd-/- cohorts did not improve 
significantly over the hidden platform trials with Hgd-/- control mice appearing to show no 
improvement in escape latency of the four hidden days testing. 
 
 
 
 
67 
 
3.3.2.3 Probe trial (day 6) 
During the probe trial, the platform was removed from the pool and each mouse 
performed a single trial. The target quadrant refers to the previous location of the platform 
during hidden platform trials. Preference to the target quadrant, indicated by >25% time 
spent within that quadrant, is indicative of the mouse’s ability to learn and consolidate 
spatial memory during hidden platform trials and the ability to recall this location the 
following day. The probe trial was carried out the day after the final hidden platform trial to 
ensure it was not assessing short-term memory. Both WT cohorts showed preference to 
the target quadrant whilst Hgd -/- cohorts showed no preference. This significant genotypic 
effect was confirmed by ANOVA (F (1, 44) = 0.5.992 P=0.0184). Nitisinone treatment had no 
effect on target quadrant preference (F 1, 44) = 0.01134 P=0.9157) (Fig. 3.7). Gallagher’s 
proximity measure confirmed WT cohorts were in closer proximity to the target quadrant 
throughout the probe trial (Table 3.1).  
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Figure 3.7 – Mean percentage of time spent in target quadrant (±SEM) during probe trial 
of the MWM in BALB/c Hgd-/- and WT nitisinone treated and control mice. Preference is 
indicated by >25% time spent within a quadrant. WT cohorts showed preference to the 
target quadrant indicating spatial learning and memory retrieval. Both Hgd-/- cohorts 
showed no preference to the target quadrant. This significant genotypic effect was 
confirmed by ANOVA (F (1, 44) = 0.5.992 P=0.0184). Treatment did not significantly affect 
quadrant preference suggesting nitisinone does not reduce learning performance. 
Differences in spatial learning between Hgd -/- and WT mice appears to be due to genotype 
and not nitisinone treatment.  
 
Hgd-/- control Hgd-/- nitisinone WT control WT nitisinone 
0.7592 0.7117 0.5517 0.6425 
Table 3.1 - Mean Gallagher proximity measures during probe trial of the MWM in BALB/c 
Hgd-/- and WT nitisinone treated and control mice, n=12 per cohort. The average distance 
in metres from the platform over the whole trial, corrected for start point and using every 
sample point for distance from the platform. Higher values indicate less spatial knowledge. 
This measure confirmed WT cohorts showed more preference to the target quadrant by 
being in closer proximity to the previous location of the platform throughout the probe 
trial. 
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3.3.3 Motor function analysis 
3.3.3.1 Rota-rod 
Within the Rota-rod test mice walk on an accelerating motorised rod; the latency to fall for 
each mouse is automatically recorded with a higher latency to fall indicative of a better 
performance. Hgd-/- cohorts performed significantly better (spent longer on the motorised 
rod) than WT cohorts across all Rota-rod trials (F (1, 16) = 68.68 P<0.0001) (Fig. 3.8). Hgd-/- 
cohorts also performed significantly better during each of the three days compared to WT 
cohorts (F (1, 16) = 4.874) P=0.0422) (day 1: P=0.0016, day 2: P=0.0011, day 3: P=<0.0001). 
In agreement with MWM trials, treatment with nitisinone had no significant effect on 
performance. All cohorts showed improvement in performance over the three days testing 
but this was greatest in Hgd-/- cohorts indicated by a significant genotype x day interaction 
(F (1, 16) P=0.0192). 
 
 
Figure 3.8 - Mean (±SEM) performance of BALB/c Hgd-/- and WT control and treated mice 
on the Rota-rod. Both WT cohorts fell earlier than Hgd-/- cohorts across the 3 days of 
testing. Hgd-/- cohorts showed greatest improvement in performance. Genotype and day 
were significant factors of performance. ** = P <0.01 **** = P<0.0001 
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3.3.3.2 Inverted grid suspension test 
Performance varied on the inverted grid test between cohorts with WTs performing 
marginally better than Hgd-/- cohorts (Figure 3.9). Two way ANOVA showed no significant 
effects of genotype or treatment with nitisinone on latency to fall (F (1, 137) = 3.262 
P=0.0731 and F (1, 137) = 1.028 P=0.3125 respectively). 
 
 
 
Figure 3.9 - Mean (±SEM) latency to fall on the inverted grid suspension test in BALB/c 
Hgd-/- and WT control and treated mice. Hgd-/- and WT cohorts showed a similar 
performance with no significant effects of genotype or treatment with nitisinone on 
latency. 
 
 
 
 
n.s. 
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3.3.4 Catwalk XT gait analysis 
The Catwalk XT gait analysis platform was used on a separate cohort of male and female, 
Hgd-/- control and WT control mice to investigate whether any significant differences in 
gait were present between genotypes prior to treatment with nitisinone. Mice within the 
subsequent study therefore received no treatment with nitisinone as we wished to assess 
whether gait was affected by joint ochronosis as previously demonstrated in human AKU 
patients [96]. This type of analysis has not previously been reported for Hgd-/- mice. The 
Catwalk XT automated system enabled a comprehensive assessment of static and dynamic 
gait parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
3.3.4.1 Bodyweight 
Bodyweight varied significantly between male cohorts due to the age of mice when 
available for testing since we had a limited timeframe of access to the gait analysis 
platform. Hgd-/- males were older (17-38 weeks) and significantly heavier than WT males 
(12-17 weeks). This was taken into consideration when comparing gait analysis parameters 
affected by weight and body size such as print area and stride length. Bodyweight did not 
differ significantly between female cohorts (Fig. 3.10). Hgd-/- cohorts age ranged between 
17 to 39 weeks, as we wished to analyse gait when the ochronotic phase of the disease had 
initiated within the joints. A natural history study by Preston and colleagues showed 
pigmented chondrocytes to be present in the BALB/c Hgd-/- mouse knee from 15 weeks of 
age and then progressively increasing across the mouse’s lifespan [70].   
 
 
Figure 3.10 - Bodyweight of male and female BALB/c Hgd-/- and WT mice tested with the 
Catwalk gait analysis platform. Hgd-/- male mice were significantly heavier than WT male 
mice due to age differences. 
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3.3.4.2 Stance phase 
Male Hgd-/- mice had significantly longer stance phases of the left and right hind limbs 
compared to WT males (t(18) = 2.41, P = 0.0269 and t(18) = 2.965, P = 0.0083 respectively). 
Both hindlimbs showed an increase of approximately 0.04 seconds or 28% compared to WT 
males. Female cohorts had similar stance phases for all limbs analysed with no significant 
differences between genotype (Fig. 3.11). 
 
 
Figure 3.11 - Mean (±SEM) stance phase for male and female BALB/c Hgd-/- and WT mice. 
Male Hgd-/- mice had significantly longer hindlimb stance phases compared to male WTs.  
Female cohorts showed no significant differences for any limb. * = P<0.05, ** = P<0.01 
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3.3.4.3 Swing phase 
Male Hgd-/- mice had significantly shorter left and right hindlimb swing phases compared 
with WT males (t(18) = 4.184, P = 0.0006 and t(18) = 4.321, P = 0.0004 respectively). These 
were decreased by approximately 0.02 seconds or 18% compared with WT males. This 
decrease in swing phase coincides with the increase in stance phase of the step cycle within 
these limbs. Female cohorts had similar swing phases for all limbs analysed with no 
significant differences between genotypes (Fig. 3.12). 
 
 
Figure 3.12 - Mean (±SEM) swing phase for male and female BALB/c Hgd-/- and WT mice. 
Male Hgd-/- mice had significantly shorter hindlimb swing phases compared to male WTs.  
Female cohorts showed no significant differences for any limb. *** = P<0.001. 
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3.3.4.4 Duty cycle 
Duty cycle expresses the weight bearing stance duration as a percentage of the step cycle 
duration. Male Hgd-/- mice had significantly higher duty cycles of the left and right 
hindlimb compared with WT males (t(18) = 3.843, P = 0.0012 and t(18) = 4.463, P = 0.0003 
respectively). These were both increased by approximately 10% compared with WT males. 
This coincides with the differences observed in the swing and stance phases of the step 
cycle within these limbs previously discussed. Hgd-/- females had a reduced duty cycle in 
the left forelimb (-3.9%) compared with the same limb in WT females (t(15) = 2.515, P = 
0.0238). The duty cycle of other limbs in female cohorts showed no significant differences 
(Fig. 3.13). 
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Figure 3.13 - Mean (±SEM) duty cycle for male and female BALB/c Hgd-/- and WT mice. 
This represents the weight bearing stance phase as percentage of the entire step cycle 
duration (stance phases + swing phases). Male Hgd-/- mice had significantly higher duty 
cycles of the hind limbs compared to male WTs.  Hgd-/- females had a reduced duty cycle in 
the left forelimb compared with the same limb in WT females * = P<0.05, ** = P<0.01, *** 
= P<0.001. 
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3.3.4.5 Regularity index and stride length 
All cohorts had a regularity index near 100% indicating no abnormalities of interlimb 
coordination (Fig. 3.14A). Stride length was the same for all limbs indicating the mice were 
using a consistent gait pattern. One-way ANOVA of stride length within cohorts did not 
reveal any significant differences between limbs therefore the combined data for all four 
limbs was used for analysis between cohorts.  Hgd-/- males mice had a significantly larger 
stride length compared with WT males (t(6) = 14.39, P<0.0001). Female cohorts had similar 
stride lengths (Fig. 3.14B). 
 
 
Figure 3.14 - Mean (±SEM) regularity index (A) and stride length (B) for male and female 
BALB/c Hgd-/- and WT mice. All cohorts had a regularity index near 100% indicating no 
abnormalities in interlimb coordination (A). Hgd-/- males had a significantly larger stride 
length than WT males. Female cohorts had similar stride lengths (B). **** = P<0.0001 
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3.3.4.6 Maximum contact intensity (paw weight bearing) 
Intensity of the print depends on the degree of contact between a paw and the glass plate 
and intensifies with increased weight bearing. Hgd-/- female mice had significantly reduced 
contact intensity for all four paws compared with WT females (left forelimb: t(15) = 5.515, 
P<0.0001, right forelimb: t(15) = 4.071, P<0.0010, left hindlimb: t(15) = 3.126, P<0.0069, 
right hindlimb: t(15) = 2.391, P<0.0304). Male Hgd-/- mice exhibited an increase in contact 
intensity of the left hindlimb compared with the same limb in WT males (t(18) = 2.381, 
P<0.0285). No other significant limb differences were apparent between male cohorts (Fig. 
3.15). 
 
 
Figure 3.15 - Mean (±SEM) maximum contact intensity (arbitrary units ranging between 0 
– 255) for male and female BALB/c Hgd-/- and WT mice. Female Hgd-/- mice had 
significantly reduced contact intensity in all four limbs compared to WT females. Male Hgd-
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/- mice showed an increase in contact intensity of the left hindlimb. * = P<0.05, ** = 
P<0.01, **** = P<0.0001. 
 
3.3.4.7 Print area 
Hgd-/- males had significantly larger print areas in all four limbs compared with WT males 
(left forelimb: t(18) = 7.4, P<0.0001, right forelimb: t(18) = 7.784, P<0.0001, left hindlimb: 
t(18) = 7.11, P<0.0001, right hindlimb: t(18) = 6.962, P<0.0001). Hgd-/- female and WT 
females had similar print areas with no significant differences between limbs (Fig. 3.16). 
 
 
Figure 3.16 - Mean (±SEM) print area for male and female BALB/c Hgd-/- and WT mice. 
Male Hgd-/- mice had significantly larger print areas in all four limbs compared to WT 
males. Female cohorts had similar print areas with no significant differences between 
limbs. **** = P<0.0001. 
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3.4 DISCUSSION 
This study aimed to determine whether tyrosinemia as a potentially adverse side effect of 
nitisinone therapy has consequences relating to spatial learning, memory or motor function 
in Hgd-/- or WT BALB/c mice. High levels of tyrosine have been linked to the delayed 
cognitive development and learning difficulties found in some patients with hereditary 
tyrosinemia type 1 (HT-1) who receive lifesaving nitisinone treatment from early life. The 
neurological and motor dysfunction associated with hereditary tyrosinemia type 3 (HT-3) 
has also been linked to the high levels of tyrosine present from birth within the condition 
[115]. The hypothesis at the beginning of this chapter was not supported by the results 
therefore the principle of using nitisinone in younger patients is valid. 
 
3.4.1 Morris water maze 
The MWM results indicated significant differences in spatial learning and memory between 
genotype but no significant effects of nitisinone treatment. This supports the earlier use of 
nitisinone in AKU patients. A recent AKU patient study investigating subclinical ochronotic 
features in alkaptonuria (SOFIA) observed pigmentation in the ear cartilage biopsy of a 16-
year old male demonstrating that ochronosis can occur in AKU patients before this age 
[165]. This suggests that starting nitisinone therapy in childhood would likely be beneficial 
for patient prognosis. The genotypic differences were apparent from the first day of testing 
and remained a continuous finding across various measured parameters. WT control and 
treated mice showed significant improvements in performance throughout the hidden 
trials with the probe trial confirming they were able to form and recall spatial memory and 
utilise this for navigation (Fig. 3.7). Hgd-/- control and treated mice showed minimal 
improvement throughout hidden trials and showed no preference to the target quadrant 
during the probe trial. This is an important finding as it may be an indication that Hgd-/- 
mice are less able to use hippocampal dependent learning for navigation or could illustrate 
deficits in the mesolimbic dopaminergic pathway involved in motivation, in this case to 
escape the pool of water. Importantly, treatment with nitisinone or the related elevation in 
tyrosine did not have a significant effect on performance for any cohort in the MWM and 
there were no indications that treatment was detrimental to the learning process.  This is in 
agreement with findings from a recent study by Hillgartner and colleagues who 
investigated learning in tyrosinemia type 1 (HT-1) and WT mice treated with nitisinone. HT-
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1 mice showed slower learning and altered behaviour, which the authors concluded was a 
result of the HT-1 genotype and not due to treatment with nitisinone [116].  
 
The results highlight that it would be useful to perform future trials with a control colony 
that were as matched to the Hgd-/- mice as possible. It would be helpful to repeat some of 
the measurements in heterozygous mice generated by crossing some of the homozygous 
colony back with WT mice and selecting the heterozygotes that have the mutation in only 
one allele (Hgd +/-). Time and resources were not sufficient to allow implementation of this 
proposed study within the present thesis but this should influence future work. 
 
3.4.2 Motor function analysis 
No obvious motor deficits were revealed in the Rota-rod or inverted grid suspension test in 
Hgd -/- mice. Hgd-/- cohorts performed better than WT in the accelerating Rota-rod test 
and improved with each trial indicating no deficits in coordination or motor function. Hgd-
/- and WT mice treated with nitisinone actually performed better than controls within the 
Rota-rod test although treatment was not a statistically significant factor (Fig. 3.8). The 
inverted grid suspension test showed no significant effect of genotype or nitisinone 
treatment (Fig. 3.9). Large intra-cohort variation was apparent but as this is an assessment 
of grip strength and the ability for the mouse to support its bodyweight this can be subject 
to normal variation between mice, as would be the case with human subjects. Similar to 
the Rota-rod, Hgd-/- and WT cohorts receiving nitisinone performed marginally better than 
controls suggesting acute increases in circulating tyrosine due to nitisinone treatment may 
have aided with performance. Tyrosine is a precursor to the catecholamine 
neurotransmitters including dopamine which is involved in motivation, arousal and learning 
[117]. Previous studies have shown even single doses of tyrosine to have a significant effect 
on working memory especially in times of neurotransmitter depletion such as during a 
stressful or cognitively demanding task [118, 119]. Motor function could also be visually 
assessed by swimming ability in MWM – all cohorts swam at roughly the same speed 
showing no specific deficit in swimming ability. Swimming is non-weight bearing so this was 
a useful measure to remove variations due to bodyweight.  
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Throughout testing there were no obvious indicators of discomfort or pain (vocalisation, 
grimace, weight loss, piloerection) apparent in the Hgd-/- mice, which may have been 
expected if mice were experiencing the same ochronotic arthropathy found in human AKU 
patients. Hgd-/- mice were past the age that ochronotic pigmentation has been shown to 
initiate although none were past 25 weeks suggesting the painful osteoarthritis that might 
be associated with later stage ochronosis was not present. Hgd-/- mice were noticeably 
more docile, less motivated to avoid human contact and easier to handle than WT mice 
after the same amount of prior handling. Anxiety related urination was also notably less 
although this was not quantitatively measured. AKU patients often report having depressed 
mood and fatigue [24, 27, 100] – this may also be the case for Hgd-/- mice. Reduced 
motivation, anxiety and fear responses could indicate involvement of the mesolimbic 
dopaminergic pathway associated with these states. Dopamine is one of the 
neuromodulators most potently acting on the mechanisms underlying these. Disruptions 
within this pathway, perhaps due to synthesis of ochronotic pigment (also found to be 
similar to neuromelanin, itself produced from L-DOPA), may be taking place within AKU 
along with enhanced pigment production by the melanin-synthetic enzyme tyrosinase as 
suggested by Taylor and colleagues [41]. A murine study by Eisenhofer found changes in 
the function and expression of tyrosinase with advancing age whereby melanin synthesis 
became more pronounced and dopamine synthesis decreased [120]. Usually, tyrosinase 
converts tyrosine to a quinone intermediary to form melanin but in the AKU individual, and 
as Taylor [41] suggests, perhaps tyrosinase polymerises HGA instead leading to ochronotic 
pigment production. Eisenhofers findings also suggest this may contribute to why 
pigmentation increases with age in AKU as tyrosinase-dependent melanin synthesis, or in 
the case of AKU, ochronotic pigment synthesis, becomes more pronounced. The reduced 
tyrosinase-dependent dopamine production could also explain why patients experience 
low mood and fatigue. 
 
3.4.3 Catwalk XT gait analysis 
The Catwalk gait analysis system was able to detect small but significant differences in 
voluntary gait during movement at self-selected speed across a small distance. The analysis 
of the data showed differences within dynamic gait parameters (stance phase (Fig. 3.11), 
duty cycle (Fig. 3.13)) of Hgd-/- males compared with WT males, indicated that these mice 
were spending a longer time during the weight bearing phases of the step cycle on their 
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hind limbs. A reason for this could simply be due to the Hgd-/- males having a larger 
bodyweight and size (Fig. 3.10). Hgd-/- males also had slight increases in both forelimb 
stance phases compared to WT males although these differences were not statistically 
significant. Gait characteristics are influenced by animal size with larger animal having been 
shown to have increased stance time and stride lengths [121]. Conversely, forelimb duty 
cycles showed no increase in the Hgd-/- males, which would be expected if the differences 
were solely due to increased body size.  
 
Previous studies investing gait in rodent models of arthritis have found these mice show a 
reduction in the weight bearing phases of an affected limb in an attempt to reduce load 
bearing that would cause pain [122, 123]. This is the case for unilateral models of arthritis 
where the condition is induced in a limb via injection of an irritant substance or mechanical 
damage caused by compression of the joint [109]. Transgenic models of osteoarthritis (OA) 
present with bilateral compensations due to systematic joint pathology [124-126]. By 
increasing the percentage of time spent on both hind limbs, the percentage of time a single 
hind limb must bear weight without contralateral support is reduced [127, 128]. This would 
represent a closer model to the Hgd-/- mouse due to joint ochronosis also being systematic 
within load bearing joints. The increases observed in Hgd-/- stance phase and duty cycle of 
the hindlimbs could be a sign that Hgd-/- males are experiencing some change in hindlimb 
sensitivity and compensate with an altered gait pattern to minimise weight bearing on a 
single limb. Higher hind-limb stance times have been observed in type IX collagen deficient 
mice that prematurely develop osteoarthritis but this was combined with a slower velocity 
and shorter stride length in order to reduce force on the affected joint [129-131]. This was 
not the case for Hgd-/- males who had a similar velocity and significantly larger stride 
length than WT males (Fig. 3.14B). Considering this, the differences in the dynamic gait 
parameters observed in Hgd-/- male could be due to a slight pathologically altered gait, but 
is most likely due to larger bodyweight and size, as any effects were very small and 
nowhere near those observed in mice with induced OA. The only effect observed in female 
cohorts was a reduced maximum contact intensity in Hgd-/- mice compared to WTs (Fig. 
3.15). This parameter is often used to assess neuropathic pain whereby intensity would be 
reduced in a painful paw [132-134]. In this case, Hgd-/- females showed a reduction across 
all four paws therefore this effect is mostly likely due to small differences in bodyweight 
between the female cohorts as WT females were slightly heavier. Regularity index and 
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stride lengths were similar for both genotypes and sexes and showed a consistent gait 
pattern and good interlimb coordination indicating no signs of ataxia. Overall gait analysis 
showed only minor effects that were dissimilar to those observed in mouse models of OA 
suggesting no obvious signs of pathologically altered gait. 
 
3.4.4 Limitations 
Mice ages varied within and between Hgd-/- and WT cohorts due to constraints with colony 
size although the mean age (weeks) for cohorts used within the MWM, rotarod and IGST 
were similar (Hgd-/-  treated: 19.7, Hgd-/- control: 19.2, WT treated: 18.1, WT control: 
18.5). These mice were neither young nor aged and consequently the difference in age did 
not likely have a significant effect on the learning process. Age differences between Hgd-/- 
and WT cohorts within the catwalk XT platform caused an effect due to the related increase 
in bodyweight that occurs as mice age, this was taken into account when examining 
parameter affected by bodyweight. Closer age matching should be considered for future 
experiments to remove this variable.  
 
The findings of this chapter are promising for the use of nitisinone as a HGA reducing 
therapy in children with AKU. Behavioural and motor function assessment indicated no 
detrimental effects of nitisinone treatment or the associated tyrosinemia on cognition or 
motor function. Any effects in mice appeared to be due to the Hgd-/- genotype and not 
nitisinone treatment. These findings aid in addressing the concerns regarding the 
neurotoxicity of elevated tyrosine in nitisinone treated children.  
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4. Balancing the reduction of plasma HGA and elevation of tyrosine in the 
treatment of AKU with nitisinone - a long-term dose response study in BALB/c 
Hgd-/- mice. 
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4.1 INTRODUCTION 
Nitisinone is highly efficacious as a reversible inhibitor of 4-hydroxyphenylpyruvate 
dioxygenase (HPPD), the enzyme responsible for homogentisic acid (HGA) synthesis [63]. 
Previous murine and human studies investigating nitisinone use in AKU have shown 
reduction of HGA to very low levels [71, 72, 55, 56]. A dose of 8mg per day (0.114mg/kg for 
70kg human) reduced urinary HGA levels by 98.8% in the recent SONIA1 human study with 
the reasonable assumption that this is low enough to prevent ochronosis [55]. Preston et al 
have shown that administration of nitisinone at 4mg/L (0.5-0.8mg/kg for 30g mouse) in the 
Hgd-/- mouse reduced plasma HGA throughout the mouse’ lifetime and completely 
prevented further deposition of ochronotic pigment from start of treatment [70]. This 
study by Preston and colleagues along with previous work within our own lab used 4mg/L 
nitisinone; the dose originally determined by the Grompe lab that enabled the HT-1 FAH-/- 
mouse model to survive. This FAH-/- model was the strain from which our AKU Hgd-/- 
mouse was derived [75].  
 
HT-1 mice and patients require nitisinone at much higher doses (1-2mg/kg per day) to 
prevent fatal complications [141]. It is important to determine a dose in the Hgd-/- mouse 
that provides therapeutic reduction of HGA whilst also minimising the elevation of tyrosine 
so that this can guide the calculation of dosage for AKU patients. There have been 
incidences of AKU patients treated with nitisinone who have shown predisposition to 
tyrosine toxicity independent of peak plasma levels. This manifests as reversible corneal 
keratopathy that requires suspension of treatment or reduction of dose to resolve [56, 57]. 
Tailoring the dose of nitisinone to provide a balanced compromise of HGA reduction whilst 
minimising the degree of tyrosinemia could therefore also benefit these patients to ensure 
uninterrupted treatment.  The only previous nitisinone dose response study in Hgd-/- mice 
within the literature by Keenan and colleagues found plasma HGA concentrations 
responded in a dose dependent manner with higher concentrations of nitisinone resulting 
in greater suppression of plasma HGA [72]. This dose response study by Keenan et al was 
short term (13 days) and started Hgd-/- mice on nitisinone treatment at 54 weeks of age to 
investigate the effect on plasma HGA. The study contained within this chapter was long-
term (40 weeks) and treated weanling (3 weeks old) Hgd-/- mice with nitisinone, when the 
ochronotic pigmentation phase of the disease had yet to initiate. We aimed to investigate 
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the lowest dose that would reduce HGA sufficiently to prevent deposition of ochronotic 
pigment in the tibio-femoral joint. 
 
4.2 HYPOTHESIS AND AIM OF STUDY 
Hypothesis: Ochronotic pigmentation of the tibio-femoral joint in the Hgd-/- mouse shows 
a dose relationship with nitisinone via plasma HGA concentration. 
The primary aim of this long-term dose response study was to determine the lowest dose 
of nitisinone required to sufficiently reduce plasma HGA levels and prevent ochronotic 
pigmentation of chondrocytes within the Hgd -/- mouse tibio-femoral joint. A second 
objective was to determine whether plasma HGA levels and the amount of ochronotic 
pigmentation within the tibio-femoral joint were correlated. Although there are many 
intermediates in the tyrosine pathway, HGA is the metabolite understood to be primarily 
responsible for the disease pathology of AKU. Along with HGA and tyrosine, this study also 
measured the metabolites upstream from the mechanism of action of nitisinone (HPPA, 
HPLA and Phenylalanine) in case these gave an indication of potential rate-limiting steps in 
the production of HGA or elucidated the status of alternative catabolic or excretory 
pathways. Establishing the minimum effective dose required to reduce plasma HGA levels 
and prevent ochronosis whilst simultaneously attempting to minimise the adverse effects 
of tyrosinemia as a result of nitisinone treatment is important for a human therapeutic 
strategy. As stated by Introne and colleagues, this is fundamental in reducing the cost of 
lifetime treatment and minimising potential side effects [56]. 
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4.3 RESULTS 
4.3.1 Plasma metabolites  
4.3.1.1 Tyrosine 
There was a marked dose-related increase in tyrosine at 20 weeks that was statistically 
significant between groups (F(3,23) = 245.18, P<0.0001) (Fig. 4.1). Tyrosine levels were 
lowest in control mice (mean (±SE) 60.6±4.8 umol/L) and increased with nitisinone dose – 
257.0±41.9umol/L, 796.7±56.0umol/L and 1455.3±45.5umol/L for 0.125mg, 0.5mg and 2mg 
nitisinone respectively. The dose response of tyrosine to nitisinone appears to plateau at 
plasma levels of around 1400umol/L in BALB/c Hgd-/- and WT mice. Treatment with a 
higher 4mg/L nitisinone dose from previous experiments have also shown tyrosine 
elevated to similar levels (Chapter 3, Fig. 3.1A). Post hoc Dunnetts test showed all doses 
were elevated significantly compared with control levels. Tyrosine levels measured at 40 
weeks remained elevated in a dose responsive manner and were significantly different 
between groups (F(3,21) = 73.702, P<0.0001) (Fig. 4.2). Post hoc tests showed 0.5mg and 
2mg were significantly elevated compared with control. 
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Figure 4.1 - Effects of nitisinone on plasma tyrosine levels after 20 weeks treatment in 
BALB/c Hgd-/- mice. Tyrosine exhibited an elevated dose response with statistically 
significant differences between groups (P<0.0001). Post hoc Dunnetts test showed all 
nitisinone doses resulted in significant elevation of tyrosine above control levels, 2mg 
cohort n=7, other cohorts n=6. ** = P<0.01 
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Figure 4.2 - Effects of nitisinone on plasma tyrosine levels after 40 weeks treatment in 
BALB/c Hgd-/- mice. Tyrosine remained elevated in a dose responsive manner with 
significant differences between groups (P<0.0001). Post hoc Dunnetts test showed 
significant elevation of tyrosine above control levels in 0.5mg and 2mg doses. 2mg cohort 
n=7, other cohorts n=6. ** = P<0.01 
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Tyrosine levels showed variation between mid and term bleeds for the 0.5mg and 2mg 
nitisinone groups (Fig. 4.3). These were significantly lower in terminal bleeds compared 
with those measured in the mid bleed 20 weeks earlier. Paired t tests showed significant 
differences between mid and terminal bleeds for 0.5mg (P=0.0013) and 2mg nitisinone 
doses (P=0.0004). Although still elevated compared to control in both bleeds, mean 
tyrosine levels showed a reduction of 265.4umol/L in the 0.5mg nitisinone group between 
bleeds and 440.3umol/L in the 2mg nitisinone group between bleeds. 
 
 
Figure 4.3 - Comparison of the effect of nitisinone dose on plasma tyrosine levels after 20 
(mid) and 40 weeks (term) treatment in BALB/c Hgd-/- mice. Elevation of tyrosine was 
lower after 40 weeks treatment in 0.5mg and 2mg nitisinone. 2mg cohort n=7, other 
cohorts n=6.. Significance from t test ** = P<0.01, *** = P<0.001. Mean ±sem. 
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4.3.1.2 HGA 
HGA levels measured at 20 weeks (mid-bleed) were significantly different between cohorts 
(P=0.0009) (Fig.4.4).  There was high intra-cohort variability in HGA levels within control 
mice (range 147.6–356.7 umol/L) and mice receiving 0.125mg (range 56.7-399.8 umol/L) 
and 0.5mg nitisinone (range 133.4-357.6 umol/L). Mice receiving 2mg nitisinone had the 
lowest HGA values and showed less variability between values (range 33.0-59.0 umol/L). 
Mean HGA values showed a decreasing dose response as nitisinone dose increased. 
Dunnetts post hoc tests confirmed mice receiving 2mg nitisinone had significantly lower 
HGA levels compared with control (P<0.01). The 0.125mg and 0.5mg nitisinone dose 
lowered mean plasma HGA but this was not statistically significant compared with control. 
 
 
Figure 4.4 - Effect of nitisinone on plasma HGA after 20 weeks treatment in BALB/c Hgd-/- 
mice. Large intra-cohort variation was apparent between control, 0.125mg and 0.5mg 
nitisinone. Post hoc Dunnetts test showed 2mg nitisinone significantly reduced HGA levels 
compared with control. 2mg cohort n=7, other cohorts n=6. ** = P<0.01 
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Terminal bleed plasma HGA levels showed a stronger, decreasing dose response 
relationship with significant differences between groups (P<0.0001) (Fig. 4.5). Less intra-
cohort variation was also apparent. Mice receiving 0.5mg and 2mg nitisinone showed 
significantly lower HGA values compared with control mice (P=<0.01). Mice receiving 
0.125mg showed a reduction in HGA compared with control but also contained an outlier 
with a HGA value higher than that of control mice. One-way ANOVA with post hoc test was 
performed including and omitting this result, in each case 0.125mg nitisinone also resulted 
in a significant reduction in HGA compared with control (P=<0.05). 
 
 
Figure 4.5 - Effect of nitisinone on plasma HGA levels after 40 weeks treatment in BALB/c 
Hgd-/- mice. HGA reduced significantly in all mice receiving nitisinone compared with 
control. 2mg cohort n=7, other cohorts n=6.Significance from post hoc Dunnetts test * = 
P<0.05, ** = P<0.01 
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Plasma HGA levels were reduced within all dose cohorts including control between mid and 
term bleeds (Fig. 4.6). Terminal bleed HGA values were significantly lower in all treatment 
groups compared with mid bleed values collected 20 weeks previously within the same 
cohort. Unexpectedly, in view of previous work that showed a relatively constant HGA level 
across the mouse lifetime [70], mean HGA values were significantly reduced by 46% 
between mid and term bleeds in control mice (P=0.0322). A similar reduction was seen in 
mice receiving 2mg nitisinone (↓40%, P=0.0142). Mice receiving 0.125mg and 0.5mg 
nitisinone followed the same trend with 61% (P=0.0168) and 73% (P=0.0117) reduction 
respectively in mean HGA levels in terminal bleeds compared with mid bleeds. This 
apparent discrepancy in plasma HGA is investigated further in chapter 5 of this thesis. 
 
 
Figure 4.6 - Comparison of effects of nitisinone dose on plasma HGA levels after 20 (mid) 
and 40 (term) weeks treatment in BALB/c Hgd-/- mice. Plasma HGA values were 
significantly lower in samples taken at 40 weeks in control and nitisinone treated mice 
compared to those sampled at 20 weeks. 2mg cohort n=7, other cohorts n=6. Significance 
from t test *= P<0.05. Mean ±sem. 
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There was high variability in plasma HGA concentrations consistent with that observed in 
AKU patients [55, 56, 58] and previous murine studies (70, 72]. This variability was 
apparent within mice of the same cohort (often littermates of the same inbred strain) and 
within the same mouse at different time points. Variation in HGA was higher in 20 week 
mid bleed samples compared to 40 week term samples for all but the 0.125mg cohort due 
to a high value outlier at the terminal bleed (table 4.1). 
 
Nitisinone Dose 
mg/L 
HGA mid bleed 
coefficient of variation (%) 
HGA term bleed 
coefficient of variation (%) 
0 35.4 18.2 
0.125 52.0 53.4 
0.5 45.1 18.3 
2.0 22.6 20.6 
Table 4.1 – Coefficient of variation for HGA from mid and term bleeds. Variability was 
lowest in 2mg nitisinone at the mid-term bleed. Variability was lower in terminal compared 
to mid bleeds in all but the 0.125mg cohort due to a high outlier. 2mg cohort n=7, other 
cohorts n=6. 
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4.3.1.3 Phenylalanine 
Phenylalanine plasma values sampled at the 20 week mid bleed showed significant 
variation between groups (P<0.0001). Mice receiving 2mg nitisinone had significantly 
elevated levels compared with control mice (P=<0.01) (Fig 4.7). Phenylalanine did not 
fluctuate significantly compared with control in mice receiving 0.125mg or 0.5mg 
nitisinone. However, terminal bleed phenylalanine values showed no significant fluctuation 
compared to control mice for any nitisinone doses (Fig 4.8). 
 
 
Figure 4.7 - Effect of nitisinone on plasma phenylalanine after 20 weeks treatment in 
BALB/c Hgd-/- mice. Mice receiving the highest 2mg dose of nitisinone showed significantly 
elevated phenylalanine levels compared to control. 2mg cohort n=7, other cohorts n=6. 
Significance from post hoc Dunnetts test ** = P<0.01. 
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Figure 4.8 - Effects of nitisinone on plasma phenylalanine after 40 weeks treatment in 
BALB/c Hgd-/- mice. No significant differences were apparent between cohorts. 2mg 
cohort n=7, other cohorts n=6. 
 
 
 
 
 
 
 
 
 
 
n.s. 
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A significant difference between mid and terminal bleeds was observed in control mice 
(P=0.0035) and in mice receiving 0.125mg nitisinone (P=0.0001) (Fig. 4.9) Mice receiving 
0.5mg nitisinone also showed variation between mid and terminal bleed values but this 
was not statistically significant. 
 
 
Figure 4.9 - Comparison of the effects of nitisinone dose on plasma phenylalanine levels 
after 20 (mid) and 40 (term) weeks treatment in BALB/c Hgd-/- mice. Control and 
0.125mg cohorts showed significantly elevated plasma phenylalanine in samples collected 
at 40 weeks compared to 20 weeks. Significance from t test ** = P<0.01, *** =P<0.001. 
Mean ±sem, 2mg cohort n=7, other cohorts n=6. 
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4.3.1.4 HPPA 
Plasma HPPA values measured at 20 weeks were significantly different between cohorts 
(P<.0001). HPPA was elevated in line with nitisinone dose (Fig. 4.10). All mice within the 
control cohort had HPPA values below the detection range (<10umol/L), the value of 
10umol/L was therefore assigned to the control group for analysis. Mice receiving 0.5mg 
and 2mg nitisinone showed significantly elevated HPPA levels compared with control 
(P<0.01). Intra-cohort variation within the 0.5mg and 2mg dose mice was also higher 
compared with control and 0.125mg cohorts. 
 
 
Figure 4.10 - Effect of nitisinone dose on plasma HPPA levels after 20 weeks treatment in 
BALB/c Hgd-/- mice. HPPA shows a significant and elevated dose response to nitisinone. 
2mg cohort n=7, other cohorts n=6. Significance from post hoc Dunnetts test ** = P<0.01. 
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Figure 4.11 - Effect of nitisinone dose on plasma HPPA levels after 40 weeks treatment in 
BALB/c Hgd-/- mice. An elevated dose response was still evident at 40 weeks although this 
was less marked than the response at 20 weeks and HPPA values were lower in all 
nitisinone treated cohorts. 2mg cohort n=7, other cohorts n=6. Significance from post hoc 
Dunnetts test ** = P<0.01. 
 
Plasma HPPA values sampled at 40 weeks were significantly reduced compared to the 20 
week mid bleed in nitisinone treated cohorts. Although a dose response was still evident 
with HPPA values highest in the 2mg cohort and these reducing in line with nitisinone dose 
(Fig. 4.11), all cohorts receiving nitisinone had HPPA values markedly lower, similar to the 
effect seen in HGA at 40 weeks (Fig. 4.6). T test results showed HPPA levels within cohorts 
were significantly reduced between mid and terminal bleeds for 0.125mg (P=0.0255), 
0.5mg (P=0.0020) and 2mg (P=0.0002) nitisinone doses (Fig. 4.12). These and other 
metabolite discrepancies are addressed in chapter 5 of this thesis. 
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Figure 4.12 - Comparison of the effects of nitisinone dose on plasma HPPA levels after 20 
(mid) and 40 (term) weeks treatment in BALB/c Hgd-/- mice. Plasma HPPA was 
significantly reduced in nitisinone treated cohorts at 40 weeks. Significance from t tests * = 
P<0.05, ** = P<0.01, *** = P<0.001. Mean ±sem, 2mg cohort n=7, other cohorts n=6. 
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4.3.1.5 HPLA 
Plasma HPLA levels at 20 weeks showed an elevated dose response in nitisinone treated 
cohorts compared to control with significant differences between cohorts (P<0.0001) (Fig. 
4.13). Control HPLA values were below detection rate (<5umol/L) so these were set at 
5umol/L for analysis. 0.125mg nitisinone dose caused elevation of HPLA compared to 
control but Dunnetts post hoc test showed this was not significant. 0.5mg and 2mg 
nitisinone caused significant elevation of HPLA compared with control (P<0.01). A similar 
effect was observed for plasma HPLA at 40 weeks, which remained elevated in a dose 
responsive manner in mice receiving nitisinone compared with control (Fig. 4.14). 
 
 
Figure 4.13 - Effect of nitisinone dose on plasma HPLA levels after 20 weeks treatment in 
BALB/c Hgd-/- mice. 0.5mg and 2mg resulted in significantly elevated HPLA compared to 
control. 0.125mg had no significant effect on HPLA. 2mg cohort n=7, other cohorts n=6. 
Significance from post hoc Dunnetts test ** = P<0.01. 
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Figure 4.14 - Effect of nitisinone dose on plasma HPLA levels after 40 weeks treatment in 
BALB/c Hgd-/- mice. 0.5mg and 2mg resulted in significantly elevated HPLA compared to 
control. 0.125mg had no significant effect on HPLA. 2mg cohort n=7, other cohorts n=6. 
Significance from post hoc Dunnetts test ** = P<0.01. 
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Mice receiving 0.5mg and 2mg nitisinone showed a significant reduction in mean plasma 
HPLA levels between 20 and 40 weeks bleeds (t test P=0.0406 and P=0.0015 respectively) 
(Fig. 4.15). Similar discrepancies were found HGA and HPPA (Fig. 4.6 and Fig. 4.12 
respectively) in which plasma values were also significantly lower at 40 weeks compared to 
20 weeks despite no change in treatment. These findings are investigated further in 
chapter 5 of this thesis. 
 
 
Figure 4.15 - Comparison of the effects of nitisinone dose on plasma HPLA levels after 20 
(mid) and 40 (term) weeks treatment in BALB/c Hgd-/- mice. Plasma HPLA was 
significantly lower at 40 weeks compared to 20 weeks in 0.5mg and 2mg nitisinone treated 
mice. Significance from t test * = P<0.05, ** = P<0.01. Mean ±sem, 2mg cohort n=7, other 
cohorts n=6. 
. 
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Overall, a systematic dose response to nitisinone was observed for all metabolites 
measured (Fig. 4.16, Fig 4.17). Phenylalanine appeared to be the most stable metabolite 
over the series of doses investigated displaying only minor fluctuations compared to 
control values. HGA, HPPA and HPLA values differed significantly within the same cohorts 
between mid and terminal plasma samples in nitisinone treated mice. Unexpectedly, HGA 
was also significantly different between mid and terminal samples in control mice who 
received no nitisinone treatment. These results prompted a further study to investigate 
whether this was a methodological or genuine finding, the results of which are presented 
and discussed in chapter 5 of this thesis. 
 
 
Figure 4.16 - Overall effect of nitisinone dose on plasma metabolites measured after 20 
weeks treatment (mid bleed) in BALB/c Hgd-/- mice. All metabolites showed a systematic 
dose response to nitisinone. Logarithmic scale to enable inclusion of tyrosine values and 
clarity of response in other metabolites. Mean ±sem, 2mg cohort n=7, other cohorts n=6. 
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Figure 4.17 - Overall effect of nitisinone dose on plasma metabolites measured after 40 
weeks treatment (terminal bleed) in BALB/c Hgd-/- mice. All metabolites showed a similar 
systematic dose response to nitisinone as observed in the 20 week mid bleed although 
values for HGA, HPPA and HPLA had decreased. Logarithmic scale to enable inclusion of 
tyrosine values and clarity of response in other metabolites. Mean ±sem, 2mg cohort n=7, 
other cohorts n=6. 
 
 
 
 
 
 
 
107 
 
4.3.2 Pigmentation quantification 
Two classification methods were used for quantification of pigmentation in the Hgd-/- 
mouse tibio-femoral joint – cellular staining only and peri-cellular and cellular staining 
combined. Both classification methods showed the same dose response for pigmentation 
measured in post mortem histological sections of the tibio-femoral joint – a decrease in 
pigmented chondrocytes for mice receiving 0.5mg and 2mg nitisinone compared with 
control (Fig. 4.18). Pigmentation was highest in control mice and those receiving 0.125mg 
nitisinone. Mice within these groups showed high intra-cohort variation in pigmentation 
levels. The lowest 0.125mg nitisinone dose did not significantly reduce pigmentation 
compared with control for either pigmentation classification method. A slight increase in 
mean(±sem) pigmentation was observed in the 0.125mg dose compared with control 
(184.8±25.3 pigmented chondrons per histological section increasing to 197.8±27.1 
respectively). Mean pigmentation in the 0.5mg dose cohort was significantly lower 
compared with control in both classifications of pigmentation (P<0.01). The 2mg/L dose 
further significantly lowered pigmentation compared with control (p=<0.0001). Overall, 
mean(±sem) cellular pigmentation levels reduced from 184.8±25.3 in the control group to 
43.0±8.2 and 5.1±1.5 in the 0.5mg/L and 2mg/L group respectively.  
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Figure 4.18 - Quantification of pigmented chondrocytes counts showing both 
classification methods - cellular staining only and peri-cellular and cellular staining 
combined, 2mg cohort n=7, other cohorts n=6. Stained with Schmorls reagent. Both 
classification systems show a significant dose response for pigmentation. The number of 
pigmented chondrocytes appeared to be unaffected by the lowest 0.125mg dose with 
pigmentation levels being similar to the control group. Pigmentation decreased by over 
75% for the 0.5mg group when compared to the control and 0.125mg groups. A similar 
dose response trend was observed in mice receiving 2mg nitisinone with pigmentation 
showing a drop of around 75% compared with the 0.5mg dose. 
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4.3.2.1 Inter-observer variability 
Both classification systems of pigmentation of chondrocytes produced consistent 
quantification with matching pigmentation trends for doses independent of the 
classification system used. To assess reliability of quantification, a second observer 
repeated cellular pigmentation counts for two sections from each cohort (Fig 4.19). An 
intraclass correlation coefficient (ICC) test with absolute agreement was run for 
pigmentation counts to assess inter-observer variability. The ICC was 0.96 and was 
significantly difference from 0 (P = 0.001) indicating excellent correlation and low inter-
observer variability. Pearson’s correlation coefficient was 0.9223 and indicated a positive 
linear correlation. This confirmed the reliability of the cellular pigmentation classification 
method. For this reason, the cellular classification quantified data was selected for use in 
subsequent analysis (Table 4.2). 
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Figure 4.19 - Inter-observer variability and correlation of cellular pigmentation 
quantification method. Scatter charts demonstrating low variability in the number of 
pigmented chondrocytes between two independent observers (RL and CK).  
 
Nitisinone 
Dose 
(mg/L) 
n Pigmentation  
classification 
Mean SD SEM 
0 control 7 Cellular 184.8 61.9 25.3 
  Cellular + peri-cellular 335.8 92.2 37.6 
0.125 6 Cellular 197.8 66.4 27.1 
  Cellular + peri-celluar 364.7 104.0 42.5 
0.5 6 Cellular 43.0 20.0 8.2 
  Cellular + peri-cellular 88.0 37.7 15.4 
2 6 Cellular 5.1 4.1 1.5 
  Cellular + peri-cellular 21.9 13.7 5.2 
Table 4.2 - Quantification of mean pigmentation in the tibio-femoral joint of 43 week old 
control and nitisinone treated BALB/c Hgd-/- mice. 
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4.3.3 Pigmentation in BALB/c Hgd-/- tibio-femoral joint 
4.3.3.1 Control mice 
Extensive cellular and peri-cellular ochronotic pigmentation was apparent throughout the 
articular calcified cartilage (ACC) of the tibio-femoral joint in control mice (Fig 4.21, Fig. 
4.22). Pigmentation was also present in the intercondylar regions and fibrocartilaginous 
entheses where attachment of ligaments result in areas of high stress. (Fig. 4.20). Control 
mice showed high variation in pigmentation levels (cellular range: 119-258, peri-cellular 
range: 235-449) and had high levels of peri-pigmented chondrocytes in the early stages of 
ochronotic pigment deposition. 
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Figure 4.20 - Pigmentation in 43 week old, BALB/c Hgd-/- control mouse (30.4). Extensive 
pigmentation of the ACC including heavily pigmented chondrocytes on the lateral tibial 
plateau and lateral femoral condyle (black arrows), close to the intercondylar region and 
attachment of cruciate ligament, areas of high stress. Stained with Schmorls reagent. Bar = 
50um. Zoomed image bar = 20um. 
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Figure 4.21 - Ochronotic pigmentation throughout the ACC of the lateral and medial 
aspects of the tibio-femoral joint of a 43 week old, BALB/c Hgd-/- control mouse (30.4).  
A: High levels of cellular pigmentation within the lateral femoral condyle and lateral tibial 
plateau. B: A heavily pigmented osteophyte was located on the medial femoral condyle 
(black arrow) - a hallmark of cartilage degradation and osteoarthritis. Stained with 
Schmorls reagent. Bar = 50um. 
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Figure 4.22 - Overview of pigmentation of the ACC in the tibio-femoral joint of two 43 
week old, BALB/c Hgd -/- control mice. A: mouse 30.1, B: mouse 30.6. These mice showed 
the highest pigmentation levels within the control cohort. Stained with Schmorls reagent. 
Bar=100um. 
 
 
 
 
 
 
 
115 
 
4.3.3.2 Nitisinone 0.125mg/L 
Pigmentation levels did not differ significantly compared to control cohorts in mice 
receiving 0.125mg nitisinone. There was extensive cellular and peri-cellular pigmented 
chondrocytes throughout the ACC of the femur and tibia. (Fig. 4.23, Fig. 4.24). As with 
control mice, pigmentation spanned into the fibrocartilaginous entheses and intercondylar 
regions.  Mice within this group showed high variation in pigmentation levels (cellular 
range 106 – 252, peri-cellular range 195-477) similar to the control group. Mean(±sem) 
pigmentation levels in this group were in fact slightly higher than control, 197.8±27.1 and 
184.8±25.3 respectively. 
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Figure 4.23 - Ochronotic pigmentation in the ACC of the tibio-femoral joint of 43 week 
old, BALB/c Hgd-/- mice receiving 0.125mg nitisinone. Pigmentation levels were similar to 
that of control mice with cellular and peri-cellular pigmented chondrocytes widespread 
throughout the joint. A & B: Along with pigmentation in the medial femoral condyle and 
medial tibial plateau, there were also signs of osteoarthritis such as fibrillations and 
damage to the hyaline articular cartilage (arrowed). C: Pigmented chondrocytes throughout 
C 
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the lateral tibial plateau and lateral femoral condyle. D: Chondrocytes showing different 
stages of ochronotic pigmentation – unpigmented (red arrow), peri-pigmented (white 
arrow) and cellular pigmented (black arrow) were present in close proximity throughout 
the ACC. Stained with Schmorls. A,B,C: bar=50um, D: bar=20um. 
 
 
 
 
 
 
 
 
 
Figure 4.24 - Overview of entire tibio-femoral joint of a 43 week old, BALB/c Hgd-/- 
mouse receiving 0.125mg nitisinone for 40 weeks. Ochronotic pigmentation was 
widespread throughout the ACC. Levels of pigmentation were similar to control mice. 
Stained with Schmorls reagent. Bar = 100um. 
 
4.3.3.3. Nitisinone 0.5mg/L  
Ochronotic pigmentation levels in the 0.5mg nitisinone cohort were significantly lower 
compared with the control cohort (P<0.01). Intra-cohort variation in pigmentation 
levels were also lower (cellular range 22-77, peri-cellular range 44-131). Cellular 
pigmentation appeared to be localised to areas of high stress such as the 
intercondyler area around the attachment of ligaments (Fig. 4.25A). Mice within this 
cohort had large areas of ACC with either early stage, peri-cellular pigmentation or 
unpigmented chondrocytes (Fig. 4.25B). 
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Figure 4.25 - Ochronotic pigmentation in 43 week old BALB/c Hgd-/- mice receiving 0.5mg 
nitisinone for 40 weeks. A: Areas of cellular pigmentation were clustered around the 
insertion of ligaments in the lateral femoral condyle (arrowed). B: Large areas of the ACC in 
the medial femoral condyle and medial tibial plateau in mouse 26.2 showed very low levels 
of pigmentation and this was mostly early stage, peri-pigmentation. Stained with Schmorls. 
Bar=50um. 
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Figure 4.26 - Overview of entire tibio-femoral joint in 43 week old BALB/c Hgd-/- mouse 
receiving 0.5mg nitisinone for 40 weeks. Pigmentation was significantly reduced compared 
with control mice. Stained with Schmorls reagent. Bar=100um. 
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4.3.3.4 Nitisinone 2mg/L 
Ochronotic pigmentation was reduced to very low levels in the 2mg nitisinone cohort with 
these being significantly lower than control levels (P<0.01) (Fig. 4.27, Fig. 4.28). Intra-cohort 
variation in pigmentation levels were also lowest (cellular range 0-13, peri-cellular range 
10-46).  
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Figure 4.27 – A&B: Very low levels of ochronotic pigmentation in the ACC of the medial 
femoral condyle and medial tibial plateau in 43 week old mice receiving 2mg nitisinone 
for 40 weeks. Stained with Schmorls reagent. Bar=50um. 
 
 
A 
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Figure 4.28 - Overview of entire tibio-femoral joint of 43 week old, BALB/c Hgd-/- mouse 
(13.6) receiving 2mg nitisinone for 40 weeks. Very low levels of pigmentation throughout 
the ACC. Stained with Schmorls. Bar=100um. 
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Comparison of ochronotic pigmentation levels between cohorts showed a visible and clear 
dose response to nitisinone with pigmentation decreasing as nitisinone dose increased (Fig. 
4.29). 
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B 
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Figure 4.29 - Comparison of ochronotic pigmentation within the ACC of the medial 
femoral condyle and medial tibial plateau in 43 week old Hgd-/- BALB/c mice receiving 
0mg (A), 0.125mg (B), 0.5mg (C) and 2mg (D) nitisinone for 40 weeks. Control and 
0.125mg cohorts showed similar high levels of pigmentation throughout the articular 
calcified cartilage. 0.5mg nitisinone resulted in a visible reduction in pigmentation. 2mg 
nitisinone reduced ochronotic pigmentation further to reach very low levels. Stained with 
Schmorls. Bar=50um. 
C 
D 
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Degradation of the hyaline articular cartilage and signs of osteoarthritis (OA) including 
fibrillations and osteophytes were apparent in several mice from control and nitisinone 
treated cohorts although these were not quantified (Fig. 4.30). These signs of OA were 
apparent even in mice who were receiving the higher doses of nitisinone who had 
therapeutically reduced plasma HGA from 3 weeks of age and displayed low levels of 
ochronotic pigmentation (Fig. 4.30 C & D). This suggests HGA/ochronotic pigmentation is 
not the only factor leading to joint arthropathy in AKU.  
 
 
Figure 4.30 - Hyaline articular cartilage damage and signs of osteoarthritis in the tibio-
femoral joint of 43 week old, control and nitisinone treated BALB/c Hgd -/- mice. Several 
mice from control and nitisinone treated groups showed signs of osteoarthritis (arrowed) 
A: An osteophyte present on the medial femoral condyle of a control mouse. B: Fibrillations 
and hyaline articular cartilage damage of the medial tibial plateau in a mouse receiving 
0.125mg nitisinone C: Severe damage to the hyaline articular cartilage of the medial tibial 
plateau, exposing the underlying articular calcified cartilage in a mouse receiving 0.5mg 
nitisinone. D: Fibrillations in the hyaline articular cartilage of the medial tibial plateau in a 
mouse receiving 2mg nitisinone. Stained with Schmorls reagent. Bar=50um. 
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4.3.4 Relationship between HGA and ochronotic pigmentation  
Nitisinone lowered plasma HGA for all treated cohorts compared with control (Fig. 4.31). 
The lowest 0.125mg nitisinone dose reduced mean plasma HGA to 89umol/L (133umol/L in 
control) but this had no significant effect on pigmentation levels. Mean pigmentation levels 
were in fact slightly higher in the 0.125mg cohort compared with control levels. The 0.5mg 
nitisinone cohort had mean plasma HGA of 51.9umnol/L and with this, a beneficial effect of 
lowered HGA on pigmentation was observed resulting in a 77% reduction in pigmentation 
compared with control. The 2mg nitisinone cohort displayed a larger decrease in mean 
plasma HGA levels of 28.7umol/L and a 97% reduction in pigmentation compared to 
control.  
 
 
Figure 4.31 - The relationship between plasma HGA concentration and ochronotic 
pigmentation is not linear. The effect of 0.125mg nitisinone was not sufficient to see a 
reduction in ochronotic pigmentation of chondrocytes within the mouse tibio-femoral joint. 
The beneficial effect of HGA reduction on pigmentation is apparent in the 0.5mg cohort 
when plasma HGA reached ~50umol/L resulting in a 75% reduction in pigmentation. The 
highest 2mg dose reduced HGA and pigmentation further. Terminal bleed HGA and 
tyrosine values plotted.  
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Over the series of doses, the relationship between plasma HGA concentration and number 
of pigmented chondrocytes was correlated. The lowest 0.125mg dose appeared to be 
effective in two individuals resulting in a reduction in pigmentation but this effect was not 
seen in the other four mice within the same cohort suggesting a dose around here is a 
critical point (Fig. 4.32). One mouse within this cohort also had a high plasma HGA value 
(185.4umol/L), higher than any values from the control cohort and seemingly an outlier, 
but interestingly this mouse had the third lowest pigmentation within the cohort. 0.5mg 
and 2mg nitisinone lowered plasma HGA sufficiently to reduce pigmentation in all 
individuals. 2mg also reduced intra-cohort variation in HGA and pigmentation levels with 
values from this cohort forming a distinct cluster.   
 
 
Figure 4.32 - The correlation of plasma HGA and ochronotic pigmentation after 40 weeks 
nitisinone treatment in BALB/c Hgd-/- mice. Plasma HGA concentration and number of 
pigmented chondrocytes was correlated over the series of doses. This correlation became 
stronger as nitisinone dose increased. The lowest non-control dose (0.125mg) lowered 
plasma HGA in all mice within the cohort but pigmentation was only reduced in two 
individuals. 0.5mg and 2mg nitisinone lowered HGA sufficiently to reduce pigmentation in 
all mice suggesting a critical value of 60umol/L must be reached before pigmentation levels 
are affected.  
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4.4 DISCUSSION 
This study set out to assess the long-term dose response of nitisinone administration in the 
Hgd-/- mouse. Previous studies have observed the short-term response of plasma HGA 
concentration and investigated the long-term effect of midlife and lifetime administration 
of one dose (4mg/L) on ochronotic pigmentation [70, 72]. Predominantly, this study aimed 
to determine the minimum effective dose of nitisinone required to lower plasma HGA and 
reduce ochronotic pigmentation whilst minimising the elevation of tyrosine. The results 
support the hypothesis set out at the beginning of this chapter with additional context 
related to tyrosine concentration. 
 
4.4.1 HGA and ochronotic pigmentation 
Plasma HGA exhibited a dose related decrease and high sensitivity to nitisinone in all 
treated cohorts but the correlation between HGA concentration and ochronotic 
pigmentation was not linear. Pigmentation levels in control mice were consistent with 
those found in mice of a similar age (40 weeks) in a natural history of ochronosis study by 
Preston and colleagues [70]. Although mice receiving 0.125mg/L nitisinone showed a mean 
reduction in plasma HGA of 33% compared with control, pigmentation levels were only 
significantly reduced in two individuals within the cohort. A mouse within this cohort (Hgd-
/- 29.3) appeared to be an outlier with very high HGA levels compared with controls and 
0.125mg cohort littermates, perhaps exhibiting a reduced sensitivity to nitisinone. The high 
variability within this group may be an indication that this was just below an effective dose 
and not quite reaching the critical therapeutic point to have a beneficial effect for the 
majority of mice. Conversely, another apparent outlier within the 0.125mg cohort (Hgd-/- 
29.2) showed very low HGA levels at the mid-term bleed with a value closer to the cohort 
receiving 2mg nitisinone. Interestingly, within Hgd-/- 29.2, tyrosine was the least elevated 
out of the cohort and HPPA and HPLA were similar to control levels. Unfortunately, this 
mouse developed a persistent sore on its tail that would not heal and had to be culled prior 
to terminal metabolite measurements. Nevertheless, this could be an example of an 
enhanced response to nitisinone and better endogenous metabolic control within the 
mouse, supporting the notion of tailored nitisinone therapy according to patient sensitivity 
[72].  
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Mice receiving 0.5mg/L and 2mg/L nitisinone had significantly reduced ochronotic 
pigmentation and plasma HGA concentrations reduced by 61% and 78% of control 
respectively. This suggests plasma HGA must be lowered to a critical threshold 
concentration before deposition of pigment within connective tissue is affected. In this 
case, the critical levels for plasma HGA appeared to be between 40-60umol/L. Below 
40umol/L resulted in a dramatic reduction in pigmentation whereas above 60umol/L 
pigmentation was similar to control and showed maximal levels of ochronosis (Fig 4.32). 
Mice receiving 0.5mg/L nitisinone exhibited lower pigmentation levels, suggesting that this 
dose provided a prophylactic effect for the joints from ochronosis whilst also producing a 
less pronounced degree of tyrosinemia than the higher 2mg/L dose (Fig 4.31). This is an 
important finding for human therapeutic use. Some patients show high sensitivity to 
nitisinone related tyrosinemia despite restricting dietary protein that manifests as a painful 
corneal keratopathy and requires cessation of treatment whilst these symptoms subside 
[138, 139]. Tailoring the dose of nitisinone for these patients so it provides a practical 
compromise of lowering HGA to relatively harmless levels whilst ensuring the degree of 
tyrosinemia is minimised in order to prevent adverse effects and guarantee continuous 
treatment is thus important for improved therapeutic outcome.    
 
4.4.2 Dosing to reduce elevation of tyrosine 
Along with HGA, a clear dose-response was observed for plasma concentrations of tyrosine 
and its associated phenolic metabolites, HPPA and HPLA, reiterating the efficacy of 
nitisinone (Fig 4.16, Fig. 4.17). Plasma tyrosine concentrations in Hgd-/- control mice were 
similar to those of untreated AKU patients but the elevation of plasma tyrosine and its 
metabolites, HPPA and HPLA post-nitisinone were more marked in the Hgd-/- mouse (Table 
1, appendix). The 0.5mg/L and 2mg/L nitisinone doses used in this study equate to higher 
concentrations than used in human AKU studies, which would explain the higher degree of 
tyrosinemia observed. Tyrosinemia is well tolerated in the mouse as the general metabolic 
activity of this species is far greater than in humans [140]. The mouse liver and kidneys are 
therefore capable of withstanding greater metabolic stresses due to their ability to rapidly 
induce and resynthesise enzymes to enable clearance of metabolic products [141]. The 
mg/kg concentration was determined for each mouse dose used in this study for 
comparison with those used in previous human studies [55, 56]. Calculations were based 
on a 30g mouse consuming 4-6ml drinking water per day [136, 137] and equated to 0.0175-
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0.025 mg/kg, 0.07-0.1mg/kg and 0.25-0.4mg/kg for 0.125mg/L, 0.5mg/L and 2mg/L 
respectively. The recent SONIA1 human study had used 10mg per day, being the nearest 
readily available dose, but this had to be reduced in some patients due to keratopathy 
presumed secondary to high tyrosine. The SONIA1 study concluded 8mg daily as the most 
efficacious dose for AKU patients, which equates to 0.114mg/kg for a 70kg patient. Within 
this study, the 0.5mg/L or 00.7-01mg/kg dose is closest to the SONIA1 8mg human dose 
and provided a practical compromise of lowering plasma HGA sufficiently to reduce 
pigmentation whilst also producing a lower degree of tyrosinemia than higher doses. This 
degree of congruence in the two species is surprising and promising for facilitating tailoring 
of treatment.  
 
4.4.3 HPPA and HPLA  
The degree of tyrosinemia and elevation of HPPA and HPLA in the 0.5mg/L and 2mg/L 
nitisinone treated cohorts were more pronounced in the mid-term bleed than the terminal 
bleed. Lock et al compared acute and chronic dosing in the mouse and showed repeated 
exposure to nitisinone reduces the extent of tyrosinemia. They observed a single dose of 
10mg/kg nitisinone in mice caused elevation of tyrosine to a maximum of 1200umol/L 
whilst 6 weeks daily administration of doses up to 160mg/kg also resulted in tyrosinemia 
but this was 50% lower than in the single dose cohort. They proposed this might reflect the 
increasing ability of the mouse liver TAT to metabolise tyrosine to HPPA and to facilitate 
clearance in the urine [141]. The differences observed in this study may also be an example 
of the mouse acclimatising to the nitisinone induced tyrosinemia and becoming more 
efficient at urinary clearance of tyrosine and its phenolic metabolites HPPA and HPLA, 
between mid-term and terminal plasma samples. Upon further reflection, although the 
terminal bleed tyrosine levels were lower that the mid-term bleed, both treatment periods 
would be considered as chronic dosing (20 and 40 weeks of daily dosing). More so, the 20 
week bleed could not be considered as an acute dose for comparison with the Lock et al 
study who only used a single dose. The possibility that the unexpected discrepancies in 
plasma levels of tyrosine, HPPA and HPLA between mid and terminal bleeds were 
methodological is investigated further in chapter five of this thesis.  
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Normally, plasma HPPA concentrations are low or undetectable due to HPPD conversion of 
HPPA to HGA. HPPD inhibition via nitisinone causes HPPA to increase and exert product 
inhibition on the enzyme tyrosine amino transferase (TAT) and its conversion of tyrosine to 
HPPA. This product inhibition of TAT by HPPA and the resulting elevation of tyrosine 
produce the tyrosinemia observed as a side effect of nitisinone therapy. The conversion of 
HPPA to HPLA is normally a dormant process. This alternative endogenous pathway can be 
activated to increase tyrosine degradation and excretion via the kidneys in an attempt to 
counteract elevated tyrosine [135]. Tyrosine, HPPA and HPLA all undergo renal clearance 
and urinary excretion but much of the tyrosine is reabsorbed explaining the observed 
higher levels of plasma tyrosine compared with HPPA and HPLA, which are more readily 
excreted in the urine [142].  
Within the terminal bleeds, two mice in the 0.5mg cohort had tyrosine values just below 
500umol/L (454.7 and 478.1) and both had equal levels of HPPA/HPLA (20.5/21.8umol/L 
and 21.5/20.4umol/L respectively). All other mice within this cohort had tyrosine values 
between 500-600umolL and HPLA that exceeded HPPA by 5-10umol/L. As tyrosine levels 
were elevated further in the 2mg nitisinone cohort, HPLA then exceeded HPPA values by up 
to 10-40 umol/L. This could suggest that conversion of HPPA to HPLA exceeds TAT synthesis 
of HPPA occurs once plasma tyrosine reaches >500umol/L. HPLA was higher than HPPA in 
mice once tyrosine reached this value suggesting this is around acritical point where the 
HPPA to HPLA conversion pathway is activated. Upon further analysis, mid-term bleeds did 
not show the same trend with HPPA and HPLA values being much higher in the 0.5mg and 
2mg bleed cohorts and HPLA never exceeding HPPA values. This was another example of 
the curious metabolite discrepancies found between bleeds. 
 
4.4.4 HGA variability  
 
There was high variability in plasma HGA concentrations consistent with that observed in 
AKU patients [55, 56, 58] and previous murine studies [70, 72] (Fig. 4.4, Fig. 4.5, Table 4.1). 
This variability was apparent within mice of the same cohort (often littermates of the same 
inbred strain) and within the same mouse at different time points. The highest 2mg dose of 
nitisinone appeared to reduce HGA variability in the 20 week, mid term bleed. Terminal 
bleed coefficients of variants were lower than mid bleed in all but the 0.125mg nitisinone 
cohort due to the high outlier mentioned previously (Hgd-/- 29.3). Interestingly, the 
coefficient of variation for the control cohort was markedly lower in the terminal (18.2%) 
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than mid bleed (35.4%) despite receiving no therapy.  Once more, this was an unexpected 
finding and seemed unlikely simply due to variation as all mice within the control cohort 
had significantly reduced plasma HGA in terminal bleeds compared to mid term bleeds. 
This finding was investigated further in chapter five. 
 
4.4.5 Mid-term and terminal bleed metabolite discrepancies 
Many of the metabolites varied significantly between mid and terminal bleeds not only in 
nitisinone treated cohorts but also in control mice. For this reason, it was necessary to 
investigate possible explanations for this. Unexpectedly, despite the control receiving no 
pharmacological intervention, all but one mouse showed significant decreases of between 
30-70% in HGA between mid and terminal bleeds. This goes against previous work by 
Preston et al who observed that although plasma HGA is subject to variation, it does not 
rise or fall significantly over the untreated Hgd-/- mouse lifetime [70]. An explanation for 
the differences observed between mid and terminal bleeds could be the site or method of 
plasma sampling. Mid-term bleeds were obtained from one of the paired lateral caudal 
veins in the lower third of the tail after the mouse had been incubated in a heat box at 38 
degrees Celsius for several minutes to aid with vasodilation. Terminal bleeds were obtained 
directly from the brachial artery after schedule 1 culling with an overdose of 
pentobarbitone sodium. In hindsight, here lies a weakness of the study – terminal bleeds 
should have been sampled from the tail immediately prior to culling to provide 
measurements that were better comparable with mid bleed samples although there was 
no prior reason to expect a systematic difference. Administration of pentoject prior to the 
terminal bleed sampling could have also affected plasma metabolites. As all cohorts 
showed significant differences in metabolites between mid and terminal bleeds, a further 
study investigating the effect of sampling method on plasma metabolites was designed and 
implemented, the results of which form chapter five of this thesis. 
 
Notwithstanding a possible methodological explanation, the lower plasma HGA between 
mid and terminal bleeds in control and nitisinone treated mice (Fig. 4.6) could have been 
due to an increased rate of ochronosis and pigment deposition between 20 and 40 weeks 
of age in the Hgd-/- mouse. Perhaps HGA polymerisation and deposition into cartilaginous 
tissue during the interval between bleeds aided to remove some HGA from the blood 
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causing a reduction in plasma concentrations. The 0.125mg nitisinone treated cohorts had 
reduced levels of HGA but this dose was not sufficient to reduce pigmentation therefore 
additional HGA was reduced by ochronosis. The reduction in HGA in the 2mg cohort 
between mid and terminal bleeds was much smaller than other cohorts, perhaps because 
HGA was lowered sufficiently to prevent pigment deposition so the rate of ochronosis due 
to increased age had less of an effect. The Hgd-/- natural history study carried out by 
Keenan et al found extensive increase in pigmentation levels between 20 and 40 weeks 
which would support this [72] but conversely, Preston et al reported plasma HGA was 
relatively constant throughout the lifetime of the mouse despite pigmentation increasing 
through life; chapter five examines these discrepancies in more detail.  
 
Phenylalanine demonstrated the least fluctuation out of the metabolites measured in 
control and nitisinone treated cohorts. Mid-term bleeds showed a significant elevation in 
mice receiving 2mg/L nitisinone compared with control, this statistically significant 
difference was not evident in the terminal bleeds due to increased intra-cohort variation 
but values were still raised (Fig. 4.7, Fig. 4.8). As an essential amino acid, phenylalanine 
cannot be synthesised by the body and is obtained solely through diet [142]. Phenylalanine 
hydroxylation to tyrosine is an irreversible process so elevated tyrosine levels as a result of 
nitisinone should not directly affect phenylalanine levels. The increase in the 2mg 
nitisinone cohort could be due to normal variation of food intake within the mice although 
this would most likely also be seen in other cohorts and was not. Mice were maintained on 
a normal protein diet throughout the study so phenylalanine intake remained similar but 
could have fluctuated slightly depending on the mouse’s intake of food prior to plasma 
sample collection. A possible explanation could be that the effects of elevated tyrosine in 
the 2mg cohort increased the mouse appetite by affecting the thyroids production of 
thyroxine, effectively inducing a state of hyperthyroidism in an attempt to clear or utilise 
the surplus tyrosine. In support of this, a study by Diarra and colleagues found 
hyperthyroidism decreased tyrosinemia and endogenous tyrosine levels in the striatum, 
adrenals and heart in rats. They concluded that the thyroid status of the rat can influence 
tyrosine uptake mechanisms and catecholamine synthesis and that this is likely due to 
thyroid hormones modulation of tyrosine hydroxylase activity, the enzyme which catalyses 
the rate limiting step in catecholamine biosynthesis [143]. This connects to another 
possible explanation whereby the increase in tyrosine is stimulating dopamine production 
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(a catecholamine), that is also linked to regulation of appetite and motivation to consume 
food [144, 145]. A study by Hardman and colleagues examining the effects of tyrosine 
depletion on appetite found participants reported significantly lower levels of hunger 
following a fixed-test meal relative to non-tyrosine depleted controls [146]. The opposite 
could be occurring in the 2mg cohort with the increased plasma tyrosine stimulating 
dopamine synthesis and in turn, the related motivational components of eating and 
stimulation of appetite. 
 
4.4.6 Limitations  
Finally, an accepted limitation of this chapter is the lack of behavioural and motor function 
testing after 40 weeks treatment with nitisinone. This could have provided data examining 
the effects of chronic nitisinone dosing in the Hgd-/- mice on learning and memory and 
would have been valuable to compare with data obtained in chapter 3. Unfortunately, this 
was a missed opportunity due to time constraints and should be considered for the future 
licencing process. 
 
The findings of this chapter demonstrated the systematic dose response of metabolites in 
the tyrosine pathway to nitisinone treatment. Data revealed plasma HGA and pigmentation 
are correlated but that this relationship does not appear to be linear with HGA having to be 
reduced to a critical level prior to pigmentation being affected. This chapter also 
demonstrated that nitisinone dose can be tailored to provide a protective HGA and 
ochronotic pigmentation lowering effect whilst also minimising the elevation of tyrosine. 
These findings have positive implications for AKU patients with a predisposition to tyrosine 
toxicity.   
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5. Investigating the arteriovenous blood metabolome relating to Alkaptonuria in 
the BALB/c Hgd-/- mouse. 
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5.1 INTRODUCTION 
This study was designed to investigate unexpected discrepancies between plasma 
metabolites in samples collected from BALB/c Hgd-/- cohorts within the nitisinone long-
term dose response study. The plasma metabolite results detailed in chapter 4 of this thesis 
(Fig. 5.1) indicated significant differences between metabolites measured in the mid-term 
bleeds and those measured in the terminal bleed. This was the case for all nitisinone 
treated cohorts; a reduction in plasma HGA was expected due to the proven HPPD 
inhibiting mode of action of nitisinone shown to be efficacious within 1-2 weeks [55, 56, 58]. 
Mid-term plasma sampled after 20 weeks treatment with nitisinone showed a dose related 
decrease in HGA but unexpectedly, terminal plasma sampled after 40 weeks treatment 
showed significant further decreases in HGA. Previous studies in humans [55, 56, 99] and 
mice [70, 72] have shown nitisinone reduces plasma HGA within 1-2 weeks and that these 
levels remain relatively constant with continued treatment of the same dose. Furthermore, 
within the long-term dose response study, a significant difference (↓46%) in plasma HGA 
was also observed within the control cohort between mid and terminal plasma samples, 
the mice from which had received no treatment or exposure to nitisinone within their 
lifetime. This difference in plasma HGA in control mice was in contradiction of previous 
work by Preston et al who concluded plasma HGA levels, although subject to variation, 
show no significant rise or fall over the Hgd-/- mouse lifetime [55].  
 
Arteriovenous discrepancies do exist for some metabolites between types of blood samples. 
Lactate for example, where arterial blood is considered the ”gold standard” sample due to 
having constant concentrations irrespective of sample site. This is because arterial blood is 
derived from a mixed venous blood composition (since all venous fields drain into the right 
atrium), providing a representative sum of all sources of tissue lactate production. By 
contrast, the concentration of lactate in venous blood can vary depending on the site of 
sampling because of variation in local tissue lactate production with central venous 
samples considered superior to peripheral venous samples [147-148]. Along with lactate, it 
has long been accepted that arteriovenous differences in glucose and nitrous oxide exist, 
highlighting the difficulty in measuring and comparing metabolic parameters between one 
blood compartment and another [149-152]. A recent paper [153] investigating 
arteriovenous metabolomics in humans found significant differences in phenylalanine, a 
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member of the tyrosine pathway, which raises the question whether this could have 
implications for the other pathway metabolites such as HGA.  
 
The literature indicates that the significant differences in metabolites observed between 
plasma samples in chapter 4 may have been methodological. In the aforementioned study, 
mid-term plasma samples were collected from one of the lateral tail veins without sedation. 
Prior to tail vein sample collection, mice were heated in an incubator to incite 
vasodilatation and briefly held in a Perspex restrainer to minimise risk of injury during 
sample collection. At the end of the study, terminal plasma samples were collected from 
the brachial vessels, providing a more arterial-like blood supply. Terminal bleed samples 
were collected after mice had been culled with an overdose of Pentoject (pentobarbitone) 
for which little research is available for its acute effects on the metabolome. A murine 
study by Clark and colleagues [154] reported that overdose with Pentoject resulted in a 
significant increase in serum miR-122 (a biomarker of liver injury) to a much greater extent 
than mice culled with CO2. They also reported significantly higher levels of miR-122 in 
samples obtained via cardiac puncture (i.e. post-cull) compared with those obtained via tail 
bleed, indicating that differences can exist between arteriovenous metabolites sampled 
minutes apart in the same animal. In consideration of these findings along with the results 
of chapter 4, the following studies were designed to assess whether the metabolite 
fluctuations were methodological providing an unintentional, yet clinically relevant finding 
that could have implications for future work. 
 
5.1.1 Study 1  
Investigation into the differences in metabolites between tail and terminal bleeds from 
chapter 4, examining the effect of collection tube and collection site 
• 9 BALB/c Hgd-/- mice (5 nitisinone treated, 4 control) 
• 2 x consecutive tail (venous) bleeds (approx 70ul each) into microvettes  
• Pentoject overdose and once unresponsive:  
• Terminal bleed (via brachial vessels) collected firstly in a microvette (70ul) and then 
into a monovette (1ml). 
139 
 
Both venous tail bleeds were sampled within several seconds of each other. Venous tail 
bleeds and arterial terminal bleed were sampled a maximum of 5 minutes apart (the time 
for Pentoject to take effect). 
 
5.1.2 Study 2  
Investigation into the trend of decreasing HGA in tail bleeds in control mice. 
• 2 BALB/c Hgd-/- control mice 
• 5 x consecutive tail (venous) bleeds into microvettes were taken to see if the trend 
in falling of HGA continues  
• Pentoject overdose and once unresponsive:  
• Terminal bleed (via brachial vessels) collected into microvette (150-200ul). 
Consecutive venous tail bleeds were sampled within several seconds of each other. Venous 
tail bleeds and arterial terminal bleed were sampled a maximum of 5 minutes apart (the 
time for Pentoject to take effect). 
 
5.1.3 Study 3  
Investigation into differences in HPPA and HPLA between venous tail and terminal arterial 
bleeds in nitisinone treated mice. 
• 3 BALB/c Hgd-/- nitisinone treated mice 
• 5 x consecutive tail bleeds were taken to see if the trend in falling of HGA 
continues,  
• Pentoject overdose and once unresponsive:  
• Terminal bleed (via brachial vessels) collected into microvette (150-200ul). 
Consecutive venous tail bleeds were sampled within several seconds of each other. Venous 
tail bleeds and arterial terminal bleed were sampled a maximum of 5 minutes apart (the 
time for Pentoject to take effect). 
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5.1.4 Study 4  
Investigation into the effect of cull method on metabolites in nitisinone treated and control 
mice. 
• BALB/c Hgd-/- mice (4 nitisinone treated, 3 control) 
• 5 x consecutive tail bleeds were taken to see if the trend in falling of HGA continues 
• Manual culling  
• Terminal bleed (via brachial vessels) collected into microvette (150-200ul). 
Consecutive venous tail bleeds were sampled within several seconds of each other. Venous 
tail bleeds and arterial terminal bleed were sampled a maximum of 45 seconds apart (the 
time taken to cull via cervical dislocation and incise the axilla to reach the brachial vessels). 
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Figure 5.1 - Differences in metabolites between mid-term and terminal bleeds in BALB/c 
Hgd-/- mice from the long-term dose response study (chapter 4). The inconsistencies in 
metabolite values, especially within those of control mice, influenced the decision to carry 
out the subsequent study discussed within this chapter. Mean ± SEM. 
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5.2 HYPOTHESIS AND AIM OF STUDY 
Hypothesis: Within the Hgd-/- mouse, circulating blood will show the same concentration 
of tyrosine breakdown pathway intermediates irrespective of point of sampling.  
Although there is high inter-individual and inter-sample variability in both mice and 
humans for HGA and tyrosine, the long-term dose response study in chapter four also 
showed a significant difference in the mean concentrations of HPPA and HPLA between 
mid and terminal bleeds for all doses of nitisinone investigated. The primary aim of this 
study was to investigate these differences in plasma metabolite concentrations between 
mid-term and terminal bleed samples. It was necessary to examine differences between 
sampling method to assess whether the observed variation in metabolites were 
methodological due to differences within sample site, sample collection or culling method.  
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5.3 RESULTS 
This study began by investigating methodological inconsistencies between the sample 
collection tubes and sampling site. Within the long-term dose response study (chapter 4), 
mid-term bleeds were sampled via one of the lateral tail veins into microvette collection 
tubes. Terminal bleeds were sampled from the brachial vessels into monovette collection 
tubes immediately after schedule one culling with Pentoject. The difference in choice of 
collection tubes had been solely due to the larger volume of blood that can be collected 
from the terminal sample site. Both samples were centrifuged and processed identically to 
obtain plasma for analysis. For the first part of the study contained within this chapter, two 
consecutive tail bleeds were collected, each approximately 70ul, into microvette tubes. 
Mice were than immediately culled via intraperitoneal overdose of Pentoject and two 
terminal bleeds were collected from the brachial vessels, one into microvette (70ul) and 
the other into a monovette (1ml) for comparison. Both venous tail bleeds were sampled 
within several seconds. Venous tail bleeds and arterial brachial bleeds were sampled a 
maximum of 5 minutes apart (time for pentoject to take effect). 
 
5.3.1 Effect of sample collection tube 
There was no significant effect of collection tube (microvette/monovette) on tyrosine 
breakdown metabolites between brachial vessel samples in control or nitisinone treated 
Hgd-/- mice. Samples prepared from both collection tubes showed similar plasma 
metabolite values (Fig. 5.2). This was also the first indication that plasma metabolite 
concentrations sampled from the brachial vessels were less variable than those sampled 
from the tail vein (Fig. 5.3). 
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Figure 5.2 - Collection tube had no significant effect on metabolite values between 
brachial arterial blood samples in control or nitisinone treated BALB/c Hgd-/- mice. Mean 
± SEM plasma metabolite values shown. Treated n=5 control n=4. 
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5.3.2 Differences in metabolites between tail bleeds 
Plasma HGA values showed variation between tail bleeds sampled just seconds apart (Fig. 
5.3). Control and nitisinone treated mice showed a decreasing trend in HGA for the second 
tail bleed. Paired t test results showed differences between the two tail bleeds in control 
mice were statistically significant (t(3)= 3.4319 P=0.0415), differences in nitisinone treated 
mice were not significant (t(4)= 2.0057 P=0.1154). There was no significant variation in the 
other metabolites between tail bleeds. 
 
 
 
Figure 5.3 - Plasma HGA values decrease between two consecutive tail bleeds sampled 
seconds apart. HGA variation is more apparent in control mice when nitisinone has not 
lowered plasma levels but all mice showed the same decreasing trend. 
 
 
Treated: n.s. 
Control: * 
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5.3.3 Differences in metabolites between sample site (venous/arterial) 
To compare venous and arterial bleeds, the mean of both venous tail bleeds (tail 1 and 2) 
and brachial arterial bleeds (microvette/monovette) were calculated to create mean ± SEM 
values for each metabolite in nitisinone treated (n=5) and control (n=4) cohorts. Mean HGA 
values were significantly lower in arterial bleeds compared to venous bleeds in nitisinone 
treated (t(9) = 3.1795 P=0.0112) and control (t(7) = 3.7064 P=0.0076) cohorts. In nitisinone 
treated cohorts, HPPA was also significantly lower in arterial bleeds compared with venous 
bleeds (t(9) = 9.7695 P=0.0001). The opposite was the case for its metabolite, HPLA, which 
was significantly higher in arterial than venous bleeds (t(9)= 15.5979 P=0.0001) (Fig. 5.4). 
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Figure 5.4 - HGA values were significantly lower in brachial bleeds in control mice. HGA 
and HPPA were significantly lower in brachial bleeds and HPLA was significantly higher in 
brachial bleeds in nitisinone treated mice. Tyrosine and phenylalanine showed no 
significant variation between bleeds. Mean ± SEM plasma metabolite values shown. 
Treated n=5 control n=4. * P=<0.05 ** P = <0.01 *** = P<0.001. 
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5.3.4 Five consecutive tail bleeds 
After finding a decreasing trend in HGA values between two consecutive tail bleeds and 
between tail and brachial arterial bleeds, we next investigated whether this decreasing 
trend continued in tail bleeds until these reached arterial bleed values. We hypothesised 
that if a number of consecutive tail bleeds were sampled, the peripheral venous blood 
would be rapidly replaced with that from a more central arterial supply and values may 
become more similar. This was investigated in control (n=2) and treated mice (n=3) so the 
differences in HGA (control), HPPA and HPLA (treated) could be further examined. Five 
consecutive tail bleeds were sampled from the right lateral tail vein, mice were culled with 
Pentoject and a terminal arterial bleed was sampled from the brachial vessels.  
 
Figure 5.5 - Control mice showed variation in HGA between tail bleeds. Mouse 44.1 
showed a dramatic 63% decrease in plasma HGA between tail 1 and tail 2 bleeds which 
then levelled for subsequent bleeds. Mouse 43.3 showed five variable tail bleed HGA values 
but less variation between tail and terminal bleeds.  
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As observed in the previous experiments, the metabolites that varied significantly were 
HGA in control cohorts (Fig. 5.5) and HPPA and HPLA in nitisinone treated cohorts (Fig. 5.6). 
One of the control mice (43.3) showed fluctuating HGA between successive tail bleeds. 
Interestingly, this was the first mouse investigated who showed similar terminal bleed 
plasma HGA to tail bleed values (tail bleed mean 220umol/L, terminal 249umol/L). The 
other control mouse (44.1) had an extremely high first tail bleed of HGA value of 
709umol/L, the subsequent four tail bleeds lowered to within normal range (for an 
untreated Hgd-/- mouse) and remained similar in the terminal bleed. In past studies, 
occasional mice have shown extremely high HGA values and these have usually been 
considered as outliers or erroneous values. It was intriguing to see that this high HGA value 
reduced by over 60% within a matter of seconds and from the same sample site suggesting 
these past high values may not have been due to human or analytical error as previously 
assumed. HPPA and HPLA followed the same trend as in previous experiments with HPPA 
being reduced in terminal arterial bleeds compared to tail bleeds, with the opposite being 
the case for HPLA. These metabolites did not differ significantly between successive tail 
bleeds (Fig. 5.6). 
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Figure 5.6 - Variation in HGA is masked by the therapeutic effect of nitisinone in treated 
Hgd-/- mice. This variation is now apparent in HPPA and HPLA between tail and terminal 
bleeds. Tyrosine removed for clarity.  
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5.3.5 Cull me+thod 
Cull method was subsequently investigated as a possible cause for the observed variation 
in metabolites between venous tail and terminal arterial samples. In the long-term dose 
response study (chapter 4) and the previous studies discussed within this chapter, mice 
were culled prior to terminal sample collection with an intraperitoneal overdose of 
Pentoject (pentobarbitone). In the previous studies of this chapter, this was performed 
immediately after tail bleed plasma samples had been collected. For the following study, 
five consecutive venous tail bleeds were sampled followed by manual culling via cervical 
dislocation. Arterial samples were then collected from the brachial vessels. Control (n=3) 
and nitisinone treated (n=4) cohorts were used for consistency with previous experiments. 
The data was then compared to data from the previous studies where the pentobarbitone 
cull method was used. If a significant effect of cull method was observed, this would only 
apply to terminal arterial samples as culling takes place between tail and terminal bleeds 
and would therefore have no effect on tail bleed plasma metabolites. 
 
The metabolites showing significant variation from each mouse are presented below to 
show each mouse followed a similar trend and this was not simply due to individual 
variation. Tyrosine and phenylalanine, as previously shown, did not vary significantly 
between bleeds so have been removed for clarity. Control mice once more showed highly 
variable plasma HGA, both between consecutive venous tail bleeds and between venous 
tail and terminal arterial bleeds. However, mean terminal bleed HGA values were lower 
than tail bleed values. Once again, a control mouse within this study (55.2) had an 
extremely high HGA value at the first tail bleed (829.5umol/L) which steadily reduced with 
subsequent bleeds over a period of 20 to 30 seconds until it was within the normal range 
for an untreated Hgd-/- mouse. Conversely, mouse 55.1 showed HGA values that increased 
significantly between the first to third tail bleed (258.7, 350.3, 567.4umol/L) which then 
reduced in the subsequent tail and terminal bleeds. Interestingly, although these control 
mice had vastly variable tail bleed HGA values, they had all showed similar lower levels in 
the terminal arterial bleed, within approximately 60umol/L of each other (Fig. 5.7). 
152 
 
 
Figure 5.7 - Tail bleed HGA values in control mice once again showed high intra and inter-
mouse variability. HGA was lowest in terminal bleeds with these values being within 
±60umol/L range between the three mice despite previous tail HGA values differing 
substantially between these mice. 
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Nitisinone treated mice showed the established trend of steadily reducing HPPA between 
tail bleed 1 and terminal bleeds as observed in the previous studies. The decrease in HPPA 
between the final tail bleed (tail 5) and terminal bleed was still present. Interestingly, the 
sharp increase in HPLA between the final tail bleed and terminal bleed that was observed in 
the previous studies was not as apparent (Fig. 5.8). HPLA levels showed minimal variation 
and were relatively stable across all bleeds in the nitisinone treated mice. As mice within 
this study were culled manually via cervical dislocation, this could be an indication that the 
pentobarbitone was responsible for the significant increase in HPLA between final tail 
bleed and terminal bleeds that were previously observed in nitisinone treated Hgd-/- mice 
(Fig. 5.4, Fig 5.6). 
 
Figure 5.8 - HPPA values in treated mice followed the same trend as observed in previous 
studies – lower levels in terminal arterial bleeds compared to tail bleeds. HPLA was much 
less variable with similar concentrations across bleeds. Mice culled with pentoject from 
previous studies showed a sharp increase in HPLA between the final tail bleed and terminal 
bleed. This trend is absent in manually culled mice suggesting the increase in HPLA may 
have been an effect relating to pentoject administration.  
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5.3.6 Combined data from terminal arterial bleeds to assess cull method 
Mean metabolite data from all terminal arterial bleeds within this chapter (control n=9, 
nitisinone treated n=12) were then combined to assess the significance of cull method on 
terminal bleed metabolites. To reiterate, mice within the final study (Fig.5.7, Fig. 5.8) were 
culled manually via cervical dislocation. This data was then compared with the data 
obtained from the previous experiments where mice were culled via overdose of Pentoject 
in order to determine whether Pentoject, as a pharmacological agent, was causing the 
differences in terminal arterial values for HGA in control mice and HPPA/HPLA in nitisinone 
treated mice. 
 
Cull method had no significant effect on terminal bleed mean HGA values for control mice 
(Fig. 5.9A) with plasma concentrations similar irrespective of cull method (t(7)=0.898 
P=0.3990) (manual: 207.3±30.67, Pentoject: 165.5±19.3). Cull method had a statistically 
significant effect on HPPA (t(10)=5.653 P=0.0002) (manual: 148.0±10.3, Pentoject: 
75.54±7.5) and HPLA (t(10)=3.395 P=0.0068) (manual: 77.0±7.0, Pentoject: 115.48±7.1) in 
nitisinone treated mice (Fig. 5.9B&C). For HPPA, terminal plasma values were higher in 
mice that were culled manually. HPLA showed the opposite with plasma values being 
higher in mice culled with Pentoject. This could indicate that Pentoject is in some way 
interacting with these metabolites and the mechanism of HPPA to HPLA conversion.  
155 
 
 
Figure 5.9 - Culling with Pentoject had a significant effect on HPPA and HPLA terminal 
arterial plasma values compared to manual culling in nitisinone treated Hgd-/- mice (B, C). 
Cull method had no significant effect on HGA values in terminal arterial bleeds of control 
Hgd-/- mice (A).  Mean ± SEM terminal bleed plasma metabolite values shown. Control: 
manual n=3, Pentoject n=6. Nitisinone treated: manual n=4, Pentoject n=8. ** = P<0.01 *** 
= P<0.001. 
A 
B 
C 
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To examine this effect of Pentoject further, the last tail bleed (sample taken immediately 
prior to culling) and the terminal arterial bleed for both cull methods were analysed for 
HPPA and HPLA. This showed HPLA sharply increased after Pentoject administration in 
terminal bleeds. This increase is absent for HPLA in manually culled mice. HPPA showed the 
same reduction between tail and terminal bleeds for both cull methods although the 
reduction was more pronounced in mice culled with Pentoject (Fig. 5.10). 
 
Figure 5.10 - Administration of Pentoject has a significant effect on terminal bleed HPPA 
and HPLA plasma values of Hgd-/- BALB/c nitisinone treated mice. Pentoject results in a 
sudden increase in HPLA which is absent in manually culled mice. The reduction of HPPA 
between venous tail and terminal arterial bleeds is more marked with Pentoject. Mean ± 
SEM.  
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5.3.7 Combined data from venous tail and terminal bleeds 
Combined venous tail and brachial arterial bleed data from this chapter (n=21 mice) 
showed HGA was consistently significantly lower in terminal bleeds of control Hgd-/- mice 
compared to tail bleeds (Fig. 5.11). ANOVA confirmed that type of bleed (tail 1, tail 2 or 
terminal) had a significant effect on plasma HGA (F (2,38) = 19.16 P<0.0001) (Table 5.1). 
This is in agreement with metabolite findings within the long-term dose response study in 
chapter four. Treatment with nitisinone masked this effect due to lowering plasma HGA 
levels so although this meant there was no statistically significant difference between 
bleeds; tail bleed values were still lower. The effect was observed in all but one of the 
twenty-one mice investigated suggesting this is a not just a methodological finding and 
HGA is genuinely lower in blood sampled from the brachial vessels compared to blood 
sampled from peripheral venous vessels. Similarly, type of bleed also had a significant 
effect on HPPA and HPLA plasma values (ANOVA F(2,38)=23.23 P<0.0001 and F(2,38)=5.986 
P<0.0055 respectively) (Table 5.1) and as observed in the long-term dose response study, 
HPPA and HPLA were found to be significantly different between venous tail and brachial 
arterial bleed samples in nitisinone treated mice. HPPA is lower in blood sampled from the 
brachial vessels compared to blood sampled from peripheral venous vessels (Fig. 5.12A). 
The opposite occurs for HPLA with this metabolite being higher in blood sampled from the 
brachial vessels compared to blood sampled from peripheral venous vessels (Fig. 5.12B), 
although this effect was more marked in mice culled with Pentoject (Fig. 5.10). 
Phenylalanine varied significantly between type of bleed in nitisinone treated mice (ANOVA 
F(2,38)=3.498 P=0.0403) (Table 5.1) but this was much less pronounced than HGA, HPPA 
and HPLA (Fig. 5.13). Tyrosine was the most consistent metabolite within this study 
showing no significant variations across blood sample sites (Fig. 5.14). 
 
 Significance from Tukey multiple comparisons post hoc test  
(P value) 
Metabolite Tail 1 - Tail 2 Tail 1 - Terminal Tail 2 - Terminal 
 Control Treated Control Treated Control Treated 
HGA 0.0256 n.s. <0.0001 n.s. 0.0004 n.s. 
HPPA n.s. n.s. n.s. <0.0001 n.s. 0.0001 
HPLA n.s. n.s. n.s. 0.0002 n.s. 0.0001 
Phenylalanine n.s. n.s. n.s. 0.0360 n.s. 0.0080 
Tyrosine n.s. n.s. n.s. n.s. n.s. n.s. 
Table 5.1 - Tukey multiple comparisons results from ANOVA post hoc tests of combined 
venous tail and brachial arterial bleed data (n=21 mice). 
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Figure 5.11 – Plasma HGA was lower in blood sampled from brachial vessels (terminal) 
compared to peripheral venous blood (tail) in BALB/c Hgd-/- mice. This statistically 
significant effect is masked in treated mice but values are still lower in terminal arterial 
bleeds than venous tail bleeds for both control and nitisinone treated cohorts. Control n=9, 
treated n=12 . Significance from Tukey multiple comparisons post hoc test. * = P<0.05, *** 
= P<0.001, **** = P<0.0001. 
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Figure 5.12 – Plasma HPPA was lower (A) and HPLA higher (B) in blood sampled from 
brachial vessels (terminal) compared to peripheral venous blood (tail) in BALB/c Hgd-/- 
mice. These metabolites are low or undetectable in controls where the effect is instead 
observed in the downstream metabolite HGA. Control n=9, treated n=12. Significance from 
Tukey multiple comparisons post hoc test. *** = P<0.001, **** = P<0.0001. 
 
 
A 
B 
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Figure 5.13 – Phenylalanine was slightly elevated in blood sampled from brachial vessels 
(terminal) compared to peripheral venous blood (tail) in nitisinone treated BALB/c Hgd-/- 
mice. This statistically significant result appeared to be likely due to higher terminal bleed 
intra-cohort variation than observed in tail bleeds as mean plasma phenylalanine values 
were similar. 
 
 
Figure 5.14 – Tyrosine showed no significant fluctuations between plasma sample site in 
control or nitisinone treated BALB/c Hgd-/- mice. Elevated plasma concentrations in 
treated mice are due to HPPD inhibition by nitisinone. Significance from Tukey multiple 
comparisons post hoc test.  
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5.4 DISCUSSION 
The findings of this chaper demonstrate the importance of standardisation of blood sample 
site for measurement of tyrosine breakdown metabolites in the Hgd-/- mouse, particularly 
when repeated blood sampling is required. The metabolite inconsistencies observed within 
the long-term dose reponse study were methodological due to differences between sample 
site which prior to this study were unknown. HGA, as the main metabolite of concern with 
regards to AKU, was the most variable between blood compartments, and therefore this is 
an important finding with implicatations for future research. These systematic differences 
in metabolites between site of sampling should be considered in some past and all future 
experiments as the inconsistencies are large enough to mask important therapeutic effects 
if not considered when comparing samples. Tail samples should be collected pre-cull for 
accurate comparison with previous plasma samples. The results do not support the 
hypothesis, consequently the method and location of serial blood sampling needs careful 
planning and further investigation. 
 
HGA was consistently found to be lower in blood sampled from brachial vessels compared 
to peripheral venous blood. When sampling from the brachial vessels, the axilla was incised 
and vessels severed to collect the sample. This sample would have provided a mixed, more 
central blood supply as the brachial vessels include the brachial artery and deep brachial 
veins. Blood sampled from this site may have had lower HGA due to more recent renal 
clearance of metabolites compared to venous peripheral blood. Evidence from a recent 
study by Taylor and Vercruysse [59] suggests HGA must reach an alkalinity threshold prior 
to conversion into pigment . Arterial blood has a slightly higher (alkali) pH compared to 
venous blood, although these pH differences are very slight due to homeostatsis [155]. 
Perhaps the slightly alkali environment results in more HGA being converted into pigment 
thus removing the metabolite from blood within the arterial supply, explaining the lower 
concentrations compared to venous blood. Increased tissue trauma would also have been 
an artefect of brachial samples due to incising of the axilla prior to sample collection. 
Brachial bleeds also exposed blood to surrounding tissues as it pooled into the body cavity 
prior to collection. HGA may have been taken up by these surrounding tissues, although 
this would have to be a very rapid mechanism so is unlikely. 
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Conversely, higher HGA concentrations in venous blood may also indicate that HGA is being 
released from the collagenous tissues. Some control mice demonstrated extremely high 
HGA levels (>700umol/L) in the first tail bleed which decreased over subsequent bleeds to 
become lowest in the terminal sample (Fig. 5.5, Fig 5.7). We had proposed that previous 
high outliers in tail bleeds could be due to relatively poor renal processing within that 
particular mouse but these findings show that in subsquent tail bleeds, HGA levels quickly 
reached normal limits for an untreated Hgd-/- mouse suggesting no renal issues. A possible 
explanation for this could have been blood stasis where stagnation of blood within the tail, 
perhaps due to less efficient peripheral ciculation, meant the blood had longer contact with 
the tissues to collect waste metabolites compared to faster flowing arterial blood. Upon 
further reflection, prior to tail vein sample collection, mice were warmed in a heat box to 
enhance blood flow to allow for easier sample collection. Heating would have likely 
reduced the effect of blood stasis within the tail by inducing vasodilation. Considering this, 
another explanation could be that increasing the mouses body temperature may have 
inturn increased metabolic rate and HGA production. The high HGA value within the first 
tail bleed which gradually reduced during consecutive bleeds may have been related to this 
increase in body temperature. Mice were removed from the heat box to collect samples 
therefore body temperature would have lowered slightly with each successive bleed 
resulting in the lower HGA values. Future work could include taking tail bleed samples 
without the use of a heat box to compare values and see if such high variation still occurs. 
 
In nitisinone treated mice, HGA was lowered by HPPD inhibition but the metabolite 
discrepancies between venous and brachial vessel samples were then found in HPPA and 
HPLA, metabolites upstream from HPPD inhibition. HPPA was higher in venous blood and 
dropped in terminal samples with the opposite occuring for its metabolite, HPLA. The 
conversion pathway of HPPA to HPLA is currently unknown but it appears to be activated as 
an alternative route for the clearance of tyrosine when elevated. Culling method had a 
significant effect on the terminal bleed values of these metabolites (Fig. 5.9, Fig. 5.10). For 
HPPA, terminal plasma values were higher in mice that were culled manually. Pentoject 
appeared to cause a decrease in terminal HPPA values. The opposite was observed for 
HPLA with Pentoject appearing to cause a marked increase in terminal bleed values. The 
increase in HPLA was much less obvious or absent in mice that were manually culled (Fig. 
5.8). As HPLA is a metabolite of HPPA, when HPPA decreases it would be assumed HPLA is 
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being synthesised and increases as a result. These findings could indicate that Pentoject is 
in some way interacting with these metabolites or catalysing the mechanism of HPPA to 
HPLA conversion.  A study by Overmyer and colleagues investigating the impact of 
anesthesia and euthanasia on metabolomics of mammalian tissues found significant fold 
change decreases in serum metabolites including tyrosine and phenylalanine compared to 
cervical dislocation when the use of Pentoject was implemented [156]. Methodological 
inconsistencies with regards to manual and Pentoject culling method must also be 
considered. When culled with Pentoject, terminal bleeds were sampled after several 
minutes; the time for the drug to take effect and the mouse to become unresponsive. For 
manual culling, terminal bleeds were sampled within a matter of seconds as the process of 
cervical dislocation causes immediate death. Pentoject (pentobarbitone) causes death via 
respiratory arrest; terminal arterial blood sampled from Pentoject culled mice may 
therefore have had a lower pH due to respiratory acidosis as ventilation and circulation 
would have been reduced or absent for a longer period of time. Perhaps HPPA to HPLA 
conversion takes place at a lower pH, as in the pentoject culled mice, or endogenous 
factors released during the several minutes prior to sampling aid with the conversion. 
Lactate dehydrogenase (LDH) is released into the bloodstream during tissue damage or cell 
death and could be a potential candidate [157].  
 
Arteriovenous perturbations in metabolites may have also been a result of the stress 
response associated with culling which could in turn cause release of cortisol and 
corticosterone [156]. During tail bleeds, mice were warmed in a heat box then gently held 
in a restrainer prior to sample colleciton. This would almost definitely induce a stress 
response due to the enviromental stressor of increase temperature (37oC) along with the 
psychological effect of temporary restraint [158]. During terminal bleeds, it could argued 
that manually culling would induce less of a stress response as the cervical dislocation 
method is completed within a matter of seconds. The highest stress response between all 
of the sampling methods would likely be overdose with Pentoject as this takes several 
minutes for the mouse to become completely unresponsive and during this time the mouse 
will hyperventilate. Cortisol levels have been shown to peak in as little as 3 minutes when 
stress is induced within a mouse so this could affect plasma metabolite levels [159]. 
Interestingly,  administration of cortisol to rodents has been shown to induce tyrosine 
aminotransferase (TAT) in the liver, reponsible for converting tyrosine to HPPA [160, 161] 
164 
 
so stress response may have been a real contributing factor to the observed fluctutations in 
tyrosine metabolites between bleeds. 
Tyrosine was the most stable metabolite between blood compartments in both control and 
treated mice which was surprising considering the large elevation observed during 
nitisinone treatment. Phenylalanine showed slight arteriovenous differences in treated 
mice within this study but not to the scale observed in chapter four where it was elevated 
for all cohorts in terminal bleeds. A possible reason for the elevation in phenylalanine 
within the long-term study could be that mice were 20 weeks older in the terminal bleed 
than in mid-term bleeds. At 43 weeks of age, when terminal bleeds were collected, the 
mice would have had an increased bodyweight and food consumption compared to at 23 
weeks when mid-term bleeds were collected. Phenylalanine is an essential amino acid that 
is derived from dietary protein. In support of this, a paper investigating amino acid 
concentrations in childen by Lepage et al [162] demonstrated that phenylalanine 
concentrations tended to increase throughout childhood and adolescence. 
 
With long-term studies comes the practicalities of long-term plasma sampling. These 
studies often require serial samples to be collected that must be obtained whilst adhering 
to the Home Office guidelines for volumes of blood taken. This is a maximum of 15% total 
blood volume within one month and a maximum of 10% total blood volume within any one 
bleed. This study has established how sensitive the metabolome is to variations between 
blood compartment, cull method and, in the case of HGA, bleeds sampled seconds apart 
from the same site. Venous tail bleeds are the preferred method for serial sampling within 
our lab as they are quick and simple to perform, minimising stress for the mouse. HGA is 
one of the primary metabolites of interest in AKU, it is therefore crucial that accurate 
plasma values are obtained for analysis. The differences in plasma HGA values observed 
between consecutive tail bleeds within this study suggest it may be advantageous to take 3 
separate tail bleeds during future studies in order to use the average value of these for 
subsequent analysis. As the metabolite differences between consecutive tail bleeds may 
have been due to increased metabolic rate as a result of warming prior to sample 
collection, it may be beneficial to try a different sampling method. Sampling from the 
lateral saphenous vein is a relatively quick method of obtaining serial blood samples from 
mice and does not require the animal to be warmed for sample collection. Anaesthesia is 
not necessary and mice are consicious throughout the procedure [163-164]. Comparison of 
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metabolites values between tail vein and saphenous vein samples would allow the effects 
of warming on the metabolome, if any, to be investigated further.  
166 
 
 
 
 
 
 
 
 
 
 
 
 
6. General Discussion 
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AKU is a chronic and progressive disease with multi-system involvement involving 
devastating joint damage and lifelong pain from early adulthood. Despite advances in the 
understanding and molecular basis of the condition, and identifying HGA as the key player 
in morbidity, over a century has passed since Garrod described AKU but still no definitive 
treatment is available.  Nitisinone is a treatment option that has the potential to lower HGA 
levels from a young age, effectively halting the disease in its tracks and vastly improving 
disease prognosis later in life. Nitisinone use in children has, up until now, only been used 
for the treatment of HT-1 in which fatal complications arise if left untreated. Concerns 
regarding the safety of elevation of tyrosine in children as an adverse effect of nitisinone 
treatment have justly been aired. This thesis presents novel data that neither nitisinone 
itself, nor the associated elevation of tyrosine has a detrimental effect on learning, memory 
or motor function in young Hgd-/- mice. It also demonstrates that plasma HGA and 
ochronotic pigmentation are correlated but that this correlation is not linear, HGA must be 
reduced to a critical level before pigmentation is significantly reduced. Additionally, this 
thesis shows that there are large discrepancies between the arteriovenous metabolome 
relating to AKU, which should be considered when comparing experimental blood samples 
and in designing sampling protocols for future studies. 
 
The findings of chapter three reported no detrimental effect of nitisinone treatment or the 
related-tyrosine elevation, which is encouraging for treatment of children with AKU. 
Concerns regarding the neurotoxicity of elevated tyrosine, especially during brain 
development, have been raised because of the cognitive development issues occasionally 
reported in HT-2 and HT-3. Neurocognitive developmental impairment has also been 
reported in some HT-1 nitisinone treated children. Within these conditions, high tyrosine 
levels are present from birth as the result of a genetic mutation or treatment with 
nitisinone. Genetic deficiency of TAT, the first enzyme of the tyrosine degradation pathway, 
in HT-2 means the conversion of tyrosine into HPPA is reduced. It has been suggested that 
mitochondrial aspartate aminotransferase acts as a compensatory substitute to aid with 
tyrosine excretion via HPPA [164] but nevertheless, tyrosine levels tend to be highest in this 
condition (>1000umol/L). Within AKU, on the other hand, the TAT tyrosine conversion 
pathway is functional, enabling renal processing and urinary excretion of HPPA/HPLA when 
tyrosine is elevated by nitisinone therapy. HT-3 has a closer metabolic resemblance to 
nitisinone treatment in AKU as inhibition of HPPD is present in both. Only a few cases of 
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HT-3 have been reported in the literature with mixed clinical findings including some 
asymptomatic cases [115, 165] suggesting that the high tyrosine concentration alone does 
not participate directly in the neuronal damage described within these patients. HPPD 
deficiency and high tyrosine in HT-3 is probably also present during the prenatal period, 
during vital stages of neurocognitive development. Three cases of women with HT-1 who 
received nitisinone throughout pregnancy are described in the literature, with the children 
reported as suffering no adverse effects and normal psychomotor development within the 
first years of life [67-69]. Similar to those with HT-3, these children would have also 
experienced elevated tyrosine during their prenatal development, further suggesting that 
the neurological dysfunction in HT-3 is not directly due to elevation of tyrosine and that 
other factors must be involved. Nitisinone treatment for children with AKU would use 
lower doses than in the treatment of HT-1 and this would be combined with a protein-
restricted diet to ensure tyrosine levels remained within clinically set safety limits. Tyrosine 
is required by the brain for the synthesis of the catecholamines, but techniques to regulate 
uptake by the brain when levels are elevated during nitisinone treatment could be 
beneficial. Tyrosine is a large neutral amino acid (LNAA) which shares a common 
transporter across the blood brain barrier with other LNAA such as tryptophan and the 
branched chain amino acids (BCAA). The ingestion of dietary LNAA has been shown to 
modify tryptophan and tyrosine uptake into the brain and their conversion to serotonin 
and catecholamine’s, respectively [166]. Choi and colleague demonstrated that ingesting 
BCAA reduces tyrosine concentrations due to competitive inhibition of the LNAA 
transporter [167]. This could potentially be used as a precautionary measure to regulate 
uptake of tyrosine within the brain alongside nitisinone therapy and a protein controlled 
diet. 
 
The data from chapter three also showed that differences between learning ability in the 
MWM were an effect of genotype and not treatment with nitisinone. There were no 
significant differences in any of our multiple measured parameters between control and 
treated cohorts, which was encouraging as this indicated nitisinone treatment did not have 
a detrimental effect on the learning process. Both control and treated wild type cohorts 
showed preference to the target quadrant and performed better overall within the MWM 
task. Both Hgd-/- cohorts were slower at learning during acquisition trials compared to wild 
type and showed no preference to the target quadrant during the probe trial. This probably 
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indicated relatively poor spatial learning and reference memory within the Hgd-/- mice. 
Such a characteristic has not been documented previously. Dopamine and the activation of 
hippocampal and striatal D1R and D5R dopamine receptors are known to be involved in 
spatial learning and memory processing [93]. Deletion or dysregulation of these receptors 
has been shown to produce deficits in acquisition of spatial memory and reduced 
hippocampal activation within the MWM [86, 91]. Dopamine is also extensively involved in 
the mesolimbic system that mediates motivated behaviour [168]. Aversive stimuli, such as 
the MWM, have been shown to stimulate dopamine synthesis as mice are motivated to 
escape the pool [169]. Hgd-/- mice were noticeably more docile and seemed less anxious to 
be handled from the beginning. This could suggest the Hgd-/- genotype demonstrate poor 
spatial learning, but could also be interpreted as an indication of reduced aversive 
behaviour and a reduction in motivated behaviour due to influences of the genotype on the 
dopaminergic system. Tyrosine is a precursor to the catecholamine neurotransmitters 
including dopamine. Administration of tyrosine has also been shown to increase 
acetylcholinesterase activity in rats [170], responsible for breaking down Acetylcholine, 
which itself also plays a role in learning and memory.  As AKU is a condition affecting 
tyrosine catabolism, these neural systems could feasibly be implicated.  
 
The characteristic features of HT-3 can include occasional loss of balance and coordination. 
Motor function assessment in chapter 3 showed Hgd-/- control and treated mice displayed 
no indications of intermittent ataxia or deficits in gross motor function. Chapter three also 
contained the results of a novel assessment of gait in the Hgd-/- mouse using the Catwalk 
XT automated platform. The chosen parameters, also used by other centres for the 
assessment of mouse models of OA, showed no obvious signs of pathologically altered gait. 
Symptomatic joint pathology in human AKU patients often presents from the third decade 
and progressively worsens with age [96]. Hgd-/- cohorts were between 17 to 39 weeks 
when gait was analysed, as this is when the ochronotic phase of the disease has been 
shown to be present [70]. Mice are quadrupedal therefore the load on weight bearing 
joints is reduced compared to human locomotion. With reduced load bearing, the joint 
damage relating to ochronosis and its effect on gait may take much longer to manifest in 
the mouse. It would be interesting to assess gait in Hgd-/- aged mice to assess whether 
symptoms of ochronotic osteoarthropathy were apparent in older mice when kidney and 
liver function were also likely to be less efficient. The principle of lower severity in mice 
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than in humans with analogous musculoskeletal mutations producing chronic disease is not 
unusual. For example, the mdx mouse that shows the mutation analogous to that 
producing Duchenne muscular dystrophy in human is much less affected in terms of motor 
function than human patients.    
 
Prior to this thesis, the correlation of HGA and ochronotic pigmentation remained 
unidentified. Results from chapter four indicated a correlation does exist although this is 
not linear. The critical plasma levels for HGA appeared to be between 40-60umol/L. Below 
40umol/L resulted in a dramatic reduction in pigmentation whereas above 60umol/L 
pigmentation was similar to control and showed maximal levels of ochronosis. This builds 
upon in vitro work by Tinti and colleagues that suggests 10umol/L HGA is insufficient to 
cause ochronosis [106]. These findings are encouraging for facilitating tailored nitisinone 
treatment as it suggests a personalised dose of nitisinone can be used that lowers HGA to 
levels that prevent ochronosis while simultaneously keeping elevation of tyrosine to a 
minimum. This is particularly important for those AKU patients who demonstrate tyrosine 
toxicity independent of peak plasma levels as it would mean that they might be able to 
receive continuous treatment with minimised risk of ocular symptoms necessitating 
withdrawal of treatment. Chapter four also showed there was a surprising degree of 
congruence between Hgd-/- mice and humans in the effect of nitisinone dose.  The SONIA1 
human study concluded that the 8mg daily dose, which equates to 0.114mg/kg for a 70kg 
human, was most efficacious for AKU patients. Within the Hgd-/- mouse study in chapter 4, 
the 0.5mg/L dose, which equates to 00.7-01mg/kg for a 30g mouse, provided a practical 
compromise of lowering HGA sufficiently to reduce pigmentation whilst also producing a 
lower degree of tyrosinemia than higher doses. This reaffirms the importance of the Hgd-/- 
mouse as an appropriate model to clarify pathophysiology and test therapies for AKU. 
 
The data presented in chapter five showed, for the first time, that the metabolome of 
tyrosine breakdown products, specifically HGA, HPPA and HPLA, were labile in the 
compartments of the circulating blood. This is important to consider when comparing 
samples, as differences are significant enough to mask potential therapeutic effects. 
Chapter five also stressed the importance of sampling tail bleeds pre-cull for comparison 
with previous serial samples during long-term studies. The use of pentobarbitone for 
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humane killing had significant effects on the tyrosine phenolic metabolites HPPA and HPLA, 
which are themselves important to analyse for evaluating tyrosine clearance during 
nitisinone treatment. Within the arteriovenous metabolome study, one group of five 
nitisinone treated littermates had tyrosine levels of around 500umol/L whilst receiving a 
dose of 4mg/L. All other mice receiving the same dose had tyrosine levels of >1000umol, 
typical within the Hgd-/- model. The lower plasma tyrosine levels within these five 
littermates suggest that they may have had a genetic advantage that enabled more 
efficient clearance of tyrosine. Plasma tyrosine levels are a reflection of inhibition of HPPD 
and the ability to clear tyrosine from the blood stream. HPPA and HPLA plasma values 
within the five littermates did not differ significantly from the other mice within the study, 
suggesting additional tyrosine was not cleared by increases in this excretory pathway. 
Increased tyrosine clearance by another mechanism may have been taking place, such as 
enhanced production of melanin or hormones. Another possible explanation may be that 
these mice had HPPD that was less sensitive to nitisinone inhibition, allowing a percentage 
of the tyrosine to be catabolised into HGA. Intriguingly, only one of the five littermates had 
HGA that was higher than would be expected when receiving the 4mg/L dose of nitisinone 
and this value was still much lower than found in untreated Hgd-/- mice. This suggests that 
these mice were just as sensitive to nitisinone as other treated mice but in addition, they 
exhibited a tyrosine clearance mechanism, other than HPPA and HPLA, that was more 
efficient. 
 
During the work reported in this thesis, we observed no cases of Hgd-/- or WT mice that 
displayed any obvious signs of ocular lesions that affected vision when receiving the highest 
doses of nitisinone (2mg or 4mg). Mice within the long-term study in chapter four had 
prolonged elevation of tyrosine (>1000umol/L) for around 40 weeks and still appeared to 
have no obvious ocular symptoms, although the cornea was not specifically examined. WT 
and Hgd-/- mice within the MWM study in chapter three all had tyrosine levels 
>1100umol/L during testing, with one wild type mouse exceeding 1800umol/L, and showed 
no deficits during the visible platform test – a test specifically designed to alert the 
experimenter to mice with visual defects. This reconfirms that the mouse has superior 
mechanisms than in human to tolerate such high plasma tyrosine with no obvious adverse 
effects. One mouse within the study reported in chapter four developed a cutaneous lesion 
at the base of the tail that would not heal and consequently had to be culled prior to the 
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end of the study. This mouse was part of the 0.125mg nitisinone cohort and had the least 
elevated tyrosine value within the cohort suggesting that this event was not a cutaneous 
symptom relating to tyrosine toxicity. 
 
A final point to consider is the role of tyrosinase in the synthesis of ochronotic 
pigmentation. Taylor and colleagues [41] mentioned a potentially useful link that is so far 
missing from the literature – an individual with both AKU and albinism that could provide 
further clues for any potential action of tyrosinase in the disease process of AKU. This thesis 
used BALB/c mice - an albino inbred mouse strain that results from a cysteine to serine 
substitution at position 85 of the tyrosinase gene. This mutation leads to non-functioning 
tyrosinase and is the reason why the BALB/c mouse is also considered a murine model of 
human tyrosinase negative oculocutaneous albinism [171-172]. This thesis therefore used a 
model that combines both AKU and albinism. Control and low dose nitisinone treated Hgd-
/- cohorts within chapter three displayed ochronotic pigmentation. Previous studies using 
BALB/c Hgd-/- mice have also demonstrated ochronotic pigmentation [70-72]. The natural 
history study by Keenan and colleagues reported BALB/c (as used in this study) and BL/6 
mice (which possess functional tyrosinase) to have similar pigmentation levels [71]. BALB/c 
mice in fact had a slightly higher pigmented chondron count range than BL/6 after 60 
weeks of age, suggesting tyrosinase does not play a leading role and that other factors 
must mediate the synthesis of pigment in this model. 
 
In summary, the work presented within this thesis presents novel findings to support the 
future licensing of nitisinone for use in AKU and opens the door to treatment in young 
patients. Early treatment has the potential to prevent the accumulating damage of high 
HGA during childhood and improve patient prognosis in later life. The results indicate no 
detrimental effect of nitisinone treatment on cognition or motor function in young BALB/c 
mice and demonstrate the feasibility of patient-tailored treatment to provide protection 
from ochronosis whilst minimising the adverse effects of elevated tyrosine. This thesis also 
presents novel data on the lability of the arteriovenous metabolome relating to AKU and 
suggests possible conditions relating to the HPPA to HPLA excretory conversion pathway. 
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7. Future work 
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The findings presented in this thesis have uncovered several lines of research that should 
be pursued in order to build upon the current understanding of the pathophysiology of 
AKU, along with the effects of nitisinone treatment. 
 
7.1 Investigate differences between arteriovenous metabolome in AKU humans 
HGA plasma levels were shown to widely vary between venous and mixed arterial blood in 
the Hgd -/- mouse. It would be interesting to see if this was the case for humans with AKU 
and whether mixed arterial samples would give more accurate HGA results. A minimally 
invasive way to obtain a more arterial-like supply would be to sample from the hand after it 
had been placed in a warmed box to assist with vasodilation. This method is currently being 
implemented in human patients for a tyrosine tracer study within our AKU research group. 
It would be interesting to analysis this metabolite data to see if differences between 
arteriovenous samples were apparent. An arterial sample could also be taken with 
permission from an AKU patient during arthroplasty surgery to compare with a previous 
venous sampled from the same patient. 
 
7.2 Heterozygous mice for further MWM trials 
The results from chapter three highlighted that it would be useful to perform future trials 
with a control colony that were as closely matched to the Hgd-/- mice as possible. It would 
be helpful to repeat some of the studies in heterozygous mice generated by crossing some 
of the homozygous colony back with WT mice and selecting the heterozygotes that have 
the mutation in only one allele (Hgd +/-). This would eliminate as far as possible the non-
AKU genetic differences between strains. A transgenic mouse model is currently being 
developed at the University of Liverpool with the hope this will give an even more accurate 
AKU model. As the model will be clean Hgd gene knock out, this will also eliminate the 
unknown non-AKU genetic differences resulting from random mutagenesis. 
 
7.3 Measuring catecholamines in the mouse brain 
The results from chapter three suggested that the Hgd-/- genotype could affect the 
catecholamines within the mouse brain. Measuring these neurotransmitters, with a specific 
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focus on dopamine, in control and nitisinone treated Hgd-/- and WT mice would allow 
analysis to see if any of these were elevated or depleted as a result of the genotype or 
treatment. Similar work is currently underway within the Royal Liverpool University 
Hospital’s Department of Clinical Biochemistry and Metabolic Medicine.  
 
7.4 Gait analysis with weight matched Hgd-/- and WT mice 
The gait analysis results in chapter three were affected by differences within bodyweight. 
Further analysis of age and bodyweight matched Hgd-/- and WT mice should be carried out 
to enable a more sensitive measure of pathological gait that may occur in AKU mice. This 
could also be investigated in aged nitisinone treated and control Hgd-/- mice to assess 
whether gait is more severely affected in later life, as in AKU patients.  
 
7.5 Quantification of OA in Hgd-/- nitisinone treated mice 
Some control and nitisinone treated mice showed signs of OA within chapter four. 
Ochronotic pigmentation is linked to early onset OA therefore this could be expected in 
control mice, but surprisingly, treated mice who had reduced HGA from weaning also 
showed OA of the tibio-femoral joint. This suggests factors other than high HGA are 
involved in the joint damage observed in AKU. It may also suggest that even low amounts 
of HGA can cause joint damage despite pigmentation being minimal or absent. A long-term 
study involving quantification of OA in nitisinone treated and control Hgd-/- cohorts, with 
age matched WT mice for comparison, would allow this to be investigated further. 
 
7.6 Cull method effect on HPPA/HPLA 
Chapter five indicated that culling with Pentoject had a significant effect on HPPA and HPLA 
values. Whether this was due to the pharmacological agent itself or endogenous factors 
released upon its administration is unknown. Further investigation into what caused this 
effect could potentially elucidate the mechanism or conditions required for stimulation of 
the HPPA to HPLA conversion pathway.  
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Appendix: Long-term dose response study metabolite data & pigmented chondron counts  
Nitisinone dose 
(mg/L) 
n Metabolite Mean  
(umol/L) 
SD SEM Coefficient 
of variation 
BALB/c Hgd-/- Mid bleed - 20 weeks  
  Tyrosine 60.6 12.6 4.8 20.8 
  HGA 247.3 87.5 33.1 35.4 
0 7 Phenylalanine 65.0 15.0 5.7 23.1 
  HPPA <10.0 - - - 
  HPLA <5.0 - - - 
  Tyrosine 257.0 110.8 41.9 43.1 
  HGA 229.6 119.3 45.1 52.0 
0.125 6 Phenylalanine 56.3 6.0 2.3 10.7 
  HPPA 56.9 24.4 9.2 42.9 
  HPLA 12.1 5.7 2.2 47.1 
  Tyrosine 796.7 137.3 56.0 17.2 
  HGA 192.2 86.6 35.3 45.1 
0.5 7 Phenylalanine 71.0 14.3 5.8 20.1 
  HPPA 188.5 69.4 28.3 36.8 
  HPLA 36.8 12.5 5.1 34.0 
  Tyrosine 1455.3 120.3 45.5 8.3 
  HGA 47.4 10.7 4.0 22.6 
2 7 Phenylalanine 104.9 9.9 3.73 9.4 
  HPPA 222.4 62.6 23.6 28.1 
  HPLA 79.4 13.9 5.3 17.5 
BALB/c Hgd -/- Term bleed - 40 weeks  
  Tyrosine 83.6 4.3 1.8 5.1 
  HGA 133.8 24.4 10.0 18.2 
0 7 Phenylalanine 89.1 7.3 3.0 8.2 
  HPPA 12.7 0.3 0.1 2.4 
  HPLA <5.0 - - - 
  Tyrosine 249.3 45.3 18.5 18.2 
  HGA 89.1 47.6 19.4 53.4 
0.125 6 Phenylalanine 84.0 9.1 3.7 10.8 
  HPPA 18.2 3.5 1.4 19.2 
  HPLA 12.0 4.9 2.0 40.8 
  Tyrosine 531.3 54.4 22.2 10.2 
  HGA 51.9 9.5 3.9 18.3 
0.5 6 Phenylalanine 89.0 4.8 1.9 5.4 
  HPPA 20.4 0.8 0.3 3.9 
  HPLA 23.6 3.0 1.2 12.7 
  Tyrosine 1015.0 218.4 82.6 21.5 
  HGA 28.7 5.9 2.2 20.6 
2 6 Phenylalanine 101.6 21.9 8.3 21.6 
  HPPA 30.3 3.5 1.3 11.6 
  HPLA 50.7 11.3 4.3 22.3 
AKU Human – SONIA1 4 week data 
  Tyrosine 56.0 15 5.3 27.8 
  HGA 30.5 12.4 4.4 32.4 
0 8 Phenylalanine 54.6 16.7 5.9 30.7 
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  HPPA 13.8 5.6 2.0 40.4 
  HPLA <5 - - - 
  Tyrosine 653.0 106 37.5 16.2 
  HGA ND - - - 
1 8 Phenylalanine 53.5 5.7 2.0 10.7 
  HPPA 37.5 15.6 5.5 41.6 
  HPLA 47.2 26.2 9.3 55.5 
  Tyrosine 715.0 171 60.5 23.9 
  HGA ND - - - 
2 8 Phenylalanine 51.6 13.0 4.6 25.2 
  HPPA 43.2 12.5 4.4 28.9 
  HPLA 47.1 7.9 2.8 16.8 
  Tyrosine 803.0 155 54.8 19.3 
  HGA ND - - - 
4 8 Phenylalanine 53.8 12.2 4.3 22.6 
  HPPA 49.6 15.3 5.4 30.8 
  HPLA 79.5 54.8 19.4 68.9 
  Tyrosine 813.0 145 15.9 17.8 
  HGA ND - - - 
8 8 Phenylalanine 54.3 11.6 4.1 21.4 
  HPPA 56.2 15.4 5.4 27.4 
  HPLA 78.7 20.1 7.1 25.5 
Table 1 - Plasma metabolites measured at 20 and 40 weeks in control and nitisinone 
treated BALB/c Hgd-/- mouse from long-term dose response study (chapter 4). Human 
data obtained via personal communication from SONIA1 study [55] ND, not detected 
(below 3.1umol/L).  
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Table 2 - Quantification of ochronotic pigmentation in 43 week old, control and nitisinone 
treated BALB/c Hgd-/- mice from long-term dose response study (chapter 4). Both 
classifications of pigmentation included. 
BALB/c 
Hgd-/- 
Nitisinone 
dose (mg/L) 
Cellular 
pigmentation 
count 
Cellular + 
peri-cellular 
pigmentation count 
30.1 0 Control 250 449 
30.2 0 Control 197 427 
30.3 0 Control 119 248 
30.4 0 Control 170 287 
30.5 0 Control 115 235 
30.6 0 Control 258 369 
29.1 0.125 106 299 
29.3 0.125 211 477 
29.4 0.125 248 359 
29.5 0.125 247 433 
29.6 0.125 252 425 
29.7 0.125 123 195 
24.1 0.5 77 131 
24.2 0.5 29 44 
26.1 0.5 33 75 
26.2 0.5 44 98 
26.3 0.5 22 51 
26.4 0.5 53 129 
13.1 2 5 22 
13.2 2 3 12 
13.3 2 4 16 
13.4 2 13 46 
13.5 2 4 12 
13.6 2 7 35 
13.7 2 0 10 
